{"title": "PDF", "author": "PDF", "url": "https://www.usc.es/cimus/sites/default/files/institutional_publications/memoria_cimus_2012-2013_v5.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n \n \n \n \nMEMORIA DE \nACTIVIDADE  \n2012 -2013   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  1 INDICE  \n1.  Introduci\u00f3n          2 \n2. Descrici\u00f3n xeral da investigaci\u00f3n        4 \n3. Estrutura e organizaci\u00f3n         9 \n4. Infra estruturas  de investigaci\u00f3n        11 \n5. Planificaci\u00f3n estrat\u00e9xica         15 \n6. Actividade no CIMUS         17 \n6.1. Actividade cient\u00edfica         17 \n6.2. Conferencias e seminarios        21 \n6.3. Divulgaci\u00f3n e comunicaci\u00f3n        22 \nANEXOS           26 \nI. Recursos humanos  \nII. Proxectos e contratos captados  \nIII. Proxectos e contratos activos  \nIV. Artigos  \nV. Libros e cap\u00edtulos de libros  \nVI. Teses  \nVII. Patentes  \nVIII. Spin -offs \nIX. Conferencias e seminarios  \nX. Estad\u00edas  \n   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  2 1. INTRODUCCI\u00d3N  \nO Centro Singular de Investigaci\u00f3n en Medicina Molecular e Enfermidades Cr\u00f3nicas (CIMUS) \nintegra xunto co CIQUS e o CITIUS a rede de centros singulares da USC, que constit\u00fae  un dos \npiares fundamentais do Campus de Excelencia Internacional Ca mpus Vida.  \nO 17 de Febreiro de 2010, o consello de goberno da USC aproba a s\u00faa creaci \u00f3n e o \nregulamento, e no mes de  Decembro de 2011 prod\u00facese  o traslado dos investigadores.  \n \nA misi\u00f3n  do CIMUS consiste en realizar unha investigaci\u00f3n b\u00e1sica de calidade contrastada,  co \nobxectivo de acadar avances na prevenci\u00f3n, entendemento e tratam ento da enfermidade \ncr\u00f3nica en base \u00f3s seguintes par\u00e1metros:  \n\uf0fc Xeraci\u00f3n de co\u00f1ecemento en base a criterios de excelencia e tra nslaci\u00f3n que permitan \na s\u00faa transferencia a nivel  asistencial e/ou industrial.  \n\uf0fc Desenvolvemento dunha estrutura que impulse a eficiencia e competitividade dos \nGrupos.  \n\uf0fc Ser un modelo de cambio cultural que potencie a implicaci\u00f3n dos profesi onais \nsanitarios en labores de investigaci\u00f3n e dos b\u00e1sicos na xeraci\u00f3n de co\u00f1ecemento en base \u00e1s \ndemandas empresariais.  \n\uf0fc Incrementar a  masa cr\u00edtica de investigadores biom\u00e9dicos con especial \u00e9nfase  na \ncaptaci\u00f3n de xoves investigadores.  \n \nFigura 1. Rede de Centros Singulares de Investigaci\u00f3n en Campus vida   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  3 A visi\u00f3n  do CIMUS se r\u00e1 ser  reco\u00f1ecidos no \u00e1mbito internacional no campo da investigaci\u00f3n en \nBiomedicina motivando \u00f3s  membros do centro para que traballen de forma conxunta nun \nambiente de cooperaci\u00f3n. Isto deber\u00e1 traducirse nunha investigaci\u00f3n:  \n\uf0fc Centrada no  paciente ne canto  \u00e1 s\u00faa tem\u00e1tica.  \n\uf0fc Uni\u00f3n cultural e organizativa dos grupos pertencentes \u00e1s distintas disciplinas.  \n\uf0fc Sistemas de xesti\u00f3n, organizaci\u00f3n e informaci\u00f3n eficientes.  \n\uf0fc Activo en canto \u00e1 s\u00faa contribuci\u00f3n \u00f3 desenvolvemento econ\u00f3mico e social de Galicia.  \n\uf0fc Vocaci\u00f3n docent e. \n\uf0fc Accesible \u00e1 cidadan\u00eda e en permanente contacto coa Sociedade.  \n\uf0fc Tecnolox\u00eda de primeiro nivel.  \n\uf0fc Excelencia investigadora.  \nAs\u00ed tam\u00e9n o CIMUS asentase e catro valores  principais:  \n\uf0fc Lidera do: Ser referente a nivel europeo grazas  \u00e1  realizaci\u00f3n dunha investigaci\u00f3n de \nalto impacto e reco\u00f1ecido prestixio nos seus \u00e1mbitos de influencia.  \n\uf0fc Excelencia e innovaci\u00f3n: Fomentar un ha investigaci\u00f3n de excelencia d acordo a \nest\u00e1ndares internaciona is e crear un medio favorable para a xe raci\u00f3n de novas  ideas, \nenfoques  e soluci \u00f3ns. \n\uf0fc Cooperaci\u00f3n e multidisciplinariedad e: Potenciar a cooperaci\u00f3n entre diferentes  \ngrupos de investigaci\u00f3n ser\u00e1  un ha das marcas  de identidad e do CIMUS. Esta debe \nestar enfocada no n so \u00f3s Grupos d o propio Centro sen\u00f3n  que de be estenderse  a \nGrupos/Centros d o entorno inmediato como p oden ser os de qu\u00edmica sint\u00e9tica \n(agrupados no Centro de Investigaci\u00f3ns  Qu\u00edmicas, CIQUS; ou os do  CITIUS). Adem ais a \nvocaci\u00f3n de referente internacional d o CIMUS  fai imprescindible  a s\u00faa  inserci\u00f3n e n \nRedes/Networks de Investiga ci\u00f3n cooperativa tanto nacionais como Internacionai s. \n\uf0fc \u00c9tica: O CIMUS pretende seguir realizando a s\u00faa  labor nun entorno \u00e9tico, transparente \ne de respeto de todas aque las normas inherentes tales como as referidas \u00e1 s de \nExperimen taci\u00f3n animal, segurida de laboral, seguridad e inform\u00e1tica etc.  \n\uf0fc Aplicaci\u00f3n, d ifusi\u00f3n e  transmisi\u00f3n d o co\u00f1ecemento: O CIMUS co nta entre  os seus \nobxectivos o trasladar os resultados da s\u00faa investigaci\u00f3n \u00e1 pr\u00e1ctica cl\u00ednica e compartir \no co\u00f1ecement o xerado coa Sociedade.  \nAtendendo a estes valores, a actividade investigadora do CIMUS atopase centrada en resolver \nproblemas relevantes no campo da biomedicina a trav\u00e9s de estratexias transdisciplinares. Para \nisto contamos con 27 grupos de investigaci\u00f3n on de 35 IPs lideran proxectos dentro das 7 \u00e1reas \ndo centro, arredor dos cales se aglutinan 45 postdocs e m\u00e1is de 100 estudantes de \ndoutoramento.   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  4 2. DESCRICI\u00d3N XERAL DA INVESTIGACI\u00d3N  \nO CIMUS comeza a s\u00faa andaina coma centro en 2007 cando un comit\u00e9 asesor exter no,  \ncomposto por investigadores de reco\u00f1ecido prestixio aval\u00eda  a os investigadores que traballan \nna area de medicina da USC e identifican as \u00e1reas m\u00e1is puxantes, con mellores perspectivas de \ncrecemento e proxecci\u00f3n e con maiores posibilidades de cara o es tablecemento de sinerxias e \no desenvolvemento de proxectos multidisciplinares. \u00c1s \u00e1reas seleccionadas son:  \n \nI. \u00c1rea de CANCRO: Centra os seus principais obxectivos na oncolox\u00eda molecular, \nno estudo de diferentes tipolox\u00edas de cancro coma son os cancros \nhereditarios(principalmente colon e mama) , o cancro de tiroides, o cancro  de \nmama, tumores SNC, mecanismos moleculares en onco x\u00e9nese  e tam\u00e9n na relaci\u00f3n \nentre virus e  cancro.  \nII. \u00c1rea de ENDOCRINOLOX\u00cdA E NUTRICI\u00d3N: Os grupos que se encontran neste \n\u00e1rea enfocan o seu traballo nas seguintes li\u00f1as de investigaci\u00f3n:  \n\uf0b7 Obesidade -Diabetes: B\u00fasqueda  de novas dianas terap \u00e9uticas. Estudos \nfisiopatol\u00f3x icos.  \nFigura 2. \u00c1reas tem\u00e1ticas de investigaci\u00f3n no CIMUS   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  5 \uf0b7 Neuroendrocrinolo x\u00eda. Control da inxesta  e gasto enerx\u00e9tico. Sensores \nenerx\u00e9ticos e metabolismo lip\u00eddico. Control d a secreci\u00f3n  de hormonas \nhipofisarias.   \n\uf0b7 C\u00e9lulas nai en gl\u00e1ndulas endocrinas.  \nIII. \u00c1rea de NEUROCIENCIA : Neste  \u00e1rea as li\u00f1as de traballo son:  \n\uf0b7 C\u00e9lulas nai, t erapia cel ular e  neuro rreparaci\u00f3n  \n\uf0b7 Tumores SNC  \n\uf0b7 Fisiolo x\u00eda dos sistemas visual e motor  \n\uf0b7 Inflamaci\u00f3n.  \nIV. \u00c1rea CARDIOVASCULAR : Os grupos pertencentes a esta \u00e1rea traballan nos \nseguintes aspectos:  \n\uf0b7 Malformaci\u00f3ns vasculares. Morfolox\u00eda celular e biolox\u00eda  celular do \nendotelio.  \n\uf0b7 Mecanismos moleculares, fisiopatolox\u00eda e desenvolvem ento de \nenfermidades  cardi ovasculares : Abordaxe investigaci\u00f3n b\u00e1sica e cl\u00ednica.  \n\uf0b7 Funci\u00f3n vascular. Sinalizaci\u00f3n en c\u00e9lulas vasculares.  \n\uf0b7 Funci\u00f3n plaquetaria. Prote\u00f3mica de plaquetas.  \nV. \u00c1rea de XEN\u00c9TICA E XEN\u00d3M ICA FUNCIONAL  A actividad e investigadora \nintegra se dentro d o Grupo da USC de Medicina Xen\u00f3mica que igualmente \nincl\u00fae  o Nodo USC d o Centro Nacional de Xenotipado. Ademai s hai varios \ngrupos cl\u00ednicos que est\u00e1n levando  a cabo un ha labor investigadora relacionada \nco establecem ento das bases xen\u00e9ticas de distintas enfermidades  e a \ncorrelaci\u00f3n xenotipo/fenotipo.  \n\uf0b7 Xen\u00e9tica  de enfermidades  neurol\u00f3xicas   \n\uf0b7 Enfermidades  xen\u00e9ticas  endocrino -metab\u00f3licas  \n\uf0b7 Cancro   \n\uf0b7 Xen\u00e9tica de poboaci\u00f3ns   \n\uf0b7 Xen\u00e9tica  evolutiva  \n\uf0b7 Xen\u00e9tica  de enfermidades  complexas . Farmaco xen\u00e9tica e \nFarmaco xen\u00f3mica   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  6 VI. \u00c1rea de FARMACOS  e TERAPIAS EXPERIMENTAIS : Div\u00eddese  en d\u00faas li\u00f1as \nde traballo diferenciadas:  \n\uf0b7 Descubrimento de f\u00e1rmacos (Innopharma) : Conta con infraestruturas  de \nalta capacidade  e  uso de est\u00e1ndares industriais en innovaci\u00f3n aberta. As\u00ed \nmesmo conta con experiencia e capacidades para a validaci\u00f3n de novas \ndianas terap\u00e9uticas, desenvolvemento de ensaios para screening de alta \ncapacidade, novos modelos traslaciona is para probas de eficacia  in vitro  e \nensaios en paneis  de seguridade e ident ificaci\u00f3n de mol\u00e9culas activas e  \noptimizaci\u00f3n das mesmas  ata chegar a candidatos a desenvolvement o \nprecl\u00ednico, e cl\u00ednico, etc.  \nConta ademais  cunha  quimioteca privile xiada de comp ostos para a \nb\u00fasqueda de hits sobre as dianas candidatas que incl\u00fae  mol\u00e9culas con \ndiversidad e qu\u00edmica e biol\u00f3 xica, f\u00e1rmacos para reposicionam ento  e \ncomp ostos exclusivos anotados biol\u00f3 xicamente . \n\uf0b7 Nanomedicina : Centrase nas seguintes aplicaci\u00f3n:  \n\uf0fc Novos enfoques  para a liberaci\u00f3n de ant\u00edxenos, f\u00e1rmacos \nproteicos e xenes a trav\u00e9s de complexas barreiras corporais \ncomo son a barreira nasal, ocular ou intestinal.  \n\uf0fc Dese\u00f1o e desenvolvemento de novos nanocarriers para a \nliberaci\u00f3n de ant\u00edxenos e investigaci\u00f3n das propiedades  \nadxuvantes -Nanovacinas  \n\uf0fc Dese\u00f1o e desenvolvemento de terapias multidiana que \nconsisten en nanocarriers -multifunci\u00f3n  que conte\u00f1en pequenos \nf\u00e1rmacos e siRNA  \n\uf0fc Investigan o mecanismo de interacci\u00f3n de materiais \nnanoestructurados co ambiente biol\u00f3xico.  \nVII. Plataforma de Bioestat istica : O grupo inclu\u00eddo  neste area transversal \natopase especializado en Modelos Aditivos Xerlizados(GAMs) e nas s\u00faas \naplicaci\u00f3n \u00e1 medicina, biolox\u00eda e ciencias ambientais. As principais li\u00f1as de \ninvestigaci\u00f3n incl\u00faen  estimaci\u00f3n e in ferencia en GAMs con interacci\u00f3ns, \nCurvas ROC con covariantes,  selecci\u00f3n de puntos de corte \u00f3ptimos , \nregresi\u00f3n cuantil, modelos aditivos multiestado(MSM) en supervivencia  \nentre outros.  \n \n   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  7 \u00c1rea de CANCRO  \nAnxo Vidal Figueroa  Cell Cycle and Oncology  \nhttp://www.usc.es/cimus/en/research/research -groups/cell -cycle -and-oncology -\ngroup -ciclon  \nClara \u00c1lvarez Villamar\u00edn  Neoplasia and Endocrine Differentiati on \nhttp://www.usc.es/cimus/en/research/research -groups/neoplasia -and-\ndifferentiation -endocrine -cells  \nRom\u00e1n P\u00e9rez Fern\u00e1ndez  Endocrine Oncology  \nhttp://www.usc.es/cimus/en/research/research -groups/endocrine -oncology  \nJos\u00e9 Antonio Costoya Puente  Molecular Oncology (MOL)  \nhttp://www.usc.es/cimus/en/research/research -groups/molecular -oncology -\nlaboratory  \nCelia M\u00aa Pombo Ramos  Cell Signalling and Stress  \nhttp://www.usc.es/cimus/en/research/research -groups/cellular -signalling -and-\nstress  \nCarmen Rivas  V\u00e1zquez  Virus and Cancer  \nhttp://www.usc.es/cimus/en/research/research -groups/virus -and-cancer   \n\u00c1rea de ENDOCRINOLOX\u00cdA E NUTRICI\u00d3N  \nCarlos Di\u00e9guez Gonz\u00e1lez  Functional Obesomic & Molecular Metabolism  \nhttp://www.usc.es/cimus/en/research/research -groups/functional -obesomics -and-\nmolecular -metabolism  \nMiguel A. L\u00f3pez P\u00e9rez  NeurObesity  \nhttp://www.usc.es/cimus/en/research/research -groups/neurobesity  \nJos\u00e9 Joaqu\u00edn Lado Abeal  Thyroid and Metabolic Disease Unit (UETeM)  \nhttp://www.usc.es/cimus/en/research/research -groups/thyroid -and-metabolic -\ndiseases -unit \nM\u00aa Carmen Garc\u00eda Garc\u00eda  Cytokines and Obesity  \nhttp://www.usc.es/cimus/en/research/research -groups/cytokines -and-obesity  \nRosa M\u00aa Se\u00f1ar\u00eds Rodr\u00edguez  Neuroendocrinology  \nhttp://www.usc.es/cimus/en/research/research -groups/neuroendocrinology -\nenergy -homeostasis -metabolism -and-cancer  \n\u00c1rea de NEUROCIENCIA  \nJos\u00e9 Luis Labandeira Garc\u00eda, M\u00aa \nJosefa Guerra Seijas, Jannette \nRodr\u00edguez Pallar\u00e9s  Parkinson Disease  \nhttp://www.usc.es/cimus/en/research/ research -groups/cell -and-molecular -\nneurobiology -parkinsons -disease  \nAntonio Canedo Lamas  Systems Electrophysiology  \nhttp://www.usc.es/cimus/en/research/research -groups/vivo -electrophysiology -\nsensorimotor -systems  \nFrancisco Gonz\u00e1lez Garc\u00eda  Visual Science  \nhttp:// www.usc.es/cimus/en/research/research -groups/neuroscience -and-\nphysiology -visual -system  \nM\u00aa \u00c1ngeles Castro P\u00e9rez  Molecular Pharmacology of G protein -coupled receptors  \nhttp://www.usc.es/cimus/en/research/research -groups/molecular -pharmacology -\ng-protein -coupled -receptors  \nJes\u00fas Rodr\u00edguez Requena  Molecular Neuropathology  \nhttp://www.usc.es/cimus/en/research/research -groups/brain -protein -malfunction  \n\u00c1rea de CARDIOVASCULAR  \nJ. R. Gonz\u00e1lez Juanatey  Cardiovascular Area  \nhttp://www.usc.es/cimus/en/research/research -groups/cardiovascular -area  \n\u00c1ngel Garc\u00eda Alonso  Platelet Proteomic  \nhttp://www.usc.es/cimus/en/research/research -groups/platelet -proteomics   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  8 Juan Zalvide Torrente  Vascular Biology  \nhttp://www.usc.es/cimus/en/research/research -groups/laboratory -vascular -\nbiology  \nDolores Vi\u00f1a  Cardiovascular Pharmacology  \nhttp://www.usc.es/cimus/en/research/research -groups/pharmacology -chronic -\ndiseases  \n\u00c1rea de F\u00c1RMACOS E TERAPIAS EXPERIMENTAIS  \nM\u00aa Isabel Loza Garc\u00eda  Biofarma  \nhttp://www.usc.es/cimus/en/research/research -groups/pharmacology -applied -\ndrug -discovery  \nM. Jos\u00e9 Alonso Fern\u00e1ndez   Nanobiopharmaceuticals  \nhttp://www.usc.es/cimus/en/research/research -groups/nanobiofar -cimus -\nnanomedicine -and-drug -delivery  \n\u00c1rea de XEN\u00c9TICA Y XEN\u00d3MICA FUNCIONAL  \n\u00c1ngel Carracedo \u00c1lvarez  Genomic Medicine  \nhttp://www.usc.es/cimus/en/research/research -groups/genomics -and-\nbioinformatics  \nFernando Dom\u00ednguez Puente  Oncology Research  \nhttp://www.usc.es/cimus/en/research/research -groups/galician -oncological -\nresearch -group  \nPlataforma BIOESTAT\u00cdSTICA  \nCarmen M\u00aa Cadarso Su\u00e1rez  Biostatistics  \nhttp://www.usc.es/cimus/en/research/research -groups/biostatistics  \nT\u00e1boa 1. Grupos e IPs do CIMUS segudo \u00e1s \u00e1reas   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  9 3. ESTRUTURA E ORGANIZACI\u00d3N  \nO modelo de funcionamento do CI MUS, compartido por todos os Centros Singulares de \nInvestigaci\u00f3n que integran a rede, bas\u00e9ase nos seguintes principios b\u00e1sicos: (1) asesoramento, \nselecci\u00f3n de investigadores e avaliaci\u00f3n continuada da actividade por parte dunha Comisi\u00f3n \nCient\u00edfica Externa; (2) actividade cient\u00edfica baseada nunha planificaci\u00f3n estrat\u00e9xica rigorosa e \nmecanismos de financiamento ligados ao cumprimento de obxectivos; (3) direcci\u00f3n cient\u00edfica \nexecutiva que coordine as capacidades dos g rupos de investigaci\u00f3n do centro; (4) xesti\u00f3n \nespecializada da actividade do centro a trav\u00e9s de \u00f3rganos de xesti\u00f3n espec\u00edficos.  \nEste modelo \u00e9 implementado a trav\u00e9s do organigrama most rado na figura 3.  \n \nComisi\u00f3n Reitora :  \n \nPresidente:   Juan J. Casares long  \nReitor da USC  \nVicepresidente:   Francisco Gonz\u00e1lez Garc\u00eda  \nVicerreitor de Investigaci\u00f3n e Innovaci\u00f3n da USC  \nMembros:   Jos\u00e9  Mar\u00eda Arias Mosquera (Anteriormente Manuel Puga Pereira)  \nPresidente do Consello Social da USC  \nLourdes Bat\u00e1n Aira  \nXerente da USC  \nCarlos Di\u00e9guez Gonz\u00e1lez  \nDirector Comisario del CIMUS  \nRogelio Conde -Pumpido Tour\u00f3n  \nDirector de Xesti\u00f3n e Valorizaci\u00f3n da I+D+i  \nFigura 3. Organigrama dos Centros Singulares   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  10  \nDirector:  \nDirector   Carlos Di\u00e9guez Gonz\u00e1lez  \nComisario   carlos.dieguez@usc.es  \n   Telf. +34881815402  \n    \nComit\u00e9 Cient\u00edfico Extern o  \n \n  M\u00aa Teresa Miras Portugal  \nUniversidade Complutense de Madrid  \n  Mario Barbosa  \n Instituto de Engenharia Biom\u00e9dica (INEB) . Universidade do Porto  \n  Manuel Tena -Sempere  \nInstituto Maimonides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC)  \n  Luis Miguel Garc\u00eda Segura  \nInstituto Cajal -CSIC (Madrid).  \nAdemais o centro conta con persoal da USC asignado \u00f3 CIMUS as\u00ed coma persoal \ncontratado polo centro:  \n\uf0b7 Xesti\u00f3n Econ\u00f3mica e Secretar\u00eda  do centro: M\u00aaLuz Mari\u00f1o \u00e9 a Xefa do Negociado de \nAsuntos Econ\u00f3micos e realiza tam\u00e9n as tarefas de Secretariado do Centro.  \n\uf0b7 \u00c1rea de lavado e esterilizaci\u00f3n: M\u00aaPilar Grueiro, t\u00e9cnico  contratada polo centro para \ndesenvolver estas tarefas, as\u00ed coma dar apoio o servizo t\u00e9cnico dos equipos e os servizo \ncentral de gases do centro.  \n\uf0b7 Servizo de Histolox\u00eda: Ana Senra, t\u00e9cnico  contratada polo centro para este servizo. \nAdemais  encargase da parte  refrixerada do almac\u00e9n.  \n\uf0b7 Animalario: Laura Meil\u00e1n e Ana Torres, t\u00e9cnicos contratadas polo centro para dar soporte \na esta infraestrutura. O investigador Anxo Vidal e o investigador responsable.  \n\uf0b7 Plataforma de Bioinform\u00e1tica: Dr. Jorge Amigo, t\u00e9cnico  de infra estruturas (MINECO) que \nda soporte a esta plataforma.  \n\uf0b7 Instalaci\u00f3n Radiactiva: Conta co Prof. Luis Lima coma supervisor e con Marisol Abella, \nt\u00e9cnico  da USC, coma t\u00e9cnico da mesma.  \n\uf0b7 Xesti \u00f3n, soporte  e calidade : Dra. C. Ruth Gonz\u00e1lez, contratada polo centro p ara realizar \ntarefas de xesti\u00f3n e soporte dos grupos, ademais  de implementar un sistema de calidade  \n\uf0b7 Relaci\u00f3n co IDIS: Yolanda M\u00aa Liste \u00e9 un t\u00e9cnico de administraci\u00f3n encargado da xesti\u00f3n \ndos grupos do CIMUS en relaci\u00f3n \u00f3 IDIS   \n \n   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  11 O persoal do centro rep\u00e1rtese  tal e como se pode observar na t\u00e1boa  2 para as \ndiferentes tarefas:  \n\u00c1rea Administrativa  \u00c1reas T\u00e9cnicas  \u00c1reas Estrat\u00e9xicas  \nNegociado e Secretar\u00eda do \ncentro: M\u00aaLuz Mari\u00f1o  (Xefa \nde negociado)  \nXesti\u00f3n : C. Ruth Gonz\u00e1lez  \nRelaci\u00f3n co IDIS: Yolanda M\u00aa \nListe  Almac\u00e9n:  M\u00aa del Sol Abella e \nAna Senra  \nSala de lavado e \nesterilizaci\u00f3n:  M\u00aa Pilar \nGrueiro  \nGases:  M\u00aa Pilar Grueiro e \nRuth Gonz\u00e1lez  \nNitr\u00f3xeno l\u00edquido:  M\u00aa Pilar \nGrueiro e Marisol Abella  \nAnimalario:  Anxo Vidal (IP \nresponsable), Laura Meil\u00e1n  e \nAna Torres (T\u00e9cnicos)  \nInstalaci\u00f3n Radiactiva : Luis \nLima (Supervisor), Marisol \nAbella (T\u00e9cnico)  \nMantemento de equipos : M\u00aa \nPilar Grueiro . \nPlataforma de \nBioinform\u00e1tica : Dr. Jorge \nAmigo Lechuga  Seminarios : Joseline Ratman, \nCristina Contreras, Marcos \nGarc\u00eda -Fuentes, Samuel \nSeoane (2012 -2013) e \nCristina Contreras, Sulay \nTovar e Amparo P\u00e9rez(2013 -\n2014).  \nT\u00e1boa 2. \u00c1reas de traballos com\u00fan e persoal asignado  \n   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  12 4. INFRAESTRUTURAS DE INVESTIGACI\u00d3N  \nAs instalaci\u00f3ns que alberg an \u00f3 CIMUS foron rematadas en Xu\u00f1o de 2010, e ocupan 12.945 m2. \nCon 39 laboratorios de investigaci\u00f3n de entre 53 y 71 m2 de superficie (2480m2) dese\u00f1ados \ndacordo \u00f3s requisitos de flexibilidade, seguridade e  sostenibilidade actuais, e un equipamento \naxustad o \u00e1s caracter\u00edsticas do traballo a realizar. O edificio ten unha capacidade para albergar \naproximadamente a 250 investigadores. A construci\u00f3n  e equipamento do CIMUS foron \ncofinanciados con fondos FEDER acadados a trav\u00e9 s de convocatorias competitivas.  \nIgual mente, disp\u00f3n de espazos (ata un total de 1.000 m2) para a instalaci\u00f3n de equipamento \ncient\u00edfico de uso xeral, que se distrib\u00faen entre as diferentes plantas facilitando as\u00ed o uso \ncompartido dos equipos dos que dispo\u00f1en os distintos grupos de investigaci\u00f3n do Centro. \nEstes espazos incl\u00faen entre outros: laboratorio de radiois\u00f3topos, laboratorios con equipos \ncom\u00fans, laboratorios de microscop\u00eda, Servizo de histolox\u00eda (para o que hai contratada unha \nt\u00e9cnico, Ana Senra) , cuartos de cultivos, laboratorio de segurid ade P2, sala branca, c\u00e1maras \nfr\u00edas, salas de conxeladores, \u00e1rea de lavado e esterilizaci\u00f3n (que conta cunha t\u00e9cnico, M\u00aa Pilar \nGrueiro) , c\u00e1maras escuras, almac\u00e9n, as\u00ed coma un animalario para pequenos roedores.  Ademais  \no CIMUS conta nas s\u00faas instalaci\u00f3ns co m icroscopio confocal SP5 pertencente a RIADT  \nAs\u00ed mesmo o centro disp\u00f3n de 40 despachos (de 12 m2), 3 salas de reuni\u00f3n (de 21 m2) e un \nauditorio con capacidade para aproximadamente un has 45 persoas, o que facilita en gran \nmedida a organizaci\u00f3n e desenvolvemento de actividades de investigaci\u00f3n, formaci\u00f3n e \ncolabo raci\u00f3n.   \n  \nImaxe 2. Servizo de Histolox\u00eda  \n Imaxe 3. Instalaci\u00f3n radiactiva  Imaxe 1. Equipos de Microscopia: Confocal , Wide -field e fluorescencia  \n \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  13  \n \n \n  \nImaxe 9. Sala P2  \n Imaxe 8. Sala Blanca  \nImaxe 5. Sala de instrumentaci\u00f3n  \ncom\u00fan  \nImaxe 4. Sala de esterilizaci\u00f3n e \nlavado.  \nImaxe 6. Innopharma  \n Imaxe 7. Sala de Cultivo   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  14 Xunto con estas infraestruturas o CIMUS conta con diversas plataformas  (Figura 4)  \nlideradas por grupos do centro  coma son a de Screening Farmacol\u00f3xico (grupo de \nMabel Loza), Nanodelivery (grupo Mar\u00eda Jos\u00e9 Alonso), Prote\u00f3mica (grupo \u00c1ngel  \nGarc\u00eda), Bioestad\u00edstica (grupo Carmen Cadarso), Fenotipado Metab\u00f3lico (Grupo Carlos \nDi\u00e9guez  e Rub\u00e9n Nogueiras ). No caso da plataforma de Bioinform\u00e1tica conta co Dr. \nJorge \u00c1migo, T\u00e9cnico de apoio a infraestruturas do Ministerio de Econom\u00eda e \nCompetitividad e. \n \n \nAdemais  o centro conta cun almac\u00e9n onde as diferentes casas comerciais po\u00f1en a \ndisposici\u00f3n dos investigadores o funxible de uso m \u00e1is com\u00fan no centro, o que vai en \nfavor de diminu\u00edr  os custes e mellora a dispo\u00f1ibilidade de material.  \n  \nFigura 4. Infraestruturas e Plataformas do CIMUS   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  15 5. PLANIFICACI\u00d3N ESTRAT\u00c9XICA  \nTrala realizaci\u00f3n dunha an\u00e1lise DAFO da situaci\u00f3n do CIMUS e o seu  entorno, no ano 2011  o \nComit\u00e9  Cient\u00edfico Externo informa o  Plan Estrat\u00e9xico do CIMUS para o per\u00edodo  2011-2014, que \nfoi posteriormente aprobado pola Comisi\u00f3n Reitora . O plan artellouse entorno a  dez \nobxectivos estrat\u00e9xicos b\u00e1sicos a acadar no cuatrienio inicial de desenvolvemento do centro. \nComo non poder\u00eda ser doutro xeito, estes obxectivos son coherente s cos obxectivos \nestrat\u00e9xicos xerais do proxecto CAMPUS VIDA, en cuxo desenvolvemento o CIMUS \u00e9, xunto \ncos restantes Centros Singulares de Investigaci\u00f3n, unha peza chave.  \nOs obxectivos propostos  no plan foron:  \n1. Desenvolver unha pol\u00edtica de investigaci\u00f3n que  sit\u00fae \u00f3 CIMUS nunha posici\u00f3n de \nexcelencia.  \n2. Impulsar a integraci\u00f3n do CIMUS no campus de excelencia internacional (CAMPUS \nVIDA) as\u00ed como a s\u00faa interacci\u00f3n con diversas  instituci\u00f3ns e centros singulares.  \n3. Dotaci\u00f3n de laboratorios de investigaci\u00f3n en conson ancia cos retos tecnol\u00f3xicos.  \n4. Financiaci\u00f3n suficiente e un sistema de xesti\u00f3n \u00e1xil e eficiente.  \n5. Implantar un sistema de calidade institucional no CIMUS.  \n6. Desenvolver unha pol\u00edtica de transferencia de co\u00f1ecementos.  \n7. Adecuar a oferta das acci\u00f3ns formativas \u00e1s necesidades do persoal do CIMUS e o seu \nentorno.  \n8. Conseguir un Centro que sirva coma  motor de integraci\u00f3n da investigaci\u00f3n biom\u00e9dica \nen Galicia potenciando especialmente  a s\u00faa interacci\u00f3n con Grupos do  IDIS.  \n9. Impulsar a dimensi\u00f3n internacional d o CIMUS en t\u00f3 dolos seus nivei s. \n10. Desenvolver  unha pol\u00edtica de imax e e comunicaci\u00f3n.  \nPara a consecuci\u00f3n destes obxectivos plante x\u00e1ronse unha serie de estratexias, se mostran \nna seguinte t\u00e1boa (t\u00e1boa  3): \nOBXECTIVOS  ESTRATEXIAS  \n1. Desenvolver unha pol\u00edtica de \ninvestigaci\u00f3n que sit\u00fae \u00f3 CIMUS \nnunha posici\u00f3n de excelencia.  a) Identificar \u00e1reas prioritarias , grupos de \ninvestigaci\u00f3n, consolidados e emerxentes . \nb) Consolidar grupos de excelencia e potenciar \ngrupos emerxentes . \nc) Impulsar a cooperaci\u00f3n e xeraci\u00f3n de siner xias \nentre grupos.  \n2. Impulsar a integraci\u00f3n do CIMUS \nno campus de excelencia \ninternacional (CAMPUS VIDA) as\u00ed \ncomo a s\u00faa interacci\u00f3n con diversas  \ninstituci\u00f3ns e centros singulares.  \n a) Promover a implicaci\u00f3n d o CIMUS no \ndesenvolvemento  do CAMPUS VIDA  \nb) Impulsar a interacci\u00f3n d o CIMUS  con o utros \nCentros de Investigaci\u00f3n (CIQUS, IDIS , CITIUS ) \n3. Dotaci\u00f3n de laboratorios de \ninvestigaci\u00f3n en consonancia cos \nretos tecnol\u00f3xicos.  a) Posta en marcha d o centro.  \nb) Desenvolver Plataformas e Servizos Com\u00fa ns de \nApoio.  \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  16 4. Financiaci\u00f3n suficiente e un \nsistema de xesti\u00f3n \u00e1xil e eficiente.  \n a) Incrementar significativamente a captaci\u00f3n de \nfondos.  \nb) Crear un ha estru tura que co\u00f1eza, planifique e \nxestione os recursos econ\u00f3micos.  \n5. Implantar un sistema de calidade \ninstitucional no CIMUS.  a) Formar en calidad e. \nb) Establecer as estruturas necesarias.  \nc) Definir un sistema de informaci\u00f3n que ax ude \u00e1 \ntoma de decisi\u00f3n s. \n6. Desenvolver unha pol\u00edtica de \ntransferencia de co\u00f1ecementos.  a) Promocionar a transferencia de co\u00f1ecementos  e \nos proxectos  de interacci\u00f3n co as empresas e \ninstituci\u00f3n s.  \n7. Adecuar a oferta das acci\u00f3ns \nformativas \u00e1s necesidades do persoal \ndo CIMUS e o seu entorno.  a) Establecer un sistema permanente de \nidentificaci\u00f3n de necesidades.  \nb) Establ ecer un sistema constante de mellora \ncontinua d a oferta educativa d o CIMUS.  \nc) Crear un ha \u00fanica estru tura que co\u00f1ez a, \nplanifique e xestione a  oferta educativa no n regrada  \ndo CIMUS e a s\u00faa  integraci\u00f3n na reg rada d a \nUniversidad e. \nd) Desenvolver  programas de formaci\u00f3n con \nsoporte nas novas  tecnolox\u00edas  que posibiliten un ha \nensinanza m\u00e1 is eficaz, as\u00ed com a a apertura d o CIMUS \na outros escenarios educativos.  \n8. Conseguir un Centro que sirva \ncoma motor de integraci\u00f3n da \ninvestigaci\u00f3n biom\u00e9dica en Galicia \npotenciando especialmente a s\u00faa \ninteracci\u00f3n con Grupos do IDIS.  \n a) Impulsar o desenvolvemento  conxunto de \nproxectos con o utros Grupos d o SUG  e do IDIS.  \nb) Desenvolvemento  de plataformas conxuntas  \nabertas  \u00e1 s\u00faa utilizaci\u00f3n por investigadores do  \nSUG/Sergas.  \n9. Impulsar a dimensi\u00f3n \ninternacional do CIMUS en t\u00f3dolos \nseus niveis.  a) Incrementar a presenza  internacional d o CIMUS.  \nb) Rentabilizar o valor internacional da  nosa oferta \ninvestigadora.  \n10. Desenvolver unha pol\u00edtica de \nimaxe e comunicaci\u00f3n.  a) Desenvolver  unha ima xe de marca CIMUS.  \n \nT\u00e1boa 3. Obxectivos e estratexias do CIMUS   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  17 6. ACTIVIDADE NO CIMUS  \n6.1. ACTIVIDADE CIENT\u00cdFICA  \n6.1.1.  Recursos humanos e captaci\u00f3n de talento  \nNeste mome nto, m\u00e1is de 200  persoas (I Ps, pos tdoutorales, estudant es de doutoramento, \nmaster, fin de grado e persoal t\u00e9cnico) desenvolven a s\u00faa labor no CIMUS.  \nNo per\u00edodo  2012 -2013 produc\u00edronse  os seguintes fitos na ca ptaci\u00f3n de talento:  \n\uf0b7 L\u00edderes de grupo(IPs) :  \nEn maio de 2011 foi lanzada unha convocatoria conxunta USC - CSIC para a incorporaci\u00f3n \nde cient\u00edficos do CSIC no CIQUS e CIMUS. A pesar das condici\u00f3ns incertas da incorporaci\u00f3n \n(debido aos regulamentos institucionais ), foron recibidas d\u00faas manifestaci\u00f3ns de \ninterese, que foron valoradas. Como resultado deste proceso de selecci\u00f3n, foi proposta a \nincorporaci\u00f3n destes cient\u00edficos do CSIC como l\u00edderes do grupo no CIQUS , coa aprobaci\u00f3n \ndo CSIC en 2012 : \n\uf0fc Carmen Rivas V\u00e1zquez: Cient\u00edfica titular do CSIC no Centro Nacional de \nBiotecnolox\u00eda (CNB), en Madrid dende 2007, onde desenvolveu a s\u00faa m\u00e1is \nrecente actividad e e que deu como resultado artigo s publicados en revistas de \nprime iro nivel dentro d a \u00e1rea de virolox\u00eda , oncolox\u00eda e  de biolox\u00eda  celular. A s\u00faa \nli\u00f1a de investigaci\u00f3n \u00e9 complementaria \u00e1 levada a cabo por outros grupos do \nCIMUS dentro da \u00e1rea oncol\u00f3xica. A s\u00faa incorporaci\u00f3n  f\u00edxose  efectiva en abril de \n2013.  \n\uf0fc Jos\u00e9 Requ ejo: Cient\u00edfico da Unidade de Biof\u00edsica do centro mixto CSIC -\nUniversidade do Pais Vasco que  se incorporar\u00eda na \u00e1rea de cancro no CIMUS, \npero  a\u00ednda estase en negociaci\u00f3ns  \n\uf0b7 Asociados Postdoutorais:  Durante o per\u00edodo  2012 -2013 o CIMUS contou cun Contratado \npolo programa Ram\u00f3n y Cajal, Dr. Rub\u00e9n Nogueiras, e 3 Contratados  Parga Pondal, Dra. \nSulay Tovar, Dra. M\u00aa Bego\u00f1a Villar  e o Dr. Marcos Garc\u00eda Fuentes (Actualmente PCD)  e un \ncontratado \u00c1ngeles Alvari\u00f1o, Dr. Juan Parg a, Esther D\u00edaz, Eduardo Dom\u00ednguez e p olas \npostdoutorais da Xunta Modalidade A: Dra. Marta Tojo e Dr. Fernando Torres e na \nmodalidade B(prorroga \u00c1ngeles Alvari\u00f1o):  Dr.Eduardo Dom\u00ednguez, Dra. Mar\u00eda  Jos\u00e9 \n\u00c1lvarez , Dra. Esther D\u00edaz . Por outra banda son 1 9 os doutores que se atopan contratados \ncomo postdourais polos diferentes grupos do centro.   \n\uf0b7 Estudantes de master e de doutoramento : Conforman o groso do persoal do centro \nsendo m\u00e1s de 100 durante este bienio e que proceden de diversos pa\u00edses  coma  Indonesia , \nItalia, Portugal, Swazilandia, Exipto, Francia, India, Azerbaian, Bangladesh, Turkmenistan, \nPakistan.                                                                                                                                                                              \n6.1.2.  Financiamento da investigaci\u00f3n :  \n\uf0b7 Proxectos Internacionais: A captaci\u00f3n de fondos dende a UE sup\u00f3n a maior porcentaxe \ndos ingresos por proxectos competitivos,  sempre por riba do 50%. Son varios os proxectos \nobtidos  neste per\u00edodo , principalmente do  Programa Marco : \n\uf0fc TransINt : Ma r\u00eda Jos\u00e9  Alonso, Carlos Di\u00e9guez    \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  18 \uf0fc ObERStre ss(Staring Grant): Miguel L\u00f3pez  \n\uf0fc OBESITY53 (Staring Grant): Rub\u00e9n Nogueiras;  \n\uf0fc DRUGS4RARE : Mabel Loza  \n\uf0fc EUROFORGENNoE : \u00c1ngel Carracedo)  \n\uf0fc FaBiMed: Jos\u00e9 Ram\u00f3n Gonz\u00e1lez  Juanatey  \n \nMenci\u00f3n aparte merece o Proxecto colaborativo Innopharma  \n(http://innopharmaplatform.com/ ), liderado por dous IPs  do centro, Mabel Loza e \u00c1ngel \nCarracedo, cun presuposto  de 10 Mill\u00f3ns de euros e que se est\u00e1 a  desenvolver no  centro.  \nAdemais  present\u00e1ronse  propostas a outras convocatorias internacionais  como \u00f3 \nprograma COST (pendente  de resoluci\u00f3n ) European Network of Lipodistrophies . O \ncoordinador d esta proposta europea \u00e9 un investigador do  CIMUS: D r.Araujo.  Nas \nInnovative Medicine  Initiative  (http://www.imi.europa.eu/ )  o grupo de Mabel  Loza \nparticipa do proxecto OPEN PHACTS  (http://www.openphacts.org/index.php ).  \n\uf0b7 Proxectos nacionais: Son 16 os proxectos captados polos investigadores do CIMUS e que \nsupo\u00f1en entre o 19% dos recursos captados cada ano. Os organismos financiadores son \nna s\u00faa maior\u00eda o Ministerio de Econom\u00eda e Innovaci\u00f3n e o Instituto de Sa\u00fade Carlos III.  \n\uf0b7 Proxectos Auton\u00f3micos:  Constit\u00faen entre o 15% (2012) e o 20%(2013) dos recursos  \ncaptados polos IPs do CIMUS, inclu\u00edndo  tam\u00e9n os recursos captados pola agrupaci\u00f3n e o \nconvenio asinado entre os centros singulares de investigaci\u00f3n e a Xunta.  \n\uf0b7 Contratos e Convenios:  Supo\u00f1en un elemento variable segundo os anos na financiaci \u00f3n, \npero sempre presente coma unha fonte de ingresos a lternativa.  \nFigura 5. Evoluci\u00f3n da captaci\u00f3n de recursos   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  19  \n6.1.3.  Produci\u00f3n cient\u00edfica e excelencia investigadora :  \n6.1.3.1.  Publicaci\u00f3ns Cient\u00edficas: Cun aumento progresivo das publicaci\u00f3ns, segundo se pode \nobservar na figura  6, durante o bienio 2012 -2013 o 65% das publicaci\u00f3ns pertencen o \nprimeiro cuartil, e incluso o 25% pertencen o primeiro decil (figura 7) o que da boa \ncont a da alta calidade das publicaci\u00f3ns, e que este aumento non foi en d etrimento da \nmesma.  \n \n \nAparellado con este incremento de publicaci\u00f3ns produciuse un increm ento no factor \nde impacto acumulado,  case  duplic\u00e1ndose dende o acadado en 2011, tal e como \npodemos observar na figura 8. \nFigura 7. N\u00ba de publicaci\u00f3ns e distribuci\u00f3n por cuartiles  \nFigura 6. Distribuci\u00f3n porcental das publicaci\u00f3ns por cuartiles   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  20  \nEstes incrementos vence reflectidos no  N\u00ba H dos investigadores do centro que neste \nbienio au mentou un promedio dun 26%.  \nUn 10% das publicaci\u00f3ns neste bienio realiz\u00e1ronse  como resultado dun traballo \ncolaborativo entre diferentes grupos do CIMUS . \n6.1.3.2.  Teses de doutoramento: No bienio 2012 -2013 present\u00e1ronse  43 teses de \ndoutor amento  dirixidas por IPs do centro, 22 en 2012 e 21 en 2013, o cal da mostra da \ncontinua actividade formativa que e mant\u00e9n no centro.  \n6.1.3.3.  Mobilidade de investigadores: O CIMUS  recibiu entre 2012 e 2013 18 investigadores \npara realizar estancias en diferentes grupos do centro, procedentes de pa\u00edses coma \nColombia, Brasil, Francia, Portugal, Turqu\u00eda, Siria, Nepal e Grecia. As\u00ed tam\u00e9n 13 \ninvestigadores do centro realizaron estancias en outros centros localizados en \ndiferentes cidades  de  Suecia, Inglaterra, EE.UU.A, M\u00e9xic o e Francia.  \n6.1.3.4.  Colaboraci\u00f3ns e proxecci\u00f3n internacional:  Das publicaci\u00f3ns do centro en 2012 -2013, \nun 35%  realizouse de forma conxunta con outros grupos internacionais.  \n6.1.3.5.  Premios e reco\u00f1eceme ntos: Durante este bienio investigadores do centro recibiron  \ndiferentes premios e reco\u00f1ecementos:  \n\uf0fc Mabel Loza: Premio Diario M\u00e9dico 2012 \u00e1 Unidade Mixta Esteve -USC,  \n\uf0fc Mabel Loza e \u00c1ngel Carracedo: Premio Diario M\u00e9dico 2013 Proxecto Innopharma  \n\uf0fc  Mar\u00eda  Jos\u00e9 Alonso: Premio Wonenburguer 2013  \nFigura 8. Factor de impacto acumulado das publicaci\u00f3ns   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  21 \uf0fc Carlos Di\u00e9guez:  Premio Novoa Santos de ASOMEGA (2013)  \n\uf0fc \u00c1nge l Garc\u00eda: premio especial d a Fundaci\u00f3n Espa\u00f1ola de Trombosis y \nHemostasia (FETH)  para pro xectos de investigaci\u00f3n b\u00e1sica o u cl\u00ednica relacionados \ncoa trombose  e a hemostas e (2013)  \n6.1.3.6.  Transferencia de tecnolox\u00eda:  \n\uf0b7 Patentes:   Solicit\u00e1ronse  un total de  5 novas patentes neste bienio. Ademais  \nfix\u00e9ronse  9 extensi\u00f3ns internacionais e obtiv\u00e9ronse  8 concesi\u00f3ns  de patentes \nsolicitadas con anterioridade.  \n\uf0b7 Spin -offs: O grupo da prof . Carmen Cadarso constitu\u00edu  unha Spin -off no 2012: \nBiostatech (http://www.biostatech.com/ )  \n6.2. CONFERENCIAS E SEMINARIOS  \n\uf0b7 Organizaci\u00f3n de congresos e workshops internacionais  \nDous dos grupos do centro lideraron a organizaci\u00f3n de  tres congresos internacionais:  \n\uf0fc 37th FEPS Meeting  (Santiago de Compostela 8 -11 Setembro 2012)grupo  de Carlos \nDi\u00e9guez  \n\uf0fc Workshop on Nanomedicine 10 de  Decembro de 2012, Santiago de Compostela,  \ngrupo de Mar\u00eda Jos\u00e9 Alonso  \n\uf0fc Erasmus Mundus Nanofar 21 -25 Outubro de 2013,grupo de Mar\u00eda Jos\u00e9 Alonso.  \nFigura 9. Carteis dos congresos internacionais organizados por investigadores do CIMUS   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  22 \uf0b7 Ciclo de seminarios : Durante o bienio 2012 -2013 celebr\u00e1ronse  un total de 55 \nconferencias no CIMUS con po\u00f1 entes  tanto  estranxeiros  coma nacionais ou do propio \ncentro. Tiveron grande impacto entre elas a do Prof. Inder Verma, celebrada no mes de \nSetembro de 2013, \u00e1 que acudiu un gran n\u00famero de xente. O Comit\u00e9 seminarios  estivo \nintegrado polos doutores  Joseline  Ratman , Cris tina Contrera s, Marcos  Garc\u00eda -Fuentes , \nSamuel  Seoane  (2012 -2013)  e Cristina Contreras , Sulay Tovar e  Amparo P\u00e9rez (2013 -2014) . \n \n \n6.3. DIVULGACI\u00d3N E COMUNICACI\u00d3N  \n\uf0b7 Web www.usc.es/cimus : CIMUS conta cunha web, actualmente en ingle\u00e9s , pero que \nestar\u00e1 dispo\u00f1oble tanto en castel\u00e1n coma en galego. Nesta web ofrecese informaci\u00f3n \ntanto do centro coma dos grupos e actividades do mesmo.  \nImaxe 10. Charla Prof. Inder Verma  \n \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  23 \uf0b7 Researchgate:  Rede social especializada no \u00e1mbito  profesional da investigaci\u00f3n, con m\u00e1is \nde 3 mill\u00f3ns de usuarios (m\u00e1is do 20% do campo da Medicina, o m\u00e1is numeroso), na que \nos investigadores do centro de forma progresiva est\u00e1n a aumentar a s\u00faa presenza e \nmantendo perf\u00eds bastante activos, polo de agora s on 40 os perf\u00eds que ten activos . \n\uf0b7 Facebook https://www.facebook.com/CIMUS.USC: O CIMUS fai a s\u00faa primeira incursi\u00f3n \nnas redes sociais  xerais  a trav\u00e9s desta plataforma, que permitir\u00e1 a interacci\u00f3n cos \ninternautas, podendo co\u00f1ecer \u00e1s s\u00faas opini\u00f3ns e aportac i\u00f3ns.  \n  \n \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  24 \uf0b7 Participaci\u00f3n no blog de Campus Vida, nas secci\u00f3ns de \u201cEn el Laboratorio con\u201d , \u201cEl Futuro \nal Microscopio\u201d e \u201c La Noticia de la Semana\u201d:  O CIMUS realizou un total de 19 \naportaci\u00f3ns entre as 3 secci\u00f3ns, que tentaban acercar a diferentes investigadore s, \nproxectos e noticias a p\u00fablico non especializado.  \n\uf0b7 Presentaci\u00f3n do centro a entorno acad\u00e9mico, empresarial e diplom\u00e1tico:   Durante os \nanos 2012 -2013 o centro recibiu  diferentes visitas procedentes destes entornos, \ninteresado en co\u00f1ecer o centro de primei ra man:  \n\uf0fc Entorno acad\u00e9mico : D\u00faas visitas Reitores  de T\u00fanez: Nos meses de Xullo(05/07/13) e \nSetembro (05/09/13)o CIMUS acolleu sendas visitas de profesores e parte do equipo \nreitoral de universidades tunecinas, no marco dunha visita \u00e1 USC coordinada pola Aul a \nde Alimentos L\u00e1cteos.  \nPresentaci\u00f3n do CIMUS nas Xornadas organizadas polo  Agrupaci\u00f3n Europea de \nCooperaci\u00f3n Territorial Galicia - Norte de Portugal (GNP -AECT) co -organiza, xunto \u00e1  \nFundaci\u00f3n CEER: Por un Crecemento Intelixente na  Eurorrexi\u00f3n Galicia \u2013 Norte de \nPortugal: A transferencia  de co\u00f1ecemento (I+D+i) das Universidades ao tecido  \nprodutivo n o marco da Estratexia 2020 da UE. \nhttp://www.gnpaect.eu/index.php?compone nte=noticias&arch=index&id=536  \n \n\uf0fc Entorno empresarial : Visitas de empresarios de Arxentina , M\u00e9xico, Portugal, Rep\u00fablica \nDominicana, R\u00edo de Xaneiro , Uruguai , Venezuela, Estados Unidos, Arag\u00f3n, Catalu\u00f1a y \nMadrid \u2013 http://www.campusvida.info/ es-noticia -casares -presenta -a-los-empresarios -\ngallegos -en-el-exterior -la-apuesta -de-la-usc-por-generar -valor -social -y-economico/    \nVisita de Directivos  de diferentes empresas entre as que podemos atopar: Novo \nNordisk, Esteve, Sanofi, Pfizer, Almirall, Jans sen Cilag Johnson & Johnson, Glaxo Smith -\nKline, Vivia biotech, Palo Biofarma, Galchimia, Horizon Genomics\u2026 estiveron \nco\u00f1ecendo o centro. e discutindo cos grupos posibles colaboraci\u00f3ns.  \nImaxe 11. Visita de reitores de Tunez   \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  25 \uf0fc Entorno diplom\u00e1tico:  Embaixadores da UE visitaron o CIMUS no marco dunha  visita \u00f3 \nCampus Vida/USC baixo o lema \u201cO valor de investigar\u201d \nhttp://www.campusvida.info/22 -embajadores -de-la-union -euro pea-en-espana -\nconocen -el-valor -de-investigar -en-campus -vida/   \n \nImaxe 12. Visita dos 22 embaixadores da UE  \n  \n\uf0b7 Divulgaci\u00f3n escolar: Dentro do programa da USC \u201cA Ponte\u201d  (prog rama da USC que \npretende tender unha ponte entre o ensino medio e a Unive rsidade) recibimos a visita de \nvarios centros de secundaria: Cole xio Calasanz, A Coru\u00f1a,IES A Pinguela, Monforte de \nLemos(Lugo), CPI Vicente Otero Valc\u00e1rcel, Carral(A Coru\u00f1a), IES Aquis Querquernis, Bande \n(Ourense),IES Celanova Celso Emilio Ferreiro, Celanova (Ourense). \nhttp://www.usc.es/es/perfis/futuros/aponte/ . \n \nImaxe 13. Visita do CPI Vicente Otero Valcarcel de Carral  \nSeminario divulgaci\u00f3n UNistem:  Participaci\u00f3n neste evento internacional sobre c \u00e9lulas \nnai celebrado en diferentes universidades o longo de toda Europa e dirixido a estudantes \nde bacharelato: http://www.campusvida.info/la -noticia -de-la-semana -estudiantes -de-\nsecundaria -de-santiago -exploraran -el-significado -de-las-celulas -madre -en-una-\nexperiencia -internacional -en-la-usc/  \n \n \n \n \n \n \n \n \n \n \n \n \n \nMEMORIA ACTIVIDADE  \n2012 -2013  26  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nI. Recursos humanos  \nII. Proxectos e contratos \ncaptados  \nIII. Proxectos e contratos \nactivos  \nIV. Artigos  \nV. Libros e cap\u00edtulos de libros  \nVI. Teses  \nVII. Patentes  \nVIII. Spin -offs \nIX. Conferencias e seminarios  \nX. Estad\u00edas  \n \n27 \n ANEXO I. RECURSOS HUMANOS  \n\uf0b7 Investigadores Principales:  \nIP Categor\u00eda  \nAnxo Vidal Figueroa  IP \nClara \u00c1lvarez Villamar\u00edn  IP \nRom\u00e1n P\u00e9rez Fern\u00e1ndez  IP \nJos\u00e9 Antonio Costoya Puente  IP \nCelia M\u00aa Pombo Ramos  IP \nJuan Zalvide Torrente  IP \nCarlos Di\u00e9guez Gonz\u00e1lez  IP, Director  \nMiguel A. L\u00f3pez P\u00e9rez  IP \nJos\u00e9 Joaqu\u00edn Lado Abeal  IP \nM\u00aa Carmen Garc\u00eda Garc\u00eda  IP \nRosa M\u00aa Se\u00f1ar\u00eds Rodr\u00edguez  IP \nJos\u00e9 Luis Labandeira Garc\u00eda  IP \nAntonio Canedo Lamas  IP \nFrancisco Gonz\u00e1lez Garc\u00eda  IP \nM\u00aa \u00c1ngeles Castro P\u00e9rez  IP \nJannette Rodr\u00edgu ez Pallar\u00e9s  IP \nJes\u00fas Rodr\u00edguez Requena  IP \nM\u00aa Josefa Guerra Seijas  IP \nJ. R. Gonz\u00e1lez Juanatey  IP \nDolores Vi\u00f1a  IP \nM. Jos\u00e9 Alonso Fern\u00e1ndez  IP \n\u00c1ngel Carracedo \u00c1lvarez  IP \nFernando Dom\u00ednguez Puente  IP \nM\u00aa Isabel Loza Garc\u00eda  IP \n\u00c1ngel Garc\u00eda Alonso  IP \nCarmen M\u00aa Cadarso Su\u00e1rez  IP \nCarmen Rivas V\u00e1zquez  IP,CSIC  \n \n\uf0b7 Investigadores Ram\u00f3n y Cajal, Parga Pondal e Juan de la Cierva:  \nNome  Posto  Data inicio  Data Final  Grupo  \nVillar Cheda, Mar\u00eda \nBego\u00f1a  Contratados Parga Pondal  29/12/2011  28/12/2013  Parkinson Disease  \n \nTovar Carro, Sulay \nA. Contratados Parga Pondal  07/07/2011  30/06/2014  Functional \nObesomic & \nMolecular \nMetabolism  \n \nGarc\u00eda Fuentes, \nMarcos  Contratados Parga Pondal  01/01/20 09 31/12/2012  Nanobiopharmace\nuticals Research  \nNogueiras Pozo, \nRub\u00e9n  Contratados Ram\u00f3 n y Cajal  02/01/2009  01/01/2014  Functional \nObesomic & 28 \n Molecular \nMetabolism  \n \nParga Martin, Juan \nAndres  Contratados \u00c1ngeles \nAlvari\u00f1o  12/01/2010  31/12/2012  Parkinson Disease  \n \nD\u00edaz Rodr\u00edguez, \nEsther  Contratado Postdoutoral \nXUNTA Modalidade \nB(Pr\u00f3rroga \u00c1ngeles  \nAlvari\u00f1o)  26/12/2013  31/12/2014  Neoplasia and \nEndocrine \nDifferentiation  \nDominguez Medina, \nEduardo  Contratado Postdoutoral \nXUNTA Modalidade \nB(Pr\u00f3rroga \u00c1ngeles \nAlvari\u00f1o)  26/12/2013  31/12/2014  Biofarma  \n\u00c1lvarez Berm\u00fadez, \nMar\u00eda Jos\u00e9  Contratado Postdoutoral \nXUNTA Modalidade \nB(Pr\u00f3rroga \u00c1ngeles \nAlvari\u00f1o)  26/12/2013  31/12/2014  Endocrine \nOncology  \nTojo Castro, Marta  Contratado Postdoutoral \nXUNTA Modalidade A  2013  2015  Functional \nObesomic & \nMolecular \nMetabolism  \nTorres And\u00f3n, \nFernando  Contratado Postdoutoral \nXUNTA Modalidade A  2013  2015  Nanobiopharmace\nuticals Research  \n\uf0b7 Persoal de apoio administrativo e t\u00e9cnico:  \nPersoal  Posto  \nM\u00aa Luz Mari\u00f1o  Xefa de Negociado de Asuntos Econ\u00f3micos e Secretaria do centro  \nM\u00aaPilar Grueiro L\u00f3pez  Tecnico servizo esterilizaci\u00f3n e lavado  \nAna Senra Vi\u00f1as  Tecnico servizo histolox\u00eda  \nLaura Meil\u00e1n Pacio  T\u00e9cnico animalario  \nAna M\u00aa Torres Caldas  T\u00e9cnico animalario  \nJorge Amigo Lechuga  T\u00e9cnico Plataforma Bioinform\u00e1tica  \nM\u00aa del Sol Abella Fern\u00e1ndez  T\u00e9cnico Instalaci\u00f3n Radiactiva e Almac\u00e9n  \nCarmen R uth Gonz\u00e1lez  T\u00e9cnico de xesti\u00f3n, soporte e calidade.  \nYolanda M\u00aa Liste Mart\u00ednez  T\u00e9cnio de administraci\u00f3n xesti\u00f3n dos grupos do CIMUS en relaci\u00f3n \u00f3 \nIDIS \n  \n \n29 ANEXO II. PROXECTOS E CONTRATOS DE INVESTIGACI\u00d3N CAPTADOS  \n\u00c1mbito  T\u00edtulo del Proyecto  IP Convocatoria/ Entidad  Importe \ntotal  \n2012  \nAut Consolidaci\u00f3n e estruturaci\u00f3n de unidades de investigaci\u00f3n \ncompetitivas - REDES.  \u00c1lvarez Villamar\u00edn, M. \nClara  Conseller\u00eda de Cultura, Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria  120.000 \u20ac  \nAut Consolidaci\u00f3n e estruturaci\u00f3n de unidades de investigaci\u00f3n \ncompetitivas - Agrupaci\u00f3ns estrat\u00e9xicas.  Di\u00e9guez Gonz\u00e1lez, Carlos  Conseller\u00eda de Cultura, Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria  250.000 \u20ac  \nAut REGID. Consolidacion e estruturacion de unidades de investigacion \ncompetitivas 2012. (Redes)  Loza Garc\u00eda, Mar\u00eda Isabel  Conseller\u00eda de Cultura, Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria  120.000 \u20ac  \nAut SIRT1 y regulaci\u00f3n hed\u00f3nica de la ingesta (Proxectos de Grupos \nEmerxentes).  Nogueiras Pozo, Rub\u00e9n  Conseller\u00eda de Cultura, Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria  98.400 \u20ac  \nAut Papel de los inhibidores del ciclo celular en la biolog\u00eda de las c\u00e9lulas \nmadre normales y tumorales - Proxectos de Grupos Emerxentes  Vidal Figueroa, Anxo  Conseller\u00eda de Cultura, Educac i\u00f3n e \nOrdenaci\u00f3n Universitaria  99.380 \u20ac  \nNac Relaciones funcionales entre las neuronas nociceptivas del \nsubn\u00facleo reticular dorsal y del n\u00facleo reticular gigantocelular en \ngatos anestesiados.  Canedo Lamas, Antonio  6 PN - Biolog\u00eda Fundamental y de Sistemas  152.100 \u20ac  \nNac Sistema renina -angiotensina en la sustancia negra. Demostraci\u00f3n y \ncaracterizaci\u00f3n funcional de un sistema intracrino. Implicaciones en \nenvejecimiento y neurodegeneraci\u00f3n.  Labandeira Garc\u00eda, Jos\u00e9 \nLuis 6 PN - Biolog\u00eda Fundamental y de Sistemas  257.400 \u20ac  \nNac Terapia celular  Labandeira Garc\u00eda, Jos\u00e9 \nLuis FIS - Redes Tem\u00e1ticas de Investigacion \nCooperativa  0 \u20ac \nNac ER Stress hipotal\u00e1mico: un nuevo mecanismo neuroendocrino de \nregulaci\u00f3n del balance energ\u00e9tico. Papel de BiP  L\u00f3pez P\u00e9rez, Miguel \nAntoni o Acci\u00f3n Estrat\u00e9gica de Salud  295.240 \u20ac  \nNac Papel de los receptores opioides como mediadores de las acciones \nneuroendocrinas de la hormona concentradora de melanina (MCH).  Nogueiras Pozo, Rub\u00e9n  6 PN - Biomedicina  204.750 \u20ac  \nNac Cancer de mama: papel de Pi t-1 y CXCR4 en el proceso de \nmet\u00e1stasis. Evaluaci\u00f3n de an\u00e1logos de vitamina D como adyuvantes \nen su tratamiento.  P\u00e9rez Fern\u00e1ndez, Rom\u00e1n  6 PN - Biomedicina  117.000 \u20ac  \nNac Efecto de las c\u00e9lulas madre mesenquimales sobre la supervivencia y \nfuncionalidad de im plantes de c\u00e9lulas dopamin\u00e9rgicas como terapia \npara la enfermedad de Parkinson  Rodr\u00edguez Pallares, \nJannette  Acci\u00f3n Estrat\u00e9gica de Salud  74.415 \u20ac   \n \n30 Nac Papel de los canales de fr\u00edo TRPM8 en la patogenia y fisiopatolog\u00f3ia \nde la obesidad. B\u00fasqueda de nuevas di anas terap\u00e9uticas.  Se\u00f1ar\u00eds Rodr\u00edguez, Rosa \nMar\u00eda  Acci\u00f3n Estrat\u00e9gica de Salud  110.715 \u20ac  \nInt New Oral Nanomedicines: Transporting Therapeutic \nMacromolecules across the Intestinal Barrier (TRANS -INT)  Alonso Fern\u00e1ndez, Mar\u00eda \nJos\u00e9  VII PM - Cooperaci\u00f3n  1.133.12 4 \n\u20ac \nInt NanoFar: European Doctorate in nanomedicine and pharmaceutical \ninnovation  Alonso Fern\u00e1ndez, Mar\u00eda \nJos\u00e9  Erasmus Mundus Programme  350.900 \u20ac  \nInt New Oral Nanomedicines: Transporting Therapeutic \nMacromolecules across the Intestinal Barrier (TRANS -INT) Di\u00e9guez Gonz\u00e1lez, Carlos  VII PM - Cooperaci\u00f3n  276.102 \u20ac  \nInt Drug Repositioning for Rare Diseases (DRUGS4RARE)  Loza Garc\u00eda, Mar\u00eda Isabel  International Rare Disease Research \nConsortium (IRDiRC) -ISCIII  134.000 \u20ac  \nCont  Contrato de Asistencia  Alonso Fern\u00e1nde z, Mar\u00eda \nJos\u00e9  Advanced in Vitro Cell Technologies, S.A.  2.700 \u20ac  \nCont  COLIVAC: novas tecnolox\u00edas para vacinas de E. coli (Feder -\nInnterconecta)  Alonso Fern\u00e1ndez, Mar\u00eda \nJos\u00e9  NANOGAP SUB -NM-POWDER, S.A.  150.000 \u20ac  \nCont  Elaboraci\u00f3n de informe pericial  Carraced o \u00c1lvarez, \u00c1ngel \nMar\u00eda  Estrada, Eduardo  5.000 \u20ac  \nCont  Determinaci\u00f3ns de xen\u00e9tica forense - probas biol\u00f3xicas  Carracedo \u00c1lvarez, \u00c1ngel \nMar\u00eda  Varias entidades  17.644 \u20ac  \nCont  Determinaci\u00f3ns de xen\u00e9tica forense - probas biol\u00f3xicas - 2012 (fase \nII) Carracedo \u00c1l varez, \u00c1ngel \nMar\u00eda  Varias entidades  11.030 \u20ac  \nCont  Determinaci\u00f3ns de xen\u00e9tica forense: probas biol\u00f3xicas - 2012 fase III  Carracedo \u00c1lvarez, \u00c1ngel \nMar\u00eda  Varias entidades  16.664 \u20ac  \nCont  A Randomized Double -blind Pacebo -controlled Phase I/II Trial of \nRNActive \u00ae-derived Cancer Vaccine (CV9104) in Asymptomatic or \nMinimally Symptomatic Patients with Metastatic Castrate -resistant \nProstrate Cancer  Costoya Puente, Jos\u00e9 \nAntonio  ABF Pharmaceutical Services GmbH  0 \u20ac \nCont  Asesor\u00eda T\u00e9cnica en relaci\u00f3n al proyeto 'Evaluac i\u00f3n de genes \nimplicados en la v\u00eda de traducci\u00f3n de la Leptina como dianas \nterap\u00e9uticas para la obesidad'  Di\u00e9guez Gonz\u00e1lez, Carlos  nLife Therapeutics, S.L.  50.000 \u20ac  \nCont  S\u00edntesis y funcionalizaci\u00f3n de AQCs (cl\u00fasteres cu\u00e1nticos \nat\u00f3micos),nanosistemas fluore scentes y nanopart\u00edculas met\u00e1licas y \nmagn\u00e9ticas,caracterizaci\u00f3n fluorescente y magn\u00e9tica,y combinaci\u00f3n \nde estas part\u00edculas con DNA para utilizaci\u00f3n en kits de diagn\u00f3stico  Dom\u00ednguez Puente, \nFernando  NANOGAP SUB -NM-POWDER, S.A.  15.000 \u20ac  \nCont  Proyecto de nan opart\u00edculas de oro conjugadas con cisplatino  Dom\u00ednguez Puente, Nanotargeting, S.L.  1.800 \u20ac   \n \n31 Fernando  \nCont  COLIVAC: novas tecnolox\u00edas para vacinas de E. coli (Feder -\nInnterconecta)  Dom\u00ednguez Puente, \nFernando  NANOGAP SUB -NM-POWDER, S.A.  75.000 \u20ac  \nCont  Screeni ng de compuestos qu\u00edmicos moduladores de la actividad de \nlos receptores de adenosina (Proxecto Innterconecta)  Loza Garc\u00eda, Mar\u00eda Isabel  Palo Biofarma, S.L.  0 \u20ac \nCont  Scientific collaboration with the aim of jointly identifying the targets \nat which compound s in chemical libraries might have, testing a set \nof selected compounds against the set of selected targets and, in the \ncase hits are found, further optimising [...]  Loza Garc\u00eda, Mar\u00eda Isabel  Chemotargets, S.L., Universidade do Minho  0 \u20ac \nCont  Efectos de D HA sobre proliferaci\u00f3n celular en l\u00edneas celulares \ntumorales mamarias  P\u00e9rez Fern\u00e1ndez, Rom\u00e1n  Hausmann -Labomar, S.L.  3.000 \u20ac  \nCont  Report of the Infrafrontier Work Package 5 with explicit construction \nplans of different research facilities  Costoya Puente, J os\u00e9 \nAntonio  Helmholtz Zentrum M\u00fcnchen  0 \u20ac \nConv  Report of the Infrafrontier Work Package 5 with explicit construction \nplans of different research facilities  Costoya Puente, Jos\u00e9 \nAntonio  Helmholtz Zentrum M\u00fcnchen  0 \u20ac \nConv  Proyecto de investigaci\u00f3n: Interac ci\u00f3n de ADN con complejos \norganomet\u00e1licos de Ru(II) y cl\u00fasteres cu\u00e1nticos at\u00f3micos (AQC's)  Dom\u00ednguez Puente, \nFernando  Obra Social 'la Caixa'  262.890 \u20ac  \nConv  Convenio para evaluar los posibles efectos terap\u00e9uticos de las \nc\u00e9lulas madre uterinas en c\u00e1ncer de mama.  P\u00e9rez Fern\u00e1ndez, Rom\u00e1n  FICEMU - Fundaci\u00f3n para la Investigaci\u00f3n en \nCelulas Madre Uterinas  10.039 \u20ac  \nConv  Realizaci\u00f3n de pericias m\u00e9dico -psiqui\u00e1tricas e a formaci\u00f3n neste \n\u00e1mbito  Carracedo \u00c1lvarez, \u00c1ngel \nMar\u00eda  Servizo Galego de Sa\u00fade  12.000 \u20ac  \nConv  Actividades de difusi\u00f3n de calidad y realizaci\u00f3n de actuaciones de \nevaluaci\u00f3n competencia de ENAC  Gonz\u00e1lez Garc\u00eda, Francisco  Entidade Nacional de Acreditaci\u00f3n  0 \u20ac \nConv  Condici\u00f3ns polas que se rexer\u00e1 a colaboraci\u00f3n entre Conseller\u00eda de \nCultura, Educaci\u00f3n e Or denaci\u00f3n Universitaria, a USC e a \nUniversidade de Vigo para complementar as axudas aos l\u00edderes dos \nprogramas starting grants e consolider  L\u00f3pez P\u00e9rez, Miguel \nAntonio  Conseller\u00eda de Cultura, Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria  150.000 \u20ac  \nConv  Condici\u00f3ns po las que se rexer\u00e1 a colaboraci\u00f3n entre Conseller\u00eda de \nCultura, Educaci\u00f3n e Ordenaci\u00f3n Universitaria, a USC e a \nUniversidade de Vigo para complementar as axudas aos l\u00edderes dos \nprogramas starting grants e consolider  Nogueiras Pozo, Rub\u00e9n  Conseller\u00eda de Cult ura, Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria  150.000 \u20ac  \nConv  Prestaci\u00f3n polo grupo GRID [ECMB] de apoio bioestat\u00edstico aos \ngrupos AVEGA (GI -1925) e OMEQUI (GI -2117) dentro das actividades \nde investigaci\u00f3n que desenvolven nos seus proxectos de Cadarso Su\u00e1rez, Carmen \nMar\u00eda  USC 6.000  \u20ac  \n \n32 investigaci\u00f3n [...]  \n2013  \nAut Matrices bioactivas para la supresi\u00f3n de c\u00e9lulas iniciadoras de \nglioma. (EMERXENTES)  Garc\u00eda Fuentes, Marcos  CONSELLERIA DE CULTURA, EDUCACION \nE ORDENACION UNIVERSITARIA  97.000 \u20ac  \nAut Consolidaci\u00f3n e estruturaci\u00f3n. (GPC) GI -2127 Grupo \nInterdis ciplinar de bioestat\u00edstica GRID ECMB.  Cadarso Su\u00e1rez, Carmen \nMar\u00eda  CONSELLERIA DE CULTURA, EDUCACION \nE ORDENACION UNIVERSITARIA  70.000 \u20ac  \nAut Consolidaci\u00f3n e estruturaci\u00f3n. (GPC) GI -2119 Mecanismos \nmoleculares da enfermedade MeMoEn.  Zalvide Torrente, Juan \nBautista  CONSELLERIA DE CULTURA, EDUCACION \nE ORDENACION UNIVERSITARIA  70.000 \u20ac  \nAut Consolidaci\u00f3n e estruturaci\u00f3n. (GRC) GI -1233 Grupo de \ninvestigaci\u00f3ns biom\u00e9dicas GIB.  Di\u00e9guez Gonz\u00e1lez, \nCarlos  CONSELLERIA DE CULTURA, EDUCACION \nE ORDENACION UNIVERSITARIA  370.000 \n\u20ac \nAut Consolidaci\u00f3n e estruturaci\u00f3n. (GRC) GI -1736 Medicina \nXen\u00f3mica GMX.  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  CONSELLERIA DE CULTURA, EDUCACION \nE ORDENACION UNIVERSITARIA  370.000 \n\u20ac \nAut Consolidaci\u00f3n e estruturaci\u00f3n. (GPC) GI -1847 Unidade de \nInvestigaci \u00f3n en Cardiolox\u00eda Celular e Molecular.  Gonz\u00e1lez Juanatey, Jos\u00e9 \nRam\u00f3n  CONSELLERIA DE CULTURA, EDUCACION \nE ORDENACION UNIVERSITARIA  70.000 \u20ac  \nAut Colaboraci\u00f3n entre a Conseller\u00eda de Cultura, Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria e as universidades do SUG para  o \nfinanciamento de centros de investigaci\u00f3n (CIMUS)  Di\u00e9guez Gonz\u00e1lez, \nCarlos  CONSELLERIA DE CULTURA, EDUCACION \nE ORDENACION UNIVERSITARIA  100.000 \n\u20ac \nAut Consolidaci\u00f3n e estruturaci\u00f3n de unidades de investigaci\u00f3n \ncompetitivas - Agrupaci\u00f3ns estrat\u00e9xicas..  Di\u00e9guez Gonz\u00e1lez, \nCarlos  Conseller\u00eda de Cultura, Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria  250.000 \n\u20ac \nNac Red de terapia celular (TERCEL)  Labandeira Garc\u00eda, Jos\u00e9 \nLuis INSTITUTO DE SALUD CARLOS III  20.500 \u20ac  \nNac Terapia celular  Labandeira Garc\u00eda, Jos\u00e9 \nLuis INSTIT UTO DE SALUD CARLOS III  73.600 \u20ac  \nNac Plataforma de recursos biomoleculares e bioinform\u00e1ticos, \nPRB2.  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  MINISTERIO DE ECONOMIA Y \nCOMPETITIVIDAD  335.876 \n\u20ac \nNac The obesity paradox in multiple prevalent diseases: a \ntranslational a pproach.  Gonz\u00e1lez Juanatey, Jos\u00e9 \nRam\u00f3n.   INSTITUTO DE SALUD CARLOS III.  302.500 \n\u20ac \nNac Construcci\u00f3n de un array de variaci\u00f3n funcional en exomas de \npoblaci\u00f3n espa\u00f1ola: B\u00fasqueda de genes implicados en c\u00e1ncer \ncolorrectal y en respuesta al tratamiento quimio ter\u00e1pico  Jorge Amigo, Maria \nTorres, Ines Quintela, \nBeatriz Sobrino, Raquel FPGMX  238.975 \n\u20ac  \n \n33 Cruz, Catuxa Celeiro  \nNac Crosstalk: catecolaminas, activaci\u00f3n del inflamasoma de la \ngrasa epic\u00e1rdica y disfunci\u00f3n endotelial y mioc\u00e1rdica. Nuevas \ndianas terap\u00e9utica s. Sonia Eiras Penas  Sociedad espa\u00f1ola de cardiolog\u00eda y \nFundaci\u00f3n espa\u00f1ola del coraz\u00f3n para \ninvestigaci\u00f3n b\u00e1sica en cardiolog\u00eda. \n10/2013 - 09/2014.  18.000 \u20ac  \nNac RED CARDIOVASCULAR.  Gonz\u00e1lez Juanatey, Jos\u00e9 \nRam\u00f3n.  INSTITUTO DE SALUD CARLOS III  69.000 \u20ac  \nNac Actividad endocrina de la grasa epic\u00e1rdica como indicador en \nla insuficiencia cardiaca.  Sonia Eiras Penas    67.760 \u20ac  \nNac Estudio del papel de los transcritos de BSCL2 en la \nadipog\u00e9nesis y en la Neurog\u00e9nesis  David Araujo    68.365 \u20ac  \nInt NanoFar: Europ ean Doctorate in nanomedicine and \npharmaceutical innovation  Alonso Fern\u00e1ndez, \nMar\u00eda Jos\u00e9  COMISION EUROPEA  245.600 \n\u20ac \nInt Fabrication and Functionalization of Biomedical Microdevices \n(FaBiMed)   Jos\u00e9 Ram\u00f3n Gonz\u00e1lez \nJuanatey (l\u00edder de \nnodo).  Uni\u00f3n Europea (F P7) 79.520 \u20ac  \nInt Discovery of rare and ultra -rare frequency Saudi population \nvariation in colorrectal cancer genes  Carracedo \u00c1lvarez  Mahmood Rasool    \nInt Innopharma      3.491.91\n6 \u20ac \nCont  Asesoramento cient\u00edfico e t\u00e9cnico naqueles proxectos \nrelacionados c on aplicaci\u00f3ns biom\u00e9dicas das nanopart\u00edculas, \nnanofibras e AQCs nos que Nanogap estea involucrado  Dom\u00ednguez Puente, \nFernando  NANOGAP SUB -NM-POWDER, S.A.  10.800 \u20ac  \nCont  Determinaci\u00f3ns de xen\u00e9tica forense: probas biol\u00f3xicas - 2013  Carracedo \u00c1lvarez, \n\u00c1ngel Ma r\u00eda Varias entidades  17.840 \u20ac  \nCont  COLIVAC: novas tecnolox\u00edas para vacinas de E. coli (Feder -\nInnterconecta)  Dom\u00ednguez Puente, \nFernando  NANOGAP SUB -NM-POWDER, S.A.  75.000 \u20ac  \nCont  COLIVAC: novas tecnolox\u00edas para vacinas de E. coli (Feder -\nInnterconecta)  Alon so Fern\u00e1ndez, \nMar\u00eda Jos\u00e9  NANOGAP SUB -NM-POWDER, S.A.  150.000 \n\u20ac \nCont  Avaliaci\u00f3n da actividade antiinflamatoria de omega -3 P\u00e9rez Fern\u00e1ndez, \nRom\u00e1n  BIOMEGA NATURAL NUTRIENTS, S.L.  35.000 \u20ac   \n \n34 Cont  Effects of Rivaroxaban on Endothelial Cells: Evidence for \nLower Risks  Gonz\u00e1lez Juanatey, Jos\u00e9 \nRam\u00f3n  BAYER HISPANIA, S.L.  76.450 \u20ac  \nConv  Convenio para evaluar los posibles efectos terap\u00e9uticos de las \nc\u00e9lulas madre uterinas en c\u00e1ncer de mama.  P\u00e9rez Fern\u00e1ndez, \nRom\u00e1n  FUNDACION PARA LA INVESTIGACION \nEN CELULAS MADRE UTERI NAS \n(FICEMU)  20.000 \u20ac  \nConv  Colaboraci\u00f3n e asesoramento para a Plataforma de \nnanomedicina 2011  Alonso Fern\u00e1ndez, \nMar\u00eda Jos\u00e9  FUNDACIO INSTITUT DE BIOENGINYERIA \nDE CATALUNYA  2.000 \u20ac  \nConv  Encontro Tecnol\u00f3xico para a An\u00e1lise dunha Base de Datos \nUtilizando Tec nolox\u00eda Matem\u00e1tica  Cadarso Su\u00e1rez, Carmen \nMar\u00eda  RED ESPA\u00d1OLA MATEMATICA -\nINDUSTRIA (MATH -IN) 600 \u20ac  \nConv  Desenvolvemento de actividades de investigaci\u00f3n \nrelacionadas coa identificaci\u00f3n de factores xen\u00e9ticos \nasociados a diversas enfermidades  Carracedo \u00c1lvare z, \n\u00c1ngel Mar\u00eda  CIBER DE SALUD MENTAL (CIBERSAM)  37.186 \u20ac  \n \nANEXO III . PROXECTOS ACTIVOS 2014  \n\u00c1mbito  Titulo  IP Contratante -Financiador  Data \nInicial  Data \nFinal  Total  \nImporte  \nAut As celulas GPS o c\u00e9lulas nai na hipofise: \nAmplificaci\u00f3n, diferenciaci\u00f3n e poten cialidade \nterap\u00e9utica  \u00c1lvarez Villamar\u00edn, \nM. Clara  PGIDT - 2007 - Biomedicina e \nciencias da sa\u00fade (CSA)  06/08/200\n9 03/12/201\n2 86.124,65 \n\u20ac \nAut Estudo do procesamento nociceptivo a nivel talamico  Canedo Lamas, \nAntonio  PGIDT - 2007 - Biomedicina e \nciencias d a sa\u00fade (CSA)  06/08/200\n9 03/12/201\n2 62.675 \u20ac  \nAut Identificaci\u00f3n de biomarcadores plaquetarios en \nenfermidades cardiovasculares mediante prote\u00f3mica \ncl\u00ednica  Garc\u00eda Alonso, \u00c1ngel  PGIDT - PXI (Programa Xeral de \nInvestigaci\u00f3n)  22/09/200\n9 31/10/201\n2 41.626 \u20ac  \nAut Estudo da mutua regulaci\u00f3n entre angiotensina e \ndopamina nos ganglios baseles. Potencial implicaci\u00f3n \nna xeneraci\u00f3n de estr\u00e9s oxidativo e \nneuroinflamaci\u00f3n  Guerra Seijas, Mar\u00eda \nJos\u00e9  PGIDT - PXI (Programa Xeral de \nInvestigaci\u00f3n)  13/07/200\n9 01/12/201\n2 89.54 5 \u20ac \nAut Relevancia da via de MTOR na resposta a isquemia e \nreperfusi\u00f3n  Pombo Ramos, Celia \nMar\u00eda  PGIDT - PXI (Programa Xeral de \nInvestigaci\u00f3n)  13/07/200\n9 01/12/201\n2 90.513 \u20ac   \n \n35 Aut Consolidaci\u00f3n e estruturaci\u00f3n de unidades de \ninvestigaci\u00f3n competitivas (Grup os de referencia \ncompetitiva)  Alonso Fern\u00e1ndez, \nMar\u00eda Jos\u00e9  Conseller\u00eda Educaci\u00f3n - Programa \nxeral de consolidaci\u00f3n e \nestruturaci\u00f3n do sistema galego de \nI+D+i  01/01/201\n0 15/11/201\n2 168.000 \u20ac  \nAut Un nuevo s\u00edndrome neurodegenerativo asociado a la \nmutaci\u00f3n R2 65X en el gen BSCL2: caracterizaci\u00f3n \ncl\u00ednica y molecular.  Ara\u00fajo Vilar, David  PGIDT - PXI (Programa Xeral de \nInvestigaci\u00f3n)  10/08/201\n0 30/09/201\n3 68.407 \u20ac  \nAut Identificaci\u00f3n de novos compostos activos no \nreceptor GPR35, un receptor orfo relacionado coa \nasma e a diabete.  Cadavid Torres, \nMar\u00eda Isabel  PGIDT - Biomedicina e Ciencias da \nSa\u00fade  08/08/201\n0 30/09/201\n3 72.542 \u20ac  \nAut Consolidaci\u00f3n e estruturaci\u00f3n de unidades de \ninvestigaci\u00f3n competitivas (Grupos de referencia \ncompetitiva)  Carracedo \u00c1lvarez, \n\u00c1ngel Mar \u00eda Conseller\u00eda Educaci\u00f3n - Programa \nxeral de consolidaci\u00f3n e \nestruturaci\u00f3n do sistema galego de \nI+D+i  01/01/201\n0 15/11/201\n2 168.000 \u20ac  \nAut Funcionalidade e regulaci\u00f3n fisiol\u00f3xica dos \nhomodimeros de GPCRS: o homodimero do receptor \n5-HT2A.  Castro P\u00e9rez, Mar\u00ed a \nde los \u00c1ngeles  PGIDT - PXI (Programa Xeral de \nInvestigaci\u00f3n)  10/08/201\n0 30/09/201\n3 76.583 \u20ac  \nAut Nanomedicamentos xen\u00e9ticos para o tratamento do \ncancro  Csaba, Noem\u00ed \nStefan\u00eda  PGIDT - PXI (Programa Xeral de \nInvestigaci\u00f3n)  10/08/201\n0 30/09/201\n3 67.390 \u20ac  \nAut Estudio da actividade neuronal no putamen ante \nunha tarefa multisensorial.  Gonz\u00e1lez Garc\u00eda, \nFrancisco  PGIDT - PXI (Programa Xeral de \nInvestigaci\u00f3n)  10/08/201\n0 30/09/201\n3 76.434 \u20ac  \nAut Sistema renina -angiotensina cerebral como diana \nterap\u00e9utica para desar rollo de terapia \nneuroprotectora en enfermedad de Parkinson.  Labandeira Garc\u00eda, \nJos\u00e9 Luis  PGIDT - Biomedicina e Ciencias da \nSa\u00fade  08/08/201\n0 30/09/201\n3 73.025 \u20ac  \nAut Un nuevo mecanismo de regulaci\u00f3n del balance \nenerg\u00e9tico: la kinasa activada por AMP hipota l\u00e1mica \ncomo moduladora del metabolismo central y \nperif\u00e9rico.  L\u00f3pez P\u00e9rez, Miguel \nAntonio  PGIDT - PXI (Programa Xeral de \nInvestigaci\u00f3n)  10/08/201\n0 30/09/201\n3 59.168 \u20ac  \nAut Desenvolvemento dun protocolo multilocus para o \ntipado xen\u00e9tico de alto rendemento da s variedades \nde giardia que parasitan humanos  Maside Rodr\u00edguez, \nJulio Manuel  PGIDT - Biomedicina e Ciencias da \nSa\u00fade  08/08/201\n0 30/09/201\n3 71.414 \u20ac  \nAut Consolidaci\u00f3n e estruturaci\u00f3n de unidades de \ninvestigaci\u00f3n competitivas (Grupos emerxentes \npromovidos p or investigadores mozos)  Nogueiras Pozo, \nRub\u00e9n  Conseller\u00eda Educaci\u00f3n - Programa \nxeral de consolidaci\u00f3n e \nestruturaci\u00f3n do sistema galego de 01/01/201\n0 15/11/201\n2 90.000 \u20ac   \n \n36 I+D+i  \nAut Papel de PIT -1 en mat\u00e1stasis de c\u00e1ncer de mama.  P\u00e9rez Fern\u00e1ndez, \nRom\u00e1n  PGIDT - PXI (Programa Xeral de \nInvestigaci\u00f3n)  10/08/201\n0 30/09/201\n3 39.100 \u20ac  \nAut S\u00edntese de novos derivados heteroc\u00edclicos e estudo \nda s\u00faa actividade biol\u00f3xica en enfermidades \nasociadas ao envellecemento.  Vi\u00f1a Castelao, Mar\u00eda \nDolores  PGIDT - PXI (Programa Xe ral de \nInvestigaci\u00f3n)  10/08/201\n0 30/09/201\n3 55.131 \u20ac  \nAut Consolidaci\u00f3n e estruturaci\u00f3n de unidades de \ninvestigaci\u00f3n competitivas (Grupos de referencia \ncompetitiva)  Labandeira Garc\u00eda, \nJos\u00e9 Luis  Conseller\u00eda de Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria - Axudas \npara a consolidaci\u00f3n e \nestruturaci\u00f3n de unidades do SUG  01/01/201\n1 31/10/201\n3 168.000 \u20ac  \nAut Consolidaci\u00f3n e estruturaci\u00f3n de unidades de \ninvestigaci\u00f3n competitivas (Grupos de referencia \ncompetitiva)  Loza Garc\u00eda, Mar\u00eda \nIsabel  Conseller\u00eda de Educaci\u00f3n e \nOrde naci\u00f3n Universitaria - Axudas \npara a consolidaci\u00f3n e \nestruturaci\u00f3n de unidades do SUG  01/01/201\n1 31/10/201\n3 168.000 \u20ac  \nAut Consolidaci\u00f3n e estruturaci\u00f3n de unidades de \ninvestigaci\u00f3n competitivas - REDES.  \u00c1lvarez Villamar\u00edn, \nM. Clara  Conseller\u00eda de Cultura,  Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria  17/06/201\n2 16/06/201\n4 120.000 \u20ac  \nAut Consolidaci\u00f3n e estruturaci\u00f3n de unidades de \ninvestigaci\u00f3n competitivas - Agrupaci\u00f3ns \nestrat\u00e9xicas..  Di\u00e9guez Gonz\u00e1lez, \nCarlos  Conseller\u00eda de Cultura, Educaci\u00f3n e \nOrdenaci\u00f3n Universi taria  17/06/201\n2 30/11/201\n3 500.000 \u20ac  \nAut REGID. Consolidacion e estruturacion de unidades de \ninvestigacion competitivas 2012. (Redes)  Loza Garc\u00eda, Mar\u00eda \nIsabel  Conseller\u00eda de Cultura, Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria  17/06/201\n2 16/06/201\n4 120.000 \u20ac  \nAut SIRT1 y regulaci\u00f3n hed\u00f3nica de la ingesta (Proxectos \nde Grupos Emerxentes).  Nogueiras Pozo, \nRub\u00e9n  Conseller\u00eda de Cultura, Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria  26/06/201\n2 25/06/201\n5 98.400 \u20ac  \nAut Papel de los inhibidores del ciclo celular en la \nbiolog\u00eda  de las c\u00e9lulas madre normales y tumorales - \nProxectos de Grupos Emerxentes  Vidal Figueroa, Anxo  Conseller\u00eda de Cultura, Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria  26/06/201\n2 25/06/201\n5 99.380 \u20ac  \nNac RECAVA  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  FIS - Redes Tem\u00e1ticas de  \nInvestigacion Cooperativa  01/01/200\n8 31/05/201\n3 34.740 \u20ac  \nNac Red tem\u00e1tica de investigaci\u00f3n cooperativa en \nBiomedicina Computacional (COMBIOMED)  Loza Garc\u00eda, Mar\u00eda \nIsabel  FIS - Redes Tem\u00e1ticas de \nInvestigacion Cooperativa  01/01/200\n8 31/12/201\n3 381.405 \u20ac  \nNac Nanovacinas: dese\u00f1o de nanoestruturas polim\u00e9ricas \npara inmunizaci\u00f3n  Alonso Fern\u00e1ndez, \nMar\u00eda Jos\u00e9  FIS 01/01/200\n9 30/06/201\n2 161.777 \u20ac  \nNac Modelos Aditivos Generalizados en estudios de \nasociaci\u00f3n, predicci\u00f3n y clasificaci\u00f3n. Aplicaciones en Cadarso Su\u00e1rez, \nCarmen Mar\u00eda  6 PN - Matem\u00e1ticas  01/01/200\n9 31/12/201\n2 106.843 \u20ac   \n \n37 Medicina y B iolog\u00eda  \nNac Cribado farmacol\u00f3gico de f\u00e1rmacos neurog\u00e9nicos \ncomo tratamiento innovador de enfermedades \nneurodegenerativas  Cadavid Torres, \nMar\u00eda Isabel  6 PN - Biomedicina  01/01/ 201\n0 31/12/201\n2 81.070 \u20ac  \nNac Estudio electrofisiol\u00f3gico de las neuronas tal\u00e1micas \nnociceptivas en gatos anestesiados  Canedo Lamas, \nAntonio  6 PN - Fisiolog\u00eda y farmacolog\u00eda  01/01/201\n0 31/12/201\n2 183.920 \u20ac  \nNac Caracterizaci\u00f3n molecular de los mecanismos \nimplicados en la transici\u00f3n de gliomas de bajo a alto \ngrado  Costoya Puente, Jos\u00e9 \nAntonio  6 PN - Biomedicina  01/01/201\n0 31/12/201\n2 72.600 \u20ac  \nNac Nanomedicinas con capacidad quimiot\u00e1ctica como \nsistemas supresores de la tumorogenicidad en \nglioblastomas  Csaba, N oem\u00ed \nStefan\u00eda  FIS 01/01/201\n0 30/06/201\n3 77.440 \u20ac  \nNac Dise\u00f1o de Nanopart\u00edculas Inorg\u00e1nicas conjugadas: \nNuevas herramientas para el tratamiento del c\u00e1ncer  Dom\u00ednguez Puente, \nFernando  6 PN - Ciencia y tecnolog\u00eda de \nmateriales  01/01/201\n0 31/12/201\n2 60.500 \u20ac  \nNac Interacci\u00f3n entre el sistema dopamin\u00e9rgico \nnigroestriatal y el sistema renina angiotensina local  Labandeira Garc\u00eda, \nJos\u00e9 Luis  6 PN - Fisiolog\u00eda y farmacolog\u00eda  01/01/201\n0 31/12/201\n2 308.550 \u20ac  \nNac Acciones de las orexinas y la hormona concentradora \nde me lanina sobre el metabolismo lip\u00eddico y de la \nclucosa, un nuevo mecanismo neuroendocrino de \nregulaci\u00f3n del balance energ\u00e9tico  L\u00f3pez P\u00e9rez, Miguel \nAntonio  FIS 01/01/201\n0 15/03/201\n3 246.840 \u20ac  \nNac Contribuci\u00f3n farmacol\u00f3gica a enfoques moleculares \ninnovadores en farmacolog\u00eda antipsic\u00f3tica  Loza Garc\u00eda, Mar\u00eda \nIsabel  6 PN - Biomedicina  01/01/201\n0 31/12/201\n2 141.570 \u20ac  \nNac Papel de los receptores opioides en la regulaci\u00f3n \nneuroendocrina de la ingesta y la homeostasis de la \nmasa corporal  Nogueiras Pozo, \nRub\u00e9n  6 PN - Fisiolog\u00eda y farmacolog\u00eda  01/01/201\n0 31/12/201\n2 145.200 \u20ac  \nNac Factor de transcripci\u00f3n Pit -1 y c\u00e1ncer de mama  P\u00e9rez Fern\u00e1ndez, \nRom\u00e1n  6 PN - Biomedicina  01/01/201\n0 31/12/201\n2 121.000 \u20ac  \nNac Discover -multidisciplinary project investigating the \nneurobiology of chronic  Rodr\u00edguez Requena, \nJes\u00fas  FIS 01/01/201\n0 31/12/201\n3 102.487 \u20ac  \nNac Funci\u00f3n de TRPM8 y TRPA1 en la homeostasis \nt\u00e9rmica y metab\u00f3lica  Se\u00f1ar\u00eds Rodr\u00edguez, \nRosa Mar\u00eda  6 PN - Fisiolog\u00eda y farmacolog\u00eda  01/01/201\n0 31/12/201\n2 121.000 \u20ac  \nNac CKIs as tumor s uppressors: roles on and beyond cell \ncycle  Vidal Figueroa, Anxo  6 PN - Biomedicina  01/01/201\n0 31/12/201\n3 145.200 \u20ac  \nNac Mecanismos fisiopatol\u00f3gicos implicados en la \u00c1lvarez Villamar\u00edn, 5 PN - Biolog\u00eda fundamental  01/01/201 31/12/201 205.700 \u20ac   \n \n38 proliferaci\u00f3n de las c\u00e9lulas foliculares tiroideas \nhumanas  M. Clara  1 3 \nNac Formaci\u00f3n de una red nacional de bioestad\u00edstica  Cadarso Su\u00e1rez, \nCarmen Mar\u00eda  Acci\u00f3ns complementarias  12/04/201\n0 14/11/201\n2 11.200 \u20ac  \nNac RESAC (Resistencia a la aspirina y al clopidogrel). \nFarma cogen\u00e9tica de antiagregantes plaquetarios.  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Programa nacional de \ninternacionalizaci\u00f3n de la I+D - \nSubprograma proyectos \ninternacionales  15/12/201\n0 14/12/201\n3 99.000 \u20ac  \nNac An\u00e1lisis prote\u00f3mico de las micropart\u00edculas y el \nsecret oma de las plaquetas como fuente de \nbiomarcadores para el s\u00edndrome coronario agudo  Garc\u00eda Alonso, \u00c1ngel  6 PN - Medicina cl\u00ednica y \nepidemiolog\u00eda  01/01/201\n1 31/12/201\n3 108.900 \u20ac  \nNac Mejora de revisi\u00f3n administrativa en la justificaci\u00f3n \nde proyectos FEDER de  la Universidade de Santiago \nde Compostela. Acci\u00f3n Complementaria, Modalidad \nG Gonz\u00e1lez Garc\u00eda, \nFrancisco  Acci\u00f3ns complementarias  16/12/201\n0 24/05/201\n3 60.000 \u20ac  \nNac Integraci\u00f3n visual, auditiva y motora en los ganglios \nbasales  Gonz\u00e1lez Garc\u00eda, \nFrancisco  6 PN - Biolog\u00eda Molecular y de \nSistemas  01/01/201\n1 31/12/201\n3 41.140 \u20ac  \nNac Estudio de la interacci\u00f3n de nanomateriales con \nant\u00edgenos: una aproximaci\u00f3n sistem\u00e1tica para el \ndesarrollo de nanovacunas (subproyecto).  Alonso Fern\u00e1ndez, \nMar\u00eda Jos\u00e9  6 PN - Biomedic ina 01/01/201\n2 31/12/201\n4 181.500 \u20ac  \nNac Consolidaci\u00f3n de la red biostatnet: nuevas estregias \nde colaboraci\u00f3n en investigaci\u00f3n, transferencia y \nformaci\u00f3n  Cadarso Su\u00e1rez, \nCarmen Mar\u00eda  Acci\u00f3ns complementarias  01/06/201\n2 31/05/201\n4 37.000 \u20ac  \nNac Inferencia en  Modelos Aditivos Generalizados: \nextensiones al an\u00e1lisis ROC con covariables, \nregresi\u00f3n cuantil y an\u00e1lisis de supervivencia. \nAplicaciones en Medicina y Biolog\u00eda (Subproyecto).  Cadarso Su\u00e1rez, \nCarmen Mar\u00eda  6 PN - Matem\u00e1ticas  01/01/201\n2 31/12/201\n4 96.558 \u20ac  \nNac Regulaci\u00f3n de la ingesta por ghrelin.  Di\u00e9guez Gonz\u00e1lez, \nCarlos  6 PN - Biomedicina  01/01/201\n2 31/12/201\n4 350.900 \u20ac  \nNac CONTRATACI\u00d3N T\u00c9CNICOS DE APOIO - Modalidade \ninfraestructuras  Gonz\u00e1lez Garc\u00eda, \nFrancisco   07/11/201\n1 06/12/201\n4 0 \u20ac \nNac HUMANFARMA  Loza Garc\u00eda, Mar\u00eda \nIsabel  6 PN Subprograma INNPACTO - \nMinisterio de Ciencia e Innovaci\u00f3n  04/05/201\n1 31/12/201\n3 373.751 \u20ac  \nNac Polyfarma: nuevas terapias para Parkinson.  Loza Garc\u00eda, Mar\u00eda 6 PN Subprograma INNPACTO - 04/05/201 31/12/201 144.694 \u20ac   \n \n39 Isabel  Ministerio de Ciencia e Innovaci\u00f3n  1 3 \nNac Estudio funcional de CCM3 y kinasas GCKIII  Zalvide Torrente, \nJuan Bautista  6 PN - Biomedicina  01/01/201\n2 31/12/201\n4 108.900 \u20ac  \nNac Relaciones funcionales entre las neuronas \nnociceptivas del subn\u00facleo reticular dorsal y d el \nn\u00facleo reticular gigantocelular en gatos \nanestesiados.  Canedo Lamas, \nAntonio  6 PN - Biolog\u00eda Fundamental y de \nSistemas  01/01/201\n3 31/12/201\n5 152.100 \u20ac  \nNac Sistema renina -angiotensina en la sustancia negra. \nDemostraci\u00f3n y caracterizaci\u00f3n funcional de un  \nsistema intracrino. Implicaciones en envejecimiento \ny neurodegeneraci\u00f3n.  Labandeira Garc\u00eda, \nJos\u00e9 Luis  6 PN - Biolog\u00eda Fundamental y de \nSistemas  01/01/201\n3 31/12/201\n5 257.400 \u20ac  \nNac Terapia celular  Labandeira Garc\u00eda, \nJos\u00e9 Luis  FIS - Redes Tem\u00e1ticas de \nInve stigacion Cooperativa  01/01/201\n3 31/05/201\n4 0 \u20ac \nNac ER Stress hipotal\u00e1mico: un nuevo mecanismo \nneuroendocrino de regulaci\u00f3n del balance \nenerg\u00e9tico. Papel de BiP  L\u00f3pez P\u00e9rez, Miguel \nAntonio  Acci\u00f3n Estrat\u00e9gica de Salud  01/01/201\n3 31/12/201\n5 295.240 \u20ac  \nNac Papel de los receptores opioides como mediadores \nde las acciones neuroendocrinas de la hormona \nconcentradora de melanina (MCH).  Nogueiras Pozo, \nRub\u00e9n  6 PN - Biomedicina  01/01/201\n3 31/12/201\n5 204.750 \u20ac  \nNac Cancer de mama: papel de Pit -1 y CXCR4 en el \nproces o de met\u00e1stasis. Evaluaci\u00f3n de an\u00e1logos de \nvitamina D como adyuvantes en su tratamiento.  P\u00e9rez Fern\u00e1ndez, \nRom\u00e1n  6 PN - Biomedicina  01/01/201\n3 31/12/201\n5 117.000 \u20ac  \nNac Efecto de las c\u00e9lulas madre mesenquimales sobre la \nsupervivencia y funcionalidad de impl antes de \nc\u00e9lulas dopamin\u00e9rgicas como terapia para la \nenfermedad de Parkinson  Rodr\u00edguez Pallares, \nJannette  Acci\u00f3n Estrat\u00e9gica de Salud  01/01/201\n3 31/12/201\n5 74.415 \u20ac  \nNac Papel de los canales de fr\u00edo TRPM8 en la patogenia y \nfisiopatolog\u00f3ia de la obesidad. B \u00fasqueda de nuevas \ndianas terap\u00e9uticas.  Se\u00f1ar\u00eds Rodr\u00edguez, \nRosa Mar\u00eda  Acci\u00f3n Estrat\u00e9gica de Salud  01/01/201\n3 31/12/201\n5 110.715 \u20ac  \nNac Red de terapia celular (TERCEL)  Labandeira Garc\u00eda, \nJos\u00e9 Luis  FIS - Redes Tem\u00e1ticas de \nInvestigacion Cooperativa  28/12/200\n6 31/12/201\n3 371.630 \u20ac  \nInt Search for new therapeutic agents against \ncomplicated obesity by reprofiling existing drugs \n(REPROBESITY)  Di\u00e9guez Gonz\u00e1lez, \nCarlos  VII PM - Cooperaci\u00f3n  01/12/200\n8 31/05/201\n2 505.919 \u20ac   \n \n40 Int Early Detection of Adverse Drug Events b y \nIntegrative Mining of Clinical Records and Biomedical \nKnowledge (ALERT)  Loza Garc\u00eda, Mar\u00eda \nIsabel  VII PM - Cooperaci\u00f3n  01/02/200\n8 31/01/201\n2 121.216 \u20ac  \nInt 'Linfonanocarriers' para el tratamiento del c\u00e1ncer \nmetast\u00e1sico (LYMPHOTARG) (ERA -NET)  Alonso Fern\u00e1 ndez, \nMar\u00eda Jos\u00e9  FIS 01/01/201\n0 30/06/201\n3 166.012 \u20ac  \nInt Genetic study of Common Hereditary Bowel Cancers \nin Hispania and the Americas (CHIBCHA)  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  VII PM - Cooperaci\u00f3n  01/06/200\n9 31/05/201\n3 540.778 \u20ac  \nInt Sharing capacity acro ss Europe in high -throughput \nsequencing technology to explore genetic variation \nin health and disease (GEUVADIS)  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  VII PM - Cooperaci\u00f3n  01/10/201\n0 30/09/201\n3 100.000 \u20ac  \nInt Cooperaci\u00f3n transnacional para la innovaci\u00f3n \ntecnol\u00f3gi ca en el desarrollo de mol\u00e9culas para el \ntratamiento de la obesidad y la diabetes (DIOMED)  Loza Garc\u00eda, Mar\u00eda \nIsabel  InterReg IVa - SUDOE  01/04/200\n9 31/03/201\n2 75.000 \u20ac  \nInt Protecting animal and human health from prions in \nfood, feed and the environment ( PRIORITY)  Rodr\u00edguez Requena, \nJes\u00fas  VII PM - Cooperaci\u00f3n  01/10/200\n9 30/09/201\n4 5.999.499 \n\u20ac \nInt The Integrated Neurobiology of Food Intake, \nAddiction and Stress (NEUROFAST)  Di\u00e9guez Gonz\u00e1lez, \nCarlos  VII PM - Cooperaci\u00f3n  01/04/201\n0 31/03/201\n5 207.780 \u20ac  \nInt European Forensic Genetics Network of Excelellence \n(EUROFORGEN -NoE)  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  VII PM - Cooperaci\u00f3n  01/01/201\n2 31/12/201\n6 546.831 \u20ac  \nInt Hypothalamic Lipotoxicity and Endoplasmic \nReticulum Stress: a New Pathophysiological \nMechanism of Ob esity (ObERStress)  L\u00f3pez P\u00e9rez, Miguel \nAntonio  VII PM - Ideas  01/12/201\n1 30/11/201\n6 1.484.000 \n\u20ac \nInt An open, integrated and sustainable chemistry, \nbiology and pharmacology knowledge resource for \ndrug discovery (OPENPHACTS)  Loza Garc\u00eda, Mar\u00eda \nIsabel  VII PM  - Cooperaci\u00f3n  01/03/201\n1 28/02/201\n4 331.760 \u20ac  \nInt p53 as a New Mediator of Energy Balance in the \nBrain (OBESITY53)  Nogueiras Pozo, \nRub\u00e9n  VII PM - Ideas  01/12/201\n1 30/11/201\n6 1.477.680 \n\u20ac \nInt Malformaciones cerebrales cavernosas. De la \npatobiolog\u00eda a estr ategias terap\u00e9uticas.  Zalvide Torrente, \nJuan Bautista  ERA-NET 01/12/201\n1 01/12/201\n4 129.000 \u20ac  \nInt New Oral Nanomedicines: Transporting Therapeutic \nMacromolecules across the Intestinal Barrier \n(TRANS -INT)  Alonso Fern\u00e1ndez, \nMar\u00eda Jos\u00e9  VII PM - Cooperaci\u00f3n  01/05/201\n2 30/04/201\n7 1.133.124 \n\u20ac \nInt NanoFar: European Doctorate in nanomedicine and \npharmaceutical innovation  Alonso Fern\u00e1ndez, \nMar\u00eda Jos\u00e9  Erasmus Mundus Programme  01/10/201\n2 30/09/201\n5 350.900 \u20ac   \n \n41 Int New Oral Nanomedicines: Transporting Therapeutic \nMacr omolecules across the Intestinal Barrier \n(TRANS -INT)  Di\u00e9guez Gonz\u00e1lez, \nCarlos  VII PM - Cooperaci\u00f3n  01/05/201\n2 30/04/201\n7 276.102 \u20ac  \nInt Drug Repositioning for Rare Diseases (DRUGS4RARE)  Loza Garc\u00eda, Mar\u00eda \nIsabel  International Rare Disease \nResearch Consorti um (IRDiRC) -ISCIII  01/02/201\n2 30/12/201\n3 134.000 \u20ac  \nInt The Human Early -Life Exposome - novel tools for \nintegrating early -life environmental exposures and \nchild health across Europe (HELIX)  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  VII PM - Cooperaci\u00f3n  01/01/201\n3 30/06/201\n7 326.227 \u20ac  \nConv  Identificaci\u00f3n mediante prote\u00f3mica de \nbiomarcadores plaquetarios en pacientes con \ns\u00edndrome coronaria aguda  Garc\u00eda Alonso, \u00c1ngel  Fundaci\u00f3n Mutua Madrile\u00f1a \nAutomovilista (MMA)  24/06/200\n9 23/06/201\n2 20.000 \u20ac  \nConv  Axudas para investiga dores no eido da Oncolox\u00eda  Alonso Fern\u00e1ndez, \nMar\u00eda Jos\u00e9  Fundaci\u00f3n Cient\u00edfica de la \nAsociaci\u00f3n Espa\u00f1ola contra el \nC\u00e1ncer  01/12/201\n0 25/01/201\n3 120.600 \u20ac  \nConv  Axuda a investigadores no \u00e1mbito da oncolox\u00eda  P\u00e9rez Fern\u00e1ndez, \nRom\u00e1n  Fundaci\u00f3n Cient\u00edfica de la \nAsociaci\u00f3n Espa\u00f1ola contra el \nC\u00e1ncer  15/08/201\n1 30/09/201\n4 135.000 \u20ac  \nConv  Medicinas celulares reprogramadas \nnanotecnol\u00f3gicamente  Garc\u00eda Fuentes, \nMarcos  Fundaci\u00f3n Ram\u00f3n Areces  27/06/201\n2 26/06/201\n5 85.345 \u20ac  \nConv  Melloras nos procesos de xesti\u00f3n da Oficina d e \nInvestigaci\u00f3n e Tecnolox\u00eda (Fase II)  Gonz\u00e1lez Garc\u00eda, \nFrancisco  USC 01/01/200\n6 31/12/201\n3 0 \u20ac \nCont  Neogenius (Proxecto Cenit)  Loza Garc\u00eda, Mar\u00eda \nIsabel  Almirall -Prodesfarma, S.A.  01/01/201\n0 31/12/201\n2 1.128.000 \n\u20ac \nCont  Soluci\u00f3ns innovadoras para acelera r a identificaci\u00f3n \ne desenvolvemento de f\u00e1rmacos para patolox\u00edas do \nsistema nervioso (proxecto Cenit DENDRIA)  Brea Floriani, Jos\u00e9 \nManuel  Oryzon Genomics  18/11/201\n0 31/12/201\n2 32.300 \u20ac  \nCont  Proxecto BRAINco Screening  Loza Garc\u00eda, Mar\u00eda \nIsabel  BRAINco Bioph arma, S.L.  25/01/201\n0 24/01/201\n2 157.000 \u20ac  \nCont  Descubrimento de novos compostos de interese \nfarmacol\u00f3xico  Loza Garc\u00eda, Mar\u00eda \nIsabel  Laboratorios Dr Esteve, S.A.  01/01/201\n0 31/12/201\n4 1.508.639 \n\u20ac \nCont  Soluci\u00f3ns innovadoras para acelerar a identificaci\u00f3n \ne desenvolvemento de f\u00e1rmacos para patolox\u00edas do \nsistema nervioso (descubrimento temper\u00e1n de \nf\u00e1rmacos) - proxecto Cenit Dendria  Loza Garc\u00eda, Mar\u00eda \nIsabel  BRAINco Biopharma, S.L.  05/05/201\n0 31/12/201\n3 706.500 \u20ac   \n \n42 Conv  Detecci\u00f3n y caracterizaci\u00f3n de modulador es \nalost\u00e9ricos de receptores GLP -1. Loza Garc\u00eda, Mar\u00eda \nIsabel  VIVIA BIOSYSTEMS, S.L.  01/03/201\n0 01/02/201\n2 92.000 \u20ac  \nConv  Estudo da xen\u00f3mica da leucemia linfoc\u00edtica cr\u00f3nica \n(proxecto LLC)  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Fundaci\u00f3 Cl\u00ednic per a la Recerca \nBiom \u00e8dica  10/05/201\n0 31/12/201\n2 272.444 \u20ac  \nConv  Ensaios biol\u00f3xicos de novos derivados do cisplatino  Dom\u00ednguez Puente, \nFernando  Institut de Recerca de l'Hospital de \nla Santa Creu y Sant Pau  15/02/201\n0 31/12/201\n2 30.000 \u20ac  \nCont  Convenio espec\u00edfico de cooperaci\u00f3n  acad\u00e9mica  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Universidad Sim\u00f3n Bol\u00edvar  27/04/201\n0 26/04/201\n5 0 \u20ac \nCont  Cooperation Agreement on Post Doctorial Project  Alonso Fern\u00e1ndez, \nMar\u00eda Jos\u00e9  Novo Nordisk A/S  15/06/201\n1 14/06/201\n3 62.035 \u20ac  \nCont  Genealogy/Parentage Servi ces Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Genomed -Diagn\u00f3sticos de \nMedicina Molecular, S.A.  01/12/201\n1 30/11/201\n2 0 \u20ac \nCont  Determinaci\u00f3ns de xen\u00e9tica forense: probas \nbiol\u00f3xicas - 2011 (II fase)  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Varias entidades  28/04/201\n1 30/06/201\n2 17.021 \u20ac  \nCont  Determinaci\u00f3ns de xen\u00e9tica forense: probas \nbiol\u00f3xicas (III fase)  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Varias entidades  15/06/201\n1 31/12/201\n2 17.653 \u20ac  \nCont  Nanovida: desenvolvemento de novos nanof\u00e1rmacos \npara o tratamento do cancro de mama basead os en \nnanopart\u00edculas polivalentes (CDTI - IDI-20110895)  Costoya Puente, Jos\u00e9 \nAntonio  Midatech Biogune, S.L.  02/05/201\n2 01/08/201\n3 153.138 \u20ac  \nCont  Asesoramento cient\u00edfico e t\u00e9cnico cunha \nperiodicidade mensual naqueles proxectos \nrelacionados con aplicaci\u00f3ns biom\u00e9dicas das \nnanopart\u00edculas, nanofibras e AQCs nos que Nanogap \nestea involucrado  Dom\u00ednguez Puente, \nFernando  NANOGAP SUB -NM-POWDER, S.A.  01/01/201\n1 31/12/201\n2 21.600 \u20ac  \nConv  Desenvolvemento das actividades do Centro \nNacional de Xenotipado. (2011, 2012)  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Instituto de Salud Carlos III  01/01/201\n1 31/12/201\n3 619.108 \u20ac  \nConv  Identificaci\u00f3n xen\u00e9tico -molecular dos restos do Sabio \nFrancisco Jos\u00e9 Caldas  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Universidad del Cauca  01/01/201\n1 08/05/201\n2 0 \u20ac \nConv Colaboraci\u00f3n entre o Hospital Universitario de \nSalamanca e a USC para a realizaci\u00f3n do estudo \nobservacional 'Genotype Associated to \nLipodystrophy in HIV'  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Hospital Universitario de \nSalamanca  07/07/201\n1 30/12/201\n2 0 \u20ac \nCont  Contrato de Asistencia  Alonso Fern\u00e1ndez, \nMar\u00eda Jos\u00e9  Advanced in Vitro Cell \nTechnologies, S.A.  01/01/201\n2 31/12/201\n2 2.700 \u20ac   \n \n43 Cont  COLIVAC: novas tecnolox\u00edas para vacinas de E. coli \n(Feder -Innterconecta)  Alonso Fern\u00e1ndez, \nMar\u00eda Jos\u00e9  NANOGAP SUB -NM-POWDER, S. A. 20/03/201\n3 31/12/201\n4 150.000 \u20ac  \nCont  Elaboraci\u00f3n de informe pericial  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Estrada, Eduardo  01/01/201\n2 30/06/201\n2 5.000 \u20ac  \nCont  Determinaci\u00f3ns de xen\u00e9tica forense - probas \nbiol\u00f3xicas  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Varias entida des 01/01/201\n2 30/06/201\n3 17.644 \u20ac  \nCont  Determinaci\u00f3ns de xen\u00e9tica forense - probas \nbiol\u00f3xicas - 2012 (fase II)  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Varias entidades  29/05/201\n2 31/12/201\n2 11.030 \u20ac  \nCont  Determinaci\u00f3ns de xen\u00e9tica forense: probas \nbiol\u00f3xicas - 2012 fase III  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Varias entidades  01/09/201\n2 31/12/201\n2 16.664 \u20ac  \nCont  A Randomized Double -blind Pacebo -controlled Phase \nI/II Trial of RNActive\u00ae -derived Cancer Vaccine \n(CV9104) in Asymptomatic or Minimally \nSymptomatic Patients wit h Metastatic Castrate -\nresistant Prostrate Cancer  Costoya Puente, Jos\u00e9 \nAntonio  ABF Pharmaceutical Services GmbH  10/10/201\n2 31/08/201\n4 0 \u20ac \nCont  Asesor\u00eda T\u00e9cnica en relaci\u00f3n al proyeto 'Evaluaci\u00f3n \nde genes implicados en la v\u00eda de traducci\u00f3n de la \nLeptina com o dianas terap\u00e9uticas para la obesidad'  Di\u00e9guez Gonz\u00e1lez, \nCarlos  nLife Therapeutics, S.L.  15/09/201\n0 30/06/201\n2 50.000 \u20ac  \nCont  S\u00edntesis y funcionalizaci\u00f3n de AQCs (cl\u00fasteres \ncu\u00e1nticos at\u00f3micos),nanosistemas fluorescentes y \nnanopart\u00edculas met\u00e1licas y \nmagn\u00e9t icas,caracterizaci\u00f3n fluorescente y \nmagn\u00e9tica,y combinaci\u00f3n de estas part\u00edculas con \nDNA para utilizaci\u00f3n en kits de diagn\u00f3stico  Dom\u00ednguez Puente, \nFernando  NANOGAP SUB -NM-POWDER, S.A.  30/04/201\n2 31/12/201\n2 15.000 \u20ac  \nCont  Proyecto de nanopart\u00edculas de oro co njugadas con \ncisplatino  Dom\u00ednguez Puente, \nFernando  Nanotargeting, S.L.  15/10/201\n2 14/04/201\n3 1.800 \u20ac  \nCont  COLIVAC: novas tecnolox\u00edas para vacinas de E. coli \n(Feder -Innterconecta)  Dom\u00ednguez Puente, \nFernando  NANOGAP SUB -NM-POWDER, S.A.  20/03/201\n3 19/05/201\n5 75.000 \u20ac  \nCont  Screening de compuestos qu\u00edmicos moduladores de \nla actividad de los receptores de adenosina (Proxecto \nInnterconecta)  Loza Garc\u00eda, Mar\u00eda \nIsabel  Palo Biofarma, S.L.  09/02/201\n2 08/03/201\n2 0 \u20ac \nCont  Scientific collaboration with the aim of join tly \nidentifying the targets at which compounds in \nchemical libraries might have, testing a set of Loza Garc\u00eda, Mar\u00eda \nIsabel  Chemotargets, S.L.,  Universidade \ndo Minho  10/04/201\n2 09/04/201\n4 0 \u20ac  \n \n44 selected compounds against the set of selected \ntargets and, in the case hits are found, further \noptimising [...]  \nCont  Efectos de DHA sobre proliferaci\u00f3n celular en l\u00edneas \ncelulares tumorales mamarias  P\u00e9rez Fern\u00e1ndez, \nRom\u00e1n  Hausmann -Labomar, S.L.  15/03/201\n2 30/04/201\n2 3.000 \u20ac  \nConv  Report of the Infrafrontier Work Package 5 with \nexplicit construction plans of dif ferent research \nfacilities  Costoya Puente, Jos\u00e9 \nAntonio  Helmholtz Zentrum M\u00fcnchen  19/11/201\n2 18/11/201\n7 0 \u20ac \nConv  Proyecto de investigaci\u00f3n: Interacci\u00f3n de ADN con \ncomplejos organomet\u00e1licos de Ru(II) y cl\u00fasteres \ncu\u00e1nticos at\u00f3micos (AQC's)  Dom\u00ednguez Puente,  \nFernando  Obra Social 'la Caixa'  01/01/201\n3 31/12/201\n6 262.890 \u20ac  \nConv  Convenio para evaluar los posibles efectos \nterap\u00e9uticos de las c\u00e9lulas madre uterinas en c\u00e1ncer \nde mama.  P\u00e9rez Fern\u00e1ndez, \nRom\u00e1n  FICEMU - Fundaci\u00f3n para la \nInvestigaci\u00f3n en Celulas Madre  \nUterinas  18/07/201\n2 31/12/201\n2 10.039 \u20ac  \nConv  Realizaci\u00f3n de pericias m\u00e9dico -psiqui\u00e1tricas e a \nformaci\u00f3n neste \u00e1mbito  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Servizo Galego de Sa\u00fade  12/04/201\n2 31/12/201\n2 12.000 \u20ac  \nConv  Actividades de difusi\u00f3n de calidad y realizac i\u00f3n de \nactuaciones de evaluaci\u00f3n competencia de ENAC  Gonz\u00e1lez Garc\u00eda, \nFrancisco  Entidade Nacional de Acreditaci\u00f3n  12/11/201\n2 11/12/201\n7 0 \u20ac \nConv  Condici\u00f3ns polas que se rexer\u00e1 a colaboraci\u00f3n entre \nConseller\u00eda de Cultura, Educaci\u00f3n e Ordenaci\u00f3n \nUniversitar ia, a USC e a Universidade de Vigo para \ncomplementar as axudas aos l\u00edderes dos programas \nstarting grants e consolider  L\u00f3pez P\u00e9rez, Miguel \nAntonio  Conseller\u00eda de Cultura, Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria  01/01/201\n2 31/12/201\n4 150.000 \u20ac  \nConv  Condici\u00f3ns polas que se rexer\u00e1 a colaboraci\u00f3n entre \nConseller\u00eda de Cultura, Educaci\u00f3n e Ordenaci\u00f3n \nUniversitaria, a USC e a Universidade de Vigo para \ncomplementar as axudas aos l\u00edderes dos programas \nstarting grants e consolider  Nogueiras Pozo, \nRub\u00e9n  Conseller\u00eda de Cu ltura, Educaci\u00f3n e \nOrdenaci\u00f3n Universitaria  01/01/201\n2 31/12/201\n4 150.000 \u20ac  \nConv  Prestaci\u00f3n polo grupo GRID [ECMB] de apoio \nbioestat\u00edstico aos grupos AVEGA (GI -1925) e \nOMEQUI (GI -2117) dentro das actividades de \ninvestigaci\u00f3n que desenvolven nos seus proxectos de \ninvestigaci\u00f3n [...]  Cadarso Su\u00e1rez, \nCarmen Mar\u00eda  USC 03/05 /201\n2 06/11/201\n3 6.000 \u20ac  \nCont  Collaborative Research Agreement between Alonso Fern\u00e1ndez, Vaxil BioTherapeutics Ltd  01/01/201 31/12/201 0 \u20ac  \n \n45 Universidade de Santiago de Compostela and Vaxil \nBiotherapeutics Ltd  Mar\u00eda Jos\u00e9  3 4 \nCont  Determinaci\u00f3ns de xen\u00e9tica f orense: probas \nbiol\u00f3xicas - 2013  Carracedo \u00c1lvarez, \n\u00c1ngel Mar\u00eda  Varias entidades  01/01/201\n3 31/12/201\n3 9.818 \u20ac  \nCont  Colaboraci\u00f3n a trav\u00e9s de expertos que act\u00faen como \nevaluador 4 d\u00edgitos Unesco -comit\u00e9  Gonz\u00e1lez Garc\u00eda, \nFrancisco  EQA Certificados I+D+i  31/01 /201\n3 30/01/201\n5 0 \u20ac \nCont  Colaboraci\u00f3n a trav\u00e9s de expertos que act\u00faen como \nexpertos t\u00e9cnicos (6 d\u00edgitos Unesco)  Gonz\u00e1lez Garc\u00eda, \nFrancisco  EQA Certificados I+D+i  31/01/201\n3 30/01/201\n5 0 \u20ac \nCont  Agreement to carry out the research conducting to \nexpand the  USC's chemical library  Loza Garc\u00eda, Mar\u00eda \nIsabel  Peakdale Molecular Limited, Ltd  07/12/201\n2 06/12/201\n7 0 \u20ac \nCont  Avaliaci\u00f3n da actividade antiinflamatoria de omega -3 P\u00e9rez Fern\u00e1ndez, \nRom\u00e1n  Biomega Natural Nutrients, S.L.  02/04/201\n3 01/04/201\n4 35.000 \u20ac  \nConv Colaboraci\u00f3n e asesoramento para a Plataforma de \nnanomedicina 2011  Alonso Fern\u00e1ndez, \nMar\u00eda Jos\u00e9  Fundaci\u00f3 Institut de Bioenginyeria \nde Catalunya  25/04/201\n3 31/12/201\n3 2.000 \u20ac  \nConv  Material Transfer Agreement 'shRNA constructs IL -\n6#2 and #4, IL8#1 and #4 ' Zalvide Torrente, \nJuan Bautista  Stichting Het Nederlands Kanker \nInstitut  04/02/201\n3 03/02/201\n4 0 \u20ac \nConv  Acuerdo de transferencia de materiales 'L\u00edneas \ncelulares que coexpresan receptores 5 -HT2A y D2'  Loza Garc\u00eda, Mar\u00eda \nIsabel  Instituto de Biomedicina y \nBiotecnolog\u00eda de Cantabria  11/01/201\n3 31/12/201\n3 0 \u20ac \nConv  Material Transfer Agreement '832/13/ and 832/3 cell \nlines'  Loza Garc\u00eda, Mar\u00eda \nIsabel  Duke University  04/02/201\n3 03/02/201\n4 0 \u20ac \n \n   \n \n46 ANEXO IV. ARTIGOS  \n\uf0b7 2012  \nT\u00edtulo  Autores  Revista  Fecha public.  Docume nto Cuartil  F.I. ISSN  \n2012         \nThrombin -receptor antagonist \nvorapaxar in acute coronary \nsyndromes.  Tricoci P, Huang Z, Held C, Moliterno \nDi, Armstrong PW, Van de Werf F, \nWhite HD, Aylward PE, Wallentin L, \nChen E, Lokhnygina Y, Pei i, Leonardi S, \nRoric k TL, Kilian AM, iennings LH, \nAmbrosio G, Bode C, Cequier A, Cornel \niH, Diaz R, Erkan A, Huber K, Hudson \nMP, iiang L, iukema iW, Lewis BS, \nLincoff AM, Montalescot G, Nicolau iC, \nOgawa H, Pfisterer M, Prieto iC, \nRuzyllo W, Sinnaeve PR, Storey RF, \nValgimigli  M, Whellan Di, Widimsky P, \nStrony i, Harrington RA, Mahaffey KW; \nTRACER Investigators.  N Engl i Med.  2012 ian \n5;366(1):20 -33 Original  Q1/D1  53,298  0028 -4793  \nThe angiotensin receptor neprilysin \ninhibitor LCZ696 in heart failure \nwith preserved eiection fra ction: a \nphase 2 double -blind randomised \ncontrolled trial.  Solomon SD, Zile M, Pieske B, Voors A, \nShah A, Kraigher -Krainer E, Shi V, \nBransford T, Takeuchi M, Gong i, \nLefkowitz M, Packer M, McMurray ii; \nProspective comparison of ARNI with \nARB on Management Of heart failUre \nwith preserved eiectioN fracTion \n(PARAMOUNT) Investigators \n(Gonzalez -iuanatey iR, Calvo C)  Lancet  2012 Oct \n20;380(9851):13\n87-95. Original  Q1/D1  38,278  0140 -6736  \nReconstructing Native American \npopulation history  Reich D, Patterson N, Campb ell D, \nTandon A, Mazieres S, Ray N, Parra \nMV, Roias W, Duque C, Mesa N, Garc\u00eda Nature  2012 Aug \n16;488(7411):37\n0-4. Original  Q1/D1  36,280  0028 -0836   \n \n47 LF, Triana O, Blair S, Maestre A, Dib iC, \nBravi CM, Bailliet G, Corach D, \nH\u00fcnemeier T, Bortolini MC, Salzano \nFM, Petzl -Erler ML, Acu\u00f1a -Alonzo V, \nAguilar -Salinas C, Canizales -Quinteros \nS, Tusi\u00e9 -Luna T, Riba L, Rodr\u00edguez -Cruz \nM, Lopez -Alarc\u00f3n M, Coral -Vazquez R, \nCanto -Cetina T, Silva -Zolezzi I, \nFernandez -Lopez iC, Contreras AV, \niimenez -Sanchez G, G\u00f3mez -V\u00e1zquez \nMi, Molina i, Carracedo A, Salas A, \nGallo C, Poletti G, Witonsky DB, \nAlkorta -Aranburu G, Sukernik RI, \nOsipova L, Fedorova SA, Vasquez R, \nVillena M, Moreau C, Barrantes R, \nPauls D, Excoffier L, Bedoya G, \nRothhammer F, Dugouion iM, Larrouy \nG, Klitz W, Labuda D, Kidd i, Kidd K, Di \nRienzo A, Freimer NB, Price AL, Ruiz -\nLinares A.  \nMutations in SLC20A2 link familial \nidiopathic basal ganglia calcification \nwith phosphate homeostasis  Wang C, Li Y, Shi L, Ren i, Patti M, \nWang T, de Oliveira iR, Sobrido Mi, \nQuint\u00e1ns B, Ba quero M, Cui X, Zhang \nXY, Wang L, Xu H, Wang i, Yao i, Dai X, \nLiu i, Zhang L, Ma H, Gao Y, Ma X, Feng \nS, Liu M, Wang QK, Forster IC, Zhang X, \nLiu iY  NAT GENET  2012 Feb \n12;44(3):254 -6 Original  Q1/D1  35,532  1061 -4036  \nMutations in the RNA exosome \ncomponent g ene EXOSC3 cause \npontocerebellar hypoplasia and \nspinal motor neuron degeneration  Wan i, Yourshaw M, Mamsa H, Rudnik -\nSch\u00f6neborn S, Menezes MP, Hong iE, \nLeong DW, Senderek i, Salman MS, \nChitayat D, Seeman P, von Moers A, \nGraul -Neumann L, Kornberg Ai, Castro -\nGago M, Sobrido Mi, Sanefuii M, Shieh \nPB, Salamon N, Kim RC, Vinters HV, NAT GENET  2012 Apr \n29;44(6):704 -8. Original  Q1/D1  35,532  1061 -4036   \n \n48 Chen Z, Zerres K, Ryan MM, Nelson SF, \nien iC  \nBMP8B increases brown adipose \ntissue thermogenesis through both \ncentra l and peripheral actions  Whittle Ai, Carobbio S, Martins L, \nSlawik M, Hondares E, V\u00e1zquez Mi, \nMorgan D, Csikasz RI, Gallego R, \nRodriguez -Cuenca S, Dale M, Virtue S, \nVillarroya F, Cannon B, Rahmouni K, \nL\u00f3pez M & Vidal -Puig A  Cell 2012 May \n11;149(4):871 -\n85. Original  Q1/D1  32,403  0092 -8674  \nKisspeptins and reproduction: \nphysiological roles and regulatory \nmechanisms.  Pinilla L,  Aguilar E,  Dieguez C,  Millar \nRP, Tena -Sempere M.  Physiol Rev  2012 \niul;92(3):1235 -\n316.  Review  Q1/D1  26,866  0031 -9333  \nSirtuin 1 and si rtuin 3: physiological \nmodulators of metabolism.  Nogueiras R,  Habegger KM,  Chaudhary \nN, Finan B,  Banks AS,  Dietrich \nMO,  Horvath TL,  Sinclair DA,  Pfluger \nPT, Tsch\u00f6p MH.  Physiol Rev.  2012 \nJul;92(3):1479 -\n514 Review  Q1/D1  26,866  0031 -9333  \nDiscovery of inhibit ors of microglial \nneurotoxicity acting through \nmultiple mechanisms using a stem -\ncell-based phenotypic assay.  H\u00f6ing S, Rudhard Y, Reinhardt P, \nGlatza M, Stehling M, Wu G, Peiker C, \nB\u00f6cker A, Parga iA, Bunk E, \nSchwamborn iC, Slack M, Sterneckert i, \nSch\u00f6ler H R. Cell Stem Cell.  2012 Nov \n2;11(5):620 -32. Original  Q1/D1  25,421  1934 -5909  \np27Kip1 directly contributes to Sox2 \ntranscriptional repression during \nembryonic stem cell differentiation.  Li H, Collado M, Villasante A, Matheu \nA, Lynch Ci, Ca\u00f1amero M, Rizzoti  K, \nCarneiro C, Mart\u00ednez G, Vidal A, Lovell -\nBadge R, Serrano M.  Cell Stem Cell  2012 Dec \n7;11(6):845 -52  Q1/D1  25,420  1934 -5909  \nIs glycated hemoglobin an accurate \nenough predictor of subclinical \nmyocardial iniury or a simple \nprecursor of advanced glycation  \nend products?  Raposeiras -Roub\u00edn S, Barreiro -Pardal \nC, Alvarez E, Gonz\u00e1lez iuanatey iR.  i Am Coll Cardiol  2012 iul \n10;60(2):166 -7. Letter  Q1/D1  14,156  0735 -1097  \nCommon variant at 16p11.2 \nconferring risk of psychosis  Steinberg S, de iong S, Mattheisen M, \nCostas i, Demontis D, iamain S, \nPietil\u00e4inen OP, Lin K, Papiol S, \nHuttenlocher i, Sigurdsson E, Vassos E, Mol Psychiatry  2012 Nov 20.  Original  Q1/D1  13,668  1359 -4184   \n \n49 Giegling I, Breuer R, Fraser G, Walker \nN, Melle I, Diurovic S, Agartz I, Tuulio -\nHenriksson A, Suvisaari i, L\u00f6nnqvist i, \nPaunio T, Olsen L, Hansen T, Ing ason A, \nPirinen M, Strengman E; GROUP, \nHougaard DM, Orntoft T, Didriksen M, \nHollegaard MV, Nordentoft M, \nAbramova L, Kaleda V, Arroio M, \nSaniu\u00e1n i, Arango C, Etain B, Bellivier F, \nM\u00e9ary A, Sch\u00fcrhoff F, Szoke A, Ribolsi \nM, Magni V, Siracusano A, Sperling S,  \nRossner M, Christiansen C, Kiemeney \nLA, Franke B, van den Berg LH, Veldink \ni, Curran S, Bolton P, Poot M, Staal W, \nRehnstrom K, Kilpinen H, Freitag CM, \nMeyer i, Magnusson P, Saemundsen E, \nMartsenkovsky I, Bikshaieva I, \nMartsenkovska I, Vashchenko O, \nRalev a M, Paketchieva K, Stefanovski \nB, Durmishi N, Peiovic Milovancevic M, \nLecic Tosevski D, Silagadze T, \nNaneishvili N, Mikeladze N, Surguladze \nS, Vincent iB, Farmer A, Mitchell PB, \nWright A, Schofield PR, Fullerton iM, \nMontgomery GW, Martin NG, Rubino \nIA, va n Winkel R, Kenis G, De Hert M, \nR\u00e9thelyi iM, Bitter I, Terenius L, \ni\u00f6nsson EG, Bakker S, van Os i, \niablensky A, Leboyer M, Bramon E, \nPowell i, Murray R, Corvin A, Gill M, \nMorris D, O'Neill FA, Kendler K, Riley B; \nWellcome Trust Case Control \nConsortium 2, C raddock N, Owen Mi, \nO'Donovan MC, Thorsteinsdottir U,  \n \n50 Kong A, Ehrenreich H, Carracedo A, \nGolimbet V, Andreassen OA, B\u00f8rglum \nAD, Mors O, Mortensen PB, Werge T, \nOphoff RA, N\u00f6then MM, Rietschel M, \nCichon S, Ruggeri M, Tosato S, Palotie \nA, St Clair D, Ruiescu D, Collier DA, \nStefansson H, Stefansson K.  \nRapid coastal spread of First \nAmericans: Novel insights from \nSouth America's Southern Cone \nmitochondrial genomes  Bodner M, Perego UA, Huber G, Fendt \nL, R\u00f6ck AW, Zimmermann B, Olivieri A, \nG\u00f3mez -Carballa A, Lancioni H, \nAngerhofer N, Bobillo MC, Corach D, \nWoodward SR, Salas A, Achilli A, \nTorroni A, Bandelt Hi, Parson W  GENOME RES  2012 \nMay;22(5):811 -\n20. Original  Q1/D1  13,608  1088 -9051  \nReconstructing ancient  \nmitochondrial DNA links between \nAfrica and Europe  Cerezo M, Achilli A, Olivieri A, Perego \nUA, G\u00f3mez -Carballa A, Brisighelli F, \nLancioni H, Woodward SR, L\u00f3pez -Soto \nM, Carracedo A, Capelli C, Torroni A, \nSalas A.  Genome Res  2012 \nMay;22(5):821 -\n6. Original  Q1/D1 13,608  1088 -9051  \nThe survival of patients with heart \nfailure with preserved or reduced \nleft ventricular eiection fraction: an \nindividual patient data meta -\nanalysis.  Meta -analysis Global Group in Chronic \nHeart Failure (MAGGIC) (Gonzalez -\niuanatey iR, Tri llo R, Gude F)  Eur Heart i  2012 \niul;33(14):1750 -\n7.  Review  Q1/D1  10,478  0195 -668X  \nComparison between universal \nmolecular screening for Lynch \nsyndrome and revised Bethesda \nguidelines in a large population -\nbased cohort of patients with \ncolorectal cancer  P\u00e9rez-Carbonell L, Ruiz -Ponte C, \nGuarinos C, Alenda C, Pay\u00e1 A, Brea A, \nEgoavil CM, Castilleio A, Barber\u00e1 VM, \nBessa X, Xicola RM, Rodr\u00edguez -Soler M, \nS\u00e1nchez -Fort\u00fan C, Acame N, Castellv\u00ed -\nBel S, Pi\u00f1ol V, Balaguer F, Buianda L, \nDe-Castro ML, Llor X, Andreu M, \nCarracedo A, Soto iL, Castells A, iover \nR. Gut 2012 \niun;61(6):865 -\n72. Original  Q1/D1  10,111  0017 -5749  \nA detailed proteomic analysis of \nrhodocytin -activated platelets Pargui\u00f1a AF, Alonso i, Rosa I, V\u00e9lez P, \nGonz\u00e1lez -L\u00f3pez Mi, Guiti\u00e1n E, Ebble iA, BLOOD  2012 Dec \n20;120(26):e117Original  Q1 9,898  0006 -4971   \n \n51 reveals novel clues on the CLEC -2 \nsignalosome: implications for CLEC -\n2 signaling regulation  Loza MI, Garc\u00eda A  -26 \nCosta da Morte' ataxia is \nspinocerebellar ataxia 36: clinical \nand genetic characterization  Garc \u00eda-Murias M, Quint\u00e1ns B, Arias M, \nSeixas AI, Cacheiro P, Tarr\u00edo R, Pardo i, \nMill\u00e1n Mi, Arias -Rivas S, Blanco -Arias \nP, Dapena D, Moreira R, Rodr\u00edguez -\nTrelles F, Sequeiros i, Carracedo A, \nSilveira I, Sobrido Mi.  Brain  2012 \nMay;135(Pt \n5):1423 -35.  Original  Q1/D1 9,457  0006 -8950  \nDopaminergic neuroprotection of \nhormonal replacement therapy in \nyoung and aged menopausal rats: \nrole of the brain angiotensin \nsystem.  Rodriguez -Perez AI, Valenzuela R, \nVillar -Cheda B, Guerra Mi, Labandeira -\nGarcia iL.  Brain  2012 ian;135 (Pt \n1):124 -38 Original  Q1/D1  9,457  0006 -8950  \nPK-sensitive PrP is infectious and \nshares basic structural features with \nPK-resistant PrP.  Sainani G, Silva Ci, Ramos A, Pastrana \nMA, Onisko BC, Erickson ML, Antaki \nEM, Dynin I, V\u00e1zquez -Fern\u00e1ndez E, \nSigurdson C i, Carter iM, Requena iR.  PLoS Pathog. \n2012;8(3):e10025\n47 2012;8(3):e1002\n547 Original  Q1 9,127  1553 -7366  \nDevelopment of a panel of genome -\nwide ancestry informative markers \nto study admixture throughout the \nAmericas  Galanter iM, Fernandez -Lopez iC, \nGignoux  CR, Barnholtz -Sloan i, \nFernandez -Rozadilla C, Via M, Hidalgo -\nMiranda A, Contreras AV, Figueroa LU, \nRaska P, iimenez -Sanchez G, Zolezzi IS, \nTorres M, Ponte CR, Ruiz Y, Salas A, \nNguyen E, Eng C, Borias L, Zabala W, \nBarreto G, Gonz\u00e1lez FR, Ibarra A, \nTaboada P, Porras L, Moreno F, \nBigham A, Gutierrez G, Brutsaert T, \nLe\u00f3n -Velarde F, Moore LG, Vargas E, \nCruz M, Escobedo i, Rodriguez -Santana \ni, Rodriguez -Cintr\u00f3n W, Chapela R, \nFord iG, Bustamante C, Seminara D, \nShriver M, Ziv E, Burchard EG, Haile R, Plos Genet  2012 Mar; \n8(3):e1002554.  Original  Q1/D1  8,694  1553 -7390   \n \n52 Parra E, Carr acedo A; LACE Consortium  \nNicotine induces negative energy \nbalance through hypothalamic \nAMP -activated protein kinase.  Mart\u00ednez de Morentin PB,  Whittle \nAi, Fern\u00f8 i,  Nogueiras R,  Di\u00e9guez \nC, Vidal -Puig A,  L\u00f3pez M.  Diabetes  2012 \nApr;61(4):807 -\n17.  Original  Q1/D1  8,286  0012 -1797  \nThe L -\u03b1-\nlysophosphatidylinositol/GPR55 \nsystem and its potential role in \nhuman obesity.  Moreno -Navarrete iM,  Catal\u00e1n \nV, Whyte L,  D\u00edaz -Arteaga A,  V\u00e1zquez -\nMart\u00ednez R,  Rote llar F,  Guzm\u00e1n \nR, G\u00f3mez -Ambrosi i,  Pulido \nMR, Russell WR,  Imbern\u00f3n M,  Ross \nRA, Malag\u00f3n MM,  Dieguez \nC, Fern\u00e1ndez -Real iM,Fr\u00fchbeck \nG, Nogueiras R.  Diabetes.  2012 \nFeb;61(2):281 -\n91. Original  Q1/D1  8,286  0012 -1797  \nAssociation study of \nnonsynonymous single nucl eotide \npolymorphisms in schizophrenia  Carrera N, Arroio M, Saniu\u00e1n i, Ramos -\nR\u00edos R, Paz E, Su\u00e1rez -Rama ii, P\u00e1ramo \nM, Agra S, Brenlla i, Mart\u00ednez S, Rivero \nO, Collier DA, Palotie A, Cichon S, \nN\u00f6then MM, Rietschel M, Ruiescu D, \nStefansson H, Steinberg S, Sig urdsson \nE, St Clair D, Tosato S, Werge T, \nStefansson K, Gonz\u00e1lez iC, Valero i, \nGuti\u00e9rrez -Zotes A, Labad A, Martorell \nL, Vilella E, Carracedo \u00c1, Costas i.  Biol Psychiatry  2012 ian 15; \n71(2):169 -77. Original  Q1/D1  8,283  0006 -3223  \nRefinement of the associati ons \nbetween risk of colorectal cancer \nand polymorphisms on \nchromosomes 1q41 and 12q13.13  Spain SL, Carvaial -Carmona LG, \nHowarth KM, iones AM, Su Z, Cazier iB, \nWilliams i, Aaltonen LA, Pharoah P, \nKerr Di, Cheadle i, Li L, Casey G, \nVodicka P, Sieber O, Lipto n L, Gibbs P, \nMartin NG, Montgomery GW, Young i, \nBaird PN, Morreau H, van Wezel T, \nRuiz -Ponte C, Fernandez -Rozadilla C, \nCarracedo A, Castells A, Castellvi -Bel S, \nDunlop M, Houlston RS, Tomlinson IP.  Hum Mol Genet  2012 Feb \n15;21(4):934 -\n46. Original  Q1/D1  7,636 0964 -6906  \nProteomic, genomic and \ntranslational approaches identify Bader V, Tomppo L, Trossbach SV, \nBradshaw Ni, Prikulis I, Leliveld SR, Lin Human Molecular \nGenetics 2012 2012 Oct \n15;21(20):4406 -Original  Q1 7,636  0964 -6906   \n \n53 CRMP1 for a role in schizophrenia \nand its underlying traits.  CY, Ishizuka K, Sawa A, Ramos A, Rosa \nI, Garc\u00eda \u00c1, Requena iR, Hipolito M, Rai \nN, Nwulia E, Henning U, Ferrea S, \nLuckhaus C, Ekelund i, Veiiola i, i\u00e4rvelin \nMR, Hennah W, Korth C  Oct \n15;21(20):4406 -\n18 18 \nAdvanced glycation  end products: a \nmysterious shadow beyond the \nrelationship between HbA1c and \natrial fibrillation.  Raposeiras -Roub\u00edn S, Barreiro -Parda C, \nRoub\u00edn -Cami\u00f1a F, Rodi\u00f1o -ianeiro BK, \nParadela -Dobarro B, Alvarez -Castro E, \nGrigorian -Shamagian L, Gonz\u00e1lez -\niuanatey iR.  Int i Cardiol  2012 iun \n14;157(3):441  Letter  Q1/D1  7,078  0167 -5273  \nEvidence for a role of advanced \nglycation end products in atrial \nfibrillation.  Raposeiras -Roub\u00edn S, Rodi\u00f1o -ianeiro \nBK, Grigorian -Shamagian L, Seoane -\nBlanco A, Moure -Gonz\u00e1lez M, Varela -\nRom\u00e1n  A, \u00c1lvarez E, Gonz\u00e1lez -iuanatey \niR. Int i Cardiol  2012 iun 14; \n157(3):397 -402.  Original  Q1/D1  7,078  0167 -5273  \nThe sirolimus -eluting Cypher Select \ncoronary stent for the treatment of \nbare -metal and drug -eluting stent \nrestenosis: insights from the  e-\nSELEC T (Multicenter Post -Market \nSurveillance) registry.  Abizaid A, Costa iR ir, Banning A, \nBartorelli AL, Dzavik V, Ellis S, Gao R, \nHolmes DR ir, ieong MH, Legrand V, \nNeumann Fi, Nyakern M, Orlick A, \nSpaulding C, Worthley S, Urban PM; e -\nSELECT Investigators (Tr illo R).  iACC Cardiovasc \nInterv  2012 ian; \n5(1):64 -71. Original  Q1/D1  6,800  1936 -8798  \nWalking beyond the GRACE (Global \nRegistry of Acute Coronary Events) \nmodel in the death risk \nstratification during hospitalization \nin patients with acute coronary \nsyndrom e: what do the AR -G \n(ACTION [Acute Coronary \nTreatment and Intervention \nOutcomes Network] Registry and \nGWTG [Get With the Guidelines] \nDatabase), NCDR (National \nCardiovascular Data Registry), and \nEuroHeart Risk Scores Provide?  Raposeiras -Roub\u00edn S, Abu -Assi E , \nCabanas -Grand\u00edo P, Agra -Bermeio RM, \nGestal -Romar\u00ed S, Pereira -L\u00f3pez E, \nFandi\u00f1o -Vaquero R, Alvarez -\u00c1lvarez B, \nCambeiro C, Rodr\u00edguez -Cordero M, \nLear P, Mart\u00ednez -Monzon\u00eds A, Pe\u00f1a -Gil \nC, Garc\u00eda -Acu\u00f1a iM, Gonz\u00e1lez -iuanatey \niR. iACC Cardiovasc \nInterv  2012 \nNov;5 (11):1117 -\n25. iournal Article  Q1/D1  6,800  1936 -8798   \n \n54 Chitosan -based nanocarriers: \nWhere do we stand?,  Garcia -Fuentes M., Alonso M.i.,  Journal of \nControlled \nRelease  2012 iul \n20;161(2):496 -\n504 Review  Q1/D1  6,499  0168 -3659  \nIn vivo light -driven DNA binding  and \ncelular uptake of DNA stains  Sanchez M, Martinez -Costas i, \nGonzalez F, Bermudez MA, Eugenio \nVazquez M, Mascare\u00f1as iL  ACS Chemical \nBiology  2012 iul \n20;7(7):1276 -\n80. Original  Q1 6,446  1554 -8929  \nDirect promoter induction of p19Arf \nby Pit -1 explains the dependence \nreceptor RET/Pit -1/p53 -induced \napoptosis in the pituitary \nsomatotroph cells.  Diaz -Rodriguez E,  Garc\u00eda -Lavandeira \nM, Perez -Romero S,  Senra A,  Ca\u00f1ibano \nC, Palmero I,  Borrello MG,  Dieguez \nC, Alvarez CV.  Oncogene.  2012 iun \n7;31(23):2824 -\n35.  Original  Q1/D1  6,373  0950 -9232  \nETV5 cooperates with LPP as a \nsensor of extracellular signals and \npromotes EMT in endometrial \ncarcinomas  Colas E, Muinelo -Romay L, Alons o-\nAlconada L, Llaurado M, Monge M, \nBarbazan i, Gonzalez M, Schoumacher \nM, Pedrola N, Ertekin T, Devis L, Ruiz A, \nCastellvi i, Doll A, Gil -Moreno A, \nVazquez -Levin M, Lapyckyi L, Lopez -\nLopez R, Robine S, Friederich E, Castro \nM, Reventos i, Vignievic D, Abal M. Oncogene  2012 Nov \n8;31(45):4778 -\n88 Original  Q1/D1  6,373  0950 -9232  \nHypothalamic mTOR pathway \nmediates thyroid hormone -induced \nhyperphagia in hyperthyroidism.  Varela L,  Mart\u00ednez -S\u00e1nchez N,  Gallego \nR, V\u00e1zquez Mi,  Roa i,  G\u00e1ndara \nM, Schoenmakers E,  Nogueira s \nR,Chatteriee K,  Tena -Sempere \nM, Di\u00e9guez C,  L\u00f3pez M.  i Pathol.  2012 \niun;227(2):209 -\n22.  Original  Q1/D1  6,318  0022 -3417  \nRenal dysfunction in patients with \nheart failure with preserved versus \nreduced eiection fraction: impact of \nthe new Chronic Kidney Dise ase-\nEpidemiology Collaboration Group \nformula.  McAlister FA, Ezekowitz i, Tarantini L, \nSquire I, Komaida M, Bayes -Genis A, \nGotsman I, Whalley G, Earle N, Poppe \nKK, Doughty RN; Meta -analysis Global \nGroup in Chronic Heart Failure \n(MAGGIC) Investigators (Gonza lez-\niuanatey iR, Grigorian -Shamagian L, \nVarela -Roman A, Maz\u00f3n -Ramos P).  Circ Heart Fail  2012 May \n1;5(3):309 -14.  Original  Q1/D1  6,286  1941 -3289  \nRenal dysfunction in patients with \nheart failure with preserved versus McAlister FA, Ezekowitz i, Tarantini L, \nSquire I, Komaida M, Bayes -Genis A, Circ Heart Fail.  2012 May \n1;5(3):309 -14.  Q1/D1  6,286  1941 -3289   \n \n55 reduced eiection fraction: impact of \nthe new Chronic Kidney Disease -\nEpidemiology Collaboration Group \nformula.  Gotsman I, Whalley G, Earle N, Poppe \nKK, Doughty RN; Meta -analysis Global \nGroup in Chronic Heart Failure \n(MAGG IC) Investigators.  \nAging -related changes in the nigral \nangiotensin system enhances \nproinflammatory and pro -oxidative \nmarkers and 6 -OHDA -induced \ndopaminergic degeneration.  Villar -Cheda B, Vale nzuela R, \nRodriguez -Perez AI, Guerra Mi, \nLabandeira -Garcia iL.  Neurobiology of  \nAging  2012 \nian;33(1):204.e1\n-11 Original  Q1/D1  6,189  0197 -4580  \nGenome -wide study links MTMR7 \ngene to variant Creutzfeldt -iakob \nrisk Sanchez -iuan P, Bishop MT, Aulchenko \nYS, Bra ndel iP, Rivadeneira F, \nStruchalin M, Lambert iC, Amouyel P, \nCombarros O, Sainz i, Carracedo A, \nUitterlinden AG, Hofman A, Zerr I, \nKretzschmar HA, Laplanche iL, Knight \nRS, Will RG, van Duiin CM.  Neurobiol Aging  2012 \niul;33(7):1487.e\n21-8.  Original  Q1/D1  6,189 0197 -4580  \nGSPE interferes with tau \naggregation in vivo: implication for \ntreating tauopathy.  Santa -Maria I, Diaz -Ruiz C, Ksiezak -\nReding H, Chen A, Ho L, Wang i, \nPasinetti GM  Neurobiology of  \nAging.  2012 \nSep;33(9):2072 -\n81 Original  Q1/D1  6,189  0197 -4580  \nUltrastructural alterations of \nAlzheimer's disease paired helical \nfilaments by grape seed -derived \npolyphenols.  Ksiezak -Reding H, Ho L, Santa -Maria I, \nDiaz -Ruiz C, Wang i, Pasinetti GM.  Neurobiology of  \nAging  2012 \niul;33(7):1427 -\n39 Original  Q1/D1  6,189  0197-4580  \nCraniopharyngiomas express \nembryonic stem cell markers (SOX2, \nOCT4, KLF4, and SOX9) as pituitary \nstem cells but do not coexpress \nRET/GFRA3 receptors.  Garcia -Lavandeira M,  Saez C,  Diaz -\nRodriguez E,  Perez -Romero S,  Senra \nA, Dieguez C,  iapon MA,  Alvar ez CV.  i Clin Endocrinol \nMetab.  2012 \nian;97(1):E80 -7. Original  Q1 5,967  0021 -972X  \nMice lacking delta opioid receptors \nresist the development of diet -\ninduced obesity  Czyzyk TA, Romero -Pic\u00f3 A, Pintar J, \nMcKinzie JH, Tsch\u00f6p MH, Statnick MA, \nNogueiras R.  FASEB J  2012 \nAug;26(8):3483 -\n92 Original  Q1/D1  5,712  0892 -6638   \n \n56 Susceptibility genetic variants \nassociated with early -onset \ncolorectal cancer  Gir\u00e1ldez MD, L\u00f3pez -D\u00f3riga A, Buianda \nL, Abul\u00ed A, Bessa X, Fern\u00e1ndez -\nRozadilla C, Mu\u00f1oz i, Cuatrecasas M, \niover R, Xic ola RM, Llor X, Piqu\u00e9 iM, \nCarracedo A, Ruiz -Ponte C, Cosme A, \nEnr\u00edquez -Navascu\u00e9s iM, Moreno V, \nAndreu M, Castells A, Balaguer F, \nCastellv\u00ed -Bel S; Gastrointestinal \nOncology Group of the Spanish \nGastroenterological Association (Salas, \nA.). Carcinogenesis  2012 \nMar;33(3):613 -\n9. Original  Q1 5,702  0143 -3334  \nDatabases for neurogenetics: \nintroduction, overview, and \nchallenges  Sobrido Mi, Cacheiro P, Carracedo A, \nBertram L.  Hum Mutat  2012 \nSep;33(9):1311 -\n4. Original  Q1 5,686  1059 -7794  \nENIGMA --evidence -based network  \nfor the interpretation of germline \nmutant alleles: an international \ninitiative to evaluate risk and \nclinical significance associated with \nsequence variation in BRCA1 and \nBRCA2 genes  Spurdle AB, Healey S, Devereau A, \nHogervorst FB, Monteiro AN, \nNathanson K L, Radice P, Stoppa -\nLyonnet D, Tavtigian S, \nWappenschmidt B, Couch Fi, Goldgar \nDE; HUMAN MUT  2012 \nian;33(1):2 -7 Original  Q1 5,686  1059 -7794  \nHuman variome proiect country \nnodes: Documenting genetic \ninformation within a country.  Patrinos GP, Smith TD, Howar d H, Al -\nMulla F, Chouchane L, Hadiisavvas A, \nHamed SA, Li XT, Marafie M, Ramesar \nRS, Ramos Fi, de Ravel T, El -Ruby MO, \nShrestha TR, Sobrido Mi, Tadmouri G, \nWitsch -Baumgartner M, Zilfalil BA, \nAuerbach AD, Carpenter K, Cutting GR, \nDung VC, Grody W, Hasler i,  iorde L, \nKaput i, Macek M, Matsubara Y, Padilla \nC, Robinson H, Roias -Martinez A, \nTaylor GR, Vihinen M, Weber T, Burn i, \nQi M, Cotton RG, Rimoin D, \n(International Confederation of HUM MUTAT  2012 \nNov;33(11):151\n3-9. Original  Q1 5,686 1059 -7794   \n \n57 Countries Advisory Council)  \nRevisiting genotype -phenotype \noverlap in neurogenetics: Triplet -\nrepeat expansions mimicking \nspastic paraplegias  Bettencourt C, Quint\u00e1ns B, Ros R, \nAmpuero I, Y\u00e1\u00f1ez Z, Pascual SI, de \nY\u00e9benes iG, Sobrido Mi  HUM MUTAT  2012 \nSep;33(9):1315 -\n23 Orig inal Q1 5,686  1059 -7794  \nAssociation of a XRCC3 \npolymorphism and rectum mean \ndose with the risk of acute radio -\ninduced gastrointestinal toxicity in \nprostate cancer patients  Fachal L, G\u00f3mez -Caama\u00f1o A, Peleteiro \nP, Carballo A, Calvo -Crespo P, S\u00e1nchez -\nGarc\u00eda M, Lobato -Busto R, Carracedo \nA, Vega A.  Radiother Oncol  2012 \nDec;105(3):321 -\n8.  Original  Q1/D1  5,580  0167 -8140  \nTGF\u03b21 SNPs and radio -induced \ntoxicity in prostate cancer patients  Fachal L, G\u00f3mez -Caama\u00f1o A, S\u00e1nchez -\nGarc\u00eda M, Carballo A, Peleteiro P, \nLobato -Busto R, Carracedo A, Vega A.  Radiother Oncol  2012 May; \n103(2):206 -9.  Research \nSupport  Q1/D1  5,580  0167 -8140  \nInvolvement of microglial \nRhoA/Rho -Kinase pathway \nactivation in the dopaminergic \nneuron death. Role of angiotensin \nvia angiotensin type 1 receptor s. Villar -Cheda B, Dominguez -Meiiide A, \nioglar B, Rodriguez -Perez AI, Guerra \nMi, Labandeira -Garcia iL  Neurobiology of  \nDisease  2012 \nAug;47(2):268 -\n79. Original  Q1 5,403  0969 -9961  \nUnmasking adenosine 2A receptors \n(A2ARs) in monkey basal ganglia \noutput neuro ns using cholera toxin \nsubunit B (CTB).  Luquin N, Sierra S, Rico Ai, G\u00f3mez -\nBautista V, Roda E, Conte -Perales L, \nFranco R, McCormick P, Labandeira -\nGarc\u00eda iL, Lanciego iL  Neurobiology of  \nDisease  2012 \nSep;47(3):347 -\n57. Original  Q1 5,403  0969 -9961  \nEffect of phosphodiesterase 7 \n(PDE7) inhibitors in experimental \nautoinmune encephalomyelitis \nmice  Redondo M, Brea iM, Perez DI, Soteras \nI, Val C, P\u00e9rez C, Morales -Garcia iA, \nAlonso -Gil S, Paul -Fernandez N, \nMartin -Alvarez R, Cadavid I, Loza I, \nPerez -Castillo A, Mengo d G, Campillo \nNE, Martinez A, Gil C  iournal Medicinal \nChemistry  2012 Apr \n12;55(7):3274 -\n84. Original  Q1 5,248  0022 -2623  \nSynthesis and biological evaluation \nof 1\u03b1,25-dihydroxyvitamin D\u2083 \nanalogues with a long side chain at Carballa, D; Seoane, S; Zacconi, F; \nP\u00e9rez, X; Rumbo, A; \u00c1lvarez -D\u00edaz, S; \nLarriba, Mi; Pere z-Fernandez, R; iournal of \nMedicinal \nChemistry  2012 Oct \n25;55(20):8642 -\n56. Original  Q1 5,248  0022 -2623   \n \n58 C12 and short C17 side chains  Munoz, A; Maestro, M; Mouri\u00f1o, A; \nTorneiro, M.  \nCharacterization of single \nnucleotide polymorphisms of \ncytochrome p450 in an Australian \ndeceased sample  Pilgrim iL, Ruiz Y, Gesteira A, Cruz R, \nGerostamoulos D, Carracedo A, \nDrummer OH.  Curr Drug Metab  2012 iun \n1;13(5):679 -92. Review  Q1/D1  5,113  1389 -2002  \nExploring the efficiency of gallic \nacid -based dendrimers as carriers in \ngene delivery  de la Fuente M*, Ravi\u00f1a M, Fern\u00e1ndez -\nMeg\u00eda E, Correa i, Sousa -Herv\u00e9s A, \nRiguera R, S\u00e1nchez A, Alonso Mi  Nanomedicine  2012 \nNov;7(11):1667 -\n81. Original  Q1 5,055  1742 -5889  \nGender and survival in patients with \nheart failure: interactions with \ndiabetes and aetiology. Results \nfrom the MAGGIC individual patient \nmeta -analysis.  Mart\u00ednez -Sell\u00e9s M, Doughty RN, Poppe \nK, Whalley GA, Earle N, Tribouilloy C, \nMcMurray ii, Swed berg K, K\u00f8ber L, \nBerry C, Squire I; Meta -Analysis Global \nGroup In Chronic Heart Failure \n(MAGGIC) (Gonzalez -iuanatey iR, \nGrigorian -Shamagian L, Varela -Roman \nA, Maz\u00f3n -Ramos P).  Eur i Heart Fail  2012 \nMay;14(5):473 -\n9.  Original  Q1 4,896  1388 -9842  \nRelationship  of serum sodium \nconcentration to mortality in a wide \nspectrum of heart failure patients \nwith preserved and with reduced \neiection fraction: an individual \npatient data meta -analysis(\u2020): \nMeta -Analysis Global Group in \nChronic heart failure (MAGGIC).  Rusinaru D, Tribouilloy C, Berry C, \nRichards AM, Whalley GA, Earle N, \nPoppe KK, Guazzi M, Macin SM, \nKomaida M, Doughty RN; MAGGIC \nInvestigators.  Eur i Heart Fail.  2012 \nOct;14(10):1139\n-46  Q1 4,896  1388 -9842  \nEndogenous erythropoietin protects \nneuroretinal function in ischemic \nretinopathy  Mowat FM, Gonzalez F, Luhmann UFO, \nLange C, Duran Y, Smith Ai, Maxwell P,  \nAli RR, Baimbridge iWB.  Am i Pathology  2012 \nApr;180(4):1726\n-39 Original  Q1/D1  4,890   0002 -9440   \nComparative analysis of platelet -\nderived microparticles rev eals \ndifferences in their amount and \nproteome depending on the \nplatelet stimulus.  Shai E, Rosa I, Pargui\u00f1a AF, Motahedeh \nS, Varon D, Garc\u00eda A.  iournal of \nProteomics  2012 Dec;76 \nSpec No.:287 -\n96. Original  Q1 4,878  1874 -3919   \n \n59 Proteomics applied to the study o f \nplatelet -related diseases: aiding the \ndiscovery of novel platelet \nbiomarkers and drug targets.  Pargui\u00f1a AF, Garc\u00eda A.  iournal of \nProteomics  2012 Dec;76 \nSpec No.:275 -\n86. Review  Q1 4,878  1874 -3919  \nThe Obestatin/GPR39 System Is Up -\nregulated by Muscle Injur y and \nFunctions as an Autocrine \nRegenerative System.  Gurriar\u00e1n -Rodr\u00edguez U, Santos -Zas I, \nAl-Massadi O, Mosteiro CS, Beiroa D, \nNogueiras R, Crujeiras AB, Seoane LM, \nSe\u00f1ar\u00eds J, Garc\u00eda -Caballero T, Gallego \nR, Casanueva FF, Pazos Y, Cami\u00f1a JP  Journal Biologic al \nChemistry  2012 Nov \n2;287(45):38379\n-89 Original  Q1 4,773  0021 -9258  \nAdaptor protein cerebral cavernous \nmalformation 3 (CCM3) mediates \nphosphorylation of the cytoskeletal \nproteins ezrin/radixin/moesin by \nmammalian Ste20 -4 to protect cells \nfrom oxidative stress.  M. Fidalgo, A. Guerrero, M. Fraile, C. \nIglesias, C.M. Pombo. i. Zalvide  iournal of \nBiological \nChemistry  2012 Mar \n30;287(14):1155\n6-65. Original  Q1 4,770    \nOlanzapine, but not aripiprazole, \nweight -independently elevates \nserum triglycerides and activ ates \nlipogenic gene expression in female \nrats.  Skrede S,  Fern\u00f8 i,  V\u00e1zquez Mi,  Fi\u00e6r \nS, Pavlin T,  Lunder N,  Vidal -Puig \nA, Di\u00e9guez C,  Berge RK,  L\u00f3pez M,  Steen \nVM. Int i \nNeuropsychophar\nmacol.  2012 \nMar;15(2):163 -\n79.  Original  Q1 4,578  1461 -1457  \nPharmacogenomic s in colorectal \ncancer: a genome -wide association \nstudy to predict toxicity after 5 -\nfluorouracil or FOLFOX \nadministration  Fernandez -Rozadilla C, Cazier iB, \nMoreno V, Crous -Bou M, Guin\u00f3 E, \nDur\u00e1n G, Lamas Mi, L\u00f3pez R, Candamio \nS, Gallardo E, Par\u00e9 L, Baiget M , P\u00e1ez D, \nL\u00f3pez -Fern\u00e1ndez LA, Corteioso L, \nGarc\u00eda MI, Buianda L, Gonz\u00e1lez D, \nGonzalo V, Rodrigo L, Re\u00f1\u00e9 iM, iover R, \nBrea -Fern\u00e1ndez A, Andreu M, Bessa X, \nLlor X, Xicola R, Palles C, Tomlinson I, \nCastellv\u00ed -Bel S, Castells A, Ruiz -Ponte C, \nCarracedo A.  Pharm acogenomi\ncs i  Original  Q1 4,536  1470 -269X  \nHuman and rat brain lipofuscin \nproteome.  Ottis P, Koppe K, Onisko B, Dynin I, \nArzberger T, Kretzschmar H, Requena \niR, Silva Ci, Huston iP, Korth C.  Proteomics  2012 \nAug;12(15 -\n16):2445 -54 Original  Q1 4,505  1615 -9853  \n \n60 Cellular distribution, regulated \nexpression, and functional role of \nthe anorexigenic peptide, \nNUCB2/nesfatin -1, in the testis.  Garc\u00eda -Galiano D,  Pineda R,  Ilhan \nT, Castellano iM,  Ruiz -Pino F,  S\u00e1nchez -\nGarrido MA,  Vazquez Mi,  Sangiao -\nAlvarellos S,  Romero -Ruiz A,  Pinilla \nL, Di\u00e9guez C,  Gayt\u00e1n F,  Tena -Sempere \nM. Endocrinology  2012 \nApr;153(4):1959\n-71. Original  Q1 4,459  0013 -7227  \nDetection of a large rearrangement \nin PALB2 in spanish breast cancer \nfamilies with male breast cancer  Blanco A, de la Hoya M, Balma\u00f1 a i, \nRam\u00f3n y Caial T, Teul\u00e9 A, Miramar MD, \nEsteban E, Infante M, Ben\u00edtez i, Torres \nA, Teiada MI, Brunet i, Gra\u00f1a B, Balb\u00edn \nM, P\u00e9rez -Segura P, Osorio A, Velasco \nEA, Chirivella I, Calvo MT, Feliubadal\u00f3 \nL, Lasa A, D\u00edez O, Carracedo A, Cald\u00e9s \nT, Vega A.  Breast  Cancer Res \nTreat  2012 Feb; \n132(1):307 -15 Original  Q1 4,431  0167 -6806  \nFocusing on New Monoamine \nOxidase Inhibitors: Differently \nSubstituted Coumarins as an \nInteresting Scaffold.  Mar\u00eda ioao Matos,  Dolores Vi\u00f1a,  Saleta \nVazquez -Rodriguez ,  Eugenio \nUriarte,  Lourdes Santana.  Curr Top Med \nChem  2012;12(20):221\n0-39 Original  Q1/D1  4,174  1568 -0266  \nHerbal Natural Products as a Source \nof Monoamine Oxidase Inhibitors: A \nreview.  Dolores Vi\u00f1a, Silvia Serra, Manuel \nLamela, Giovanna Delogu  Curr Top Med \nChem  2012;12(20):2 13\n1-44. Original  Q1/D1  4,174  1568 -0266  \nHistory and therapeutic use of \nMAO -A inhibitors: a historical \nperspective of mao -a inhibitors as \nantidepressant drug.  Y\u00e1\u00f1ez M,  Pad\u00edn iF,  Arranz -Tagarro \niA, Cami\u00f1a M,  Laguna R.  Curr Top Med \nChem.  2012;12(20):227\n5-82 Review  Q1/D1  4,174  1568 -0266  \nCardiac protein changes in \nischaemic and dilated \ncardiomyopathy: a proteomic study \nof human left ventricular tissue  Rosell\u00f3 -Llet\u00ed E, Alonso i, Cort\u00e9s R, \nAlmenar L, Mart\u00ednez -Dolz L, S\u00e1nchez -\nL\u00e1zaro I, Lago F, Azor\u00edn I, iuanatey i R, \nPortol\u00e9s M, Rivera M.  i Cell Mol Med  2012 \nOct;16(10):2471\n-86.  Original  Q1 4,125  1582 -1838  \nX-ray cross -complementing group 1 \nand thymidylate synthase \npolymorphisms might predict \nresponse to chemoradiotherapy in \nrectal cancer patients  Lamas Mi, Duran G , Gomez A, Balboa \nE, Anido U, Bernardez B, Rana -Diez P, \nLopez R, Carracedo A, Barros F.  Int i Radiat Oncol \nBiol Phys  2012 ian \n1;82(1):138 -44 Original  Q1 4,105  0360 -3016   \n \n61 Breast feeding, parity and breast \ncancer subtypes in a Spanish cohort  Redondo CM, Gago -Dom\u00ednguez M, \nPonte SM, Castelo ME, iiang X, Garc\u00eda \nAA, Fern\u00e1ndez MP, Tom\u00e9 MA, Fraga \nM, Gude F, Mart\u00ednez ME, Garz\u00f3n VM, \nCarracedo \u00c1, Castelao iE.  Plos One  2012;7(7):e4054\n3 Original  Q1 4,092  1932 -6203  \nDetoxifying antitumoral drugs via \nnanoconiugation: the case of gold \nnanoparticles and cisplatin  ioan Comenge, Carmen Sotelo, \nFrancisco Romero, Oscar Gallego, \nAgust\u00ed Barnadas, Tom\u00e1s Garc\u00eda -\nCaballero Parada, Fernando \nDom\u00ednguez, V\u00edctor F. Puntes  PLoS ONE  2012;7(10):e475\n62. Research \nArticle  Q1 4,092  1932 -6203  \nDifferences in MEF2 and NFAT \ntranscriptional pathways according \nto human heart failure aetiology.  Cort\u00e9s R, Rivera M, Rosell\u00f3 -Llet\u00ed E, \nMart\u00ednez -Dolz L, Almenar L, Azor\u00edn I, \nLago F, Gonz\u00e1lez -iuanatey iR, Portol\u00e9s \nM. Plos One  2012;7(2):e3091\n5. Original  Q1 4,092  1932 -6203  \nFamily history and breast cancer \nhormone receptor status in a \nSpanish cohort  iiang X, Castelao iE, Chavez -Uribe E, \nFernandez Rodriguez B, Celeiro Mu\u00f1oz \nC, Redondo CM, Pe\u00f1a Fernandez M, \nNovo Dominguez A, Pereira CD, \nMart\u00ednez ME, Garc\u00eda -Caballero  T, Fraga \nRodriguez M, Ant\u00fanez i, Carracedo A, \nForteza -Vila i, Gago -Dominguez M.  Plos One  2012;7(1):e2945\n9.  Original  Q1 4,092  1932 -6203  \nGenetic Continuity in the Franco -\nCantabrian Region: New Clues from \nAutochthonous Mitogenomes.  G\u00f3mez -Carballa A, Olivie ri A, Behar \nDM, Achilli A, Torroni A, Salas A  PLOS ONE  2012;7(3):e3285\n1. Original  Q1 4,092  1932 -6203  \nHeart failure induces significant \nchanges in nuclear pore complex of \nhuman cardiomyocytes.  Taraz\u00f3n E, Rivera M, Rosell\u00f3 -Llet\u00ed E, \nMolina -Navarro MM, S\u00e1nche z-L\u00e1zaro \nIi, Espa\u00f1a F, Montero iA, Lago F, \nGonz\u00e1lez -iuanatey iR, Portol\u00e9s M.  PLoS One  2012;7(11):e489\n57. Original  Q1 4,092  1932 -6203  \nHypothalamic mTOR signaling \nmediates the orexigenic action of \nghrelin.  Martins L,  Fern\u00e1ndez -Mallo D,  Novelle \nMG,  V\u00e1zquez M i, Tena -Sempere \nM, Nogueiras R,  L\u00f3pez M,  Di\u00e9guez C.  PLoS One  2012;7(10):e469\n23.  Original  Q1 4,092  1932 -6203  \nIncreased expression of fatty -acid \nand calcium metabolism genes in \nfailing human heart.  Garc\u00eda -R\u00faa V, Otero MF, Lear PV, \nRodr\u00edguez -Penas D, Feii\u00f3o -Band\u00edn S, \nNoguera -Moreno T, Calaza M, Alvarez -Plos One  2012;7(6):e3750\n5.  Original  Q1 4,092  1932 -6203   \n \n62 Barredo M, Mosquera -Leal A, \nParrington i, Brugada i, Portol\u00e9s M, \nRivera M, Gonz\u00e1lez -iuanatey iR, Lago F.  \nMultiple Local and Recent Founder \nEffects of TG M1 in Spanish Families  Fachal L, Rodr\u00edguez -Pazos L, Ginarte M, \nToribio i, Salas A, Vega A  PLOS ONE  2012;7(4):e3358\n0 Original  Q1 4,092  1932 -6203  \nStraightforward inference of \nancestry and admixture proportions \nthrough ancestry -informative \ninsertion deletion  multiplexing  Pereira R, Phillips C, Pinto N, Santos C, \ndos Santos SE, Amorim A, Carracedo \u00c1, \nGusm\u00e3o L.  Plos One  2012;7(1):e2968\n4. Original  Q1 4,092  1932 -6203  \nStructural organization of \nMammalian prions as probed by \nlimited proteolysis.  V\u00e1zquez -Fern\u00e1ndez E, Alonso i, \nPastrana MA, Ramos A, Stitz L, Vidal E, \nDynin I, Petsch B, Silva Ci, Requena iR.  PLoS One. \n2012;7(11):e5011\n1 2012 \nDec;7(11):e5011\n1 Original  Q1 4,092  1932 -6203  \nUniparental markers of \ncontemporary italian population \nreveals details on its pre -roman \nheritage  Brisighelli F, Alvarez -Iglesias V, \nFondevila M, Blanco -Verea A, \nCarracedo A, Pascali VL, Capelli C, Salas \nA. Plos One  2012;7(12):e507\n94. Original  Q1 4,092  1932 -6203  \nVariability of NT -proBNP and its \nrelationship with inflammatory \nstatus in p atients with stable \nessential hypertension: a 2 -year \nfollow -up study.  Rosell\u00f3 -Llet\u00ed E, Calabuig iR, Morillas P, \nCort\u00e9s R, Mart\u00ednez -Dolz L, Almenar L, \nGonz\u00e1lez -iuanatey iR, Lauwers C, \nSalvador A, Portol\u00e9s M, Bertomeu V, \nRivera M.  Plos One  2012;7(2):e3118\n9.  Original  Q1 4,092  1932 -6203  \nAcute effects of orexigenic \nantipsychotic drugs on lipid and \ncarbohydrate metabolism in rat.  iassim G,  Skrede S,  V\u00e1zquez \nMi, Wergedal H,  Vik-Mo AO,  Lunder \nN, Di\u00e9guez C,  Vidal -Puig A,  Berge \nRK, L\u00f3pez M,Steen VM,  Fern\u00f8 i.  Psycho pharmacol\nogy (Berl).  2012 \nFeb;219(3):783 -\n94.  Original  Q1 4,077  0033 -3158  \nInfluence of metabolic syndrome on \ndevelopment of cardiac allograft \nvasculopathy in the transplanted \nheart.  S\u00e1nchez -G\u00f3mez iM, Mart\u00ednez -Dolz L, \nS\u00e1nchez -L\u00e1zaro I, Almenar L, S\u00e1nchez -\nLacuesta E, Mu\u00f1oz -Giner B, Portol\u00e9s \nM, Rivera M, Valera -Rom\u00e1n A, \nGonz\u00e1lez -iuanatey iR, Teiada -Ponce D, \nAg\u00fcero i, Buend\u00eda F, Salvador A.  Transplantation  2012 ian \n15;93(1):106 -\n11. Original  Q1/D1  4,003  0041 -1337  \nDopaminergic degeneration is \nenhanced by chron ic brain \nhypoperfusion and inhibited by Rodriguez -Perez AI, Dominguez -\nMeiiide A, Lanciego iL, Guerra Mi, \nLabandeira -Garcia iL  Age (Dordr)  2012 Sep 18  Original  Q1 3,948  PMID:22986\n582  \n \n63 angiotensin receptor blockage.  \nMitochondrial ATP -sensitive \npotassium chan nels enhance \nangiotensin -induced oxidative \ndamage and dopaminergic neuron \ndegeneration. Relevance for aging -\nassociated susceptibility to \nParkinson's disease.  Rodriguez -Pallares i, Parga iA, ioglar B, \nGuerra Mi, Labandeira -Garcia iL.  Age (Dordr).  2012 \nAug;3 4(4):863 -\n80 Original  Q1 3,948  PMID:21713\n375 \nA Potential Nanomedicine \nConsisting of Heparin -Loaded \nPolysaccharide Nanocarriers for the \nTreatment of Asthma  Oyarzun -Ampuero FA, Brea i, Loza MI, \nAlonso Mi, Torres D  Macromolecular \nBioscience  2012 \nFeb;12(2):176 -\n83 Original  Q1 3,886  1616 -5187  \nInvolvement of PPAR -\u03b3 in the \nneuroprotective and anti -\ninflammatory effects of angiotensin \ntype 1 receptor inhibition: effects of \nthe receptor antagonist telmisartan \nand receptor deletion in a mouse \nMPTP model of Parkinson's disease.  Garrido -Gil P, ioglar B, Rodriguez -Perez \nAI, Guerra Mi, Labandeira -Garcia iL.  journal of  \nNeuroinflammati\non 2012 Feb \n22;9:38  Original  Q2 3,827  1742 -2094  \nChanges in lipid transport -involved \nproteins of epicardial adipose tissue \nassociated with coronary artery \ndisease.  Salgado -Somoza A, Teiieira -Fern\u00e1ndez \nE, Fern\u00e1ndez AL, Gonz\u00e1lez -iuanatey iR, \nEiras S.  Atherosclerosis  2012 \nOct;224(2):492 -\n9.  Original  Q1 3,794  0021 -9150  \nCografting of carotid body cells \nimproves the long -term survival, \nfiber outgrowth and functional \neffects of grafted dopaminergic \nneurons.  Rodriguez -Pallares i, ioglar B, Mu\u00f1oz -\nManchado AB, Villadiego i, Toledo -Aral \nii, Labandeira -Garcia iL  Regenerative  \nMedicine  2012 \nMay;7(3):309 -\n22. Original  Q1 3,718  PMID:22594\n325 \nNo evidence that maior mtDNA \nEuropean haplogroups confer risk \nto schiz ophrenia  Mosquera -Miguel A, Torrell H, Abasolo \nN, Arroio M, Paz E, Ramos -R\u00edos R, Agra \nS, P\u00e1ramo M, Brenlla i, Mart\u00ednez S, \nVilella E, Valero i, Guti\u00e9rrez -Zotes A, AM i MED GENET \nB \nNEUROPSYCHIAT\nR GENET  2012 \niun;159B(4):414\n-21 Original  Q1 3,705  1552 -4841   \n \n64 Martorell L, Costas i, Salas A  \nSNP variants within the vanilloid \nTRPV1 and TRPV3 receptor genes \nare associated with migraine in the \nSpanish population  Carre\u00f1o O, Corominas R, Fern\u00e1ndez -\nMorales i, Cami\u00f1a M, Sobrido Mi, \nFern\u00e1ndez -Fern\u00e1ndez iM, Pozo -Rosich \nP, Co rmand B, Macaya A  AM i MED GENET \nB \nNEUROPSYCHIAT\nR GENET  2012 \nian;159B(1):94 -\n103.  Original  Q1 3,705  1552 -4841  \nExpression and regulation of \nchemerin during rat pregnancy.  Garces MF,  Sanchez E,  Acosta Bi,  Angel \nE, Ru\u00edz AI,  Rubio -Romero iA,  Di\u00e9guez \nC, Nogueir as R,  Caminos iE.  Placenta  2012 \nMay;33(5):373 -\n8.  Original  Q1/D1  3,693  0143 -4004  \nFirst SCA36 patients in Europe: \nclinical, physiological and imaging \ndetails of 10 families  Arias, M.; Garcia -Murias, M.; Quintans, \nB.; Arias -Rivas, S.; Pardo, i; Vazquez, F.;  \nDapena, D.; Cacheiro, P.; Blanco -Arias, \nP.; Carracedo, A. y Sobrido, M.i.  Eur j Neurol  2012 Sep; \nVolume: \n19   Special \nIssue: \nSI   Supplement: \n1   Pages: 41 -41. Meeting \nabstract  Q1 3,692  1351 -5101  \nValidation study of genetic factors \ncontributing to Parkin son's disease \nin Spanish and Latin American \npopulations  Sesar, A.; Cacheiro, P.; Camina -Tato, \nM.; Lopez, M.; Quintans, B.; Alonso, E.; \nCebrian, E.; Castro, A.; Carracedo, A. y \nSobrido, Mi.  Eur i Neurol  2012 Sep;  \nVolume: 19   \nSpecial Issue: SI   \nSupplement : 1   \nPages: 307 -307.  Meeting \nabstract  Q1 3,692  1351 -5101  \nIdentification in silico and \nexperimental validation of novel \nphosphodiesterase 7 inhibitors with \nefficacy in experimental \nautoimmune encephalomyelitis \nmice  Redondo M, Palomo V, Brea i, P\u00e9rez \nDI, M art\u00edn -\u00c1lvarez R, P\u00e9rez C, Pa\u00fal -\nFern\u00e1ndez N, Conde S, Cadavid MI, \nLoza MI, Mengod G, Mart\u00ednez A, Gil C, \nCampillo NE  ACS Chemical \nNeuroscience  2012 Oct \n17;3(10):793 -\n803 Original  Q1 3,676  1948 -7193  \nInterdisciplinary approach to the \ndemography of iamaica  Deas on ML, Salas A, Newman SP, \nMacaulay VA, St A Morrison EY, \nPitsiladis YP  BMC EVOL BIOL  2012 Feb \n23;12:24  Original  Q2 3,521  1471 -2148  \nDefining stem cell types: \nunderstanding the therapeutic \npotential of ESCs, ASCs, and iPS cells  Alvarez CV, Garcia -Lavandeir a M, \nGarcia -Rendueles ME, Diaz -Rodriguez \nE,Garcia -Rendueles AR, Perez -Romero \nS, Vila TV, Rodrigues iS, Lear PV, Bravo \nSB. i Mol Endocrinol.  2012 Aug \n30;49(2):R89 -\n111 Original/Origi\nnal Q2 3,485  0952 -5041   \n \n65 Nutritional, hormonal and depot -\ndependent regulation  of the \nexpression of the small GTPase \nRab18 in rodent adipose tissue  Pulido MR, Rabanal -Ruiz Y, \nAlmabouada F, Diaz -Ruiz A, Burrell \nMA, Vazquez Mi, Casta\u00f1o iP, Kineman \nRD, Luque RM, Di\u00e9guez C, Vazquez -\nMartinez RM, Malagon MM  i Mol Endocrinol  2012 Dec \n31;50 (1):19 -29. Original  Q2 3,485  0952 -5041  \nA replication study of a GWAS \nfinding in migraine does not \nidentify association in a Spanish \ncase -control sample.  Sintas C, Carre\u00f1o O, Fern\u00e1ndez -\nMorales i, Cacheiro P, Sobrido Mi, \nNarberhaus B, Pozo -Rosich P, Macaya \nA, Cormand B  Cephalalgia  2012 \nOct;32(14):1076\n-80 Original  Q1 3,430  0333 -1024  \nCharacterization of the \nhomodimerization interface and \nfunctional hotspots of the CXCR4 \nchemokine receptor  Rodr\u00edguez, D.; Guti\u00e9rrez -de-Ter\u00e1n, H  Proteins  \n 2012 \nAug;80(8):1919 -\n28 Original  Q2 3,392  0887 -3585  \nThe atypical cannabinoid O -1602 \nstimulates food intake and \nadiposity in rats.  D\u00edaz -Arteaga A,  V\u00e1zquez Mi,  Vazquez -\nMart\u00ednez R,  Pulido MR,  Suarez \ni, Vel\u00e1squez DA,  L\u00f3pez M,  Ross RA,  de \nFonseca FR,  Bermudez -Silva \nFi, Malag\u00f3n MM,  Di\u00e9guez C,  Nogueiras \nR. Diabetes Obes \nMetab.  2012 \nMar;14(3):234 -\n43.  Original  Q2 3,379  1462 -8902  \nNeuroprotective efficacy of \nquinazoline type phosphodiesterase \n7 inhibitors in cellular cultures and \nexperimental stroke model  Redondo M, Zarruk iG, Ceballos P, \nP\u00e9rez DI, P\u00e9rez C, Perez -Castillo A, \nMoro MA, Brea i, Val C, Cadavid MI, \nLoza MI, Campillo NE, Mart\u00ednez A, Gil C  European iournal \nof Medicinal \nChemistry  2012 \nian;47(1):175 -\n85 Original  Q1 3,346  0223 -5234  \nNew chromene scaffolds for \nadenosine A(2A) receptors : \nsynthesis, pharmacology and \nstructure -activity relationships.  Areias F, Costa M, Castro M, Brea i, \nGregori -Puigian\u00e9 E, Proen\u00e7a MF, \nMestres i, Loza MI.  European iournal \nof medicinal \nchemistry  2012 \nAug;54:303 -10 Original  Q1 3,346  0223 -5234 \n(Print)  \nPredict ive value of advanced \nglycation end products for the \ndevelopment of post -infarction \nheart failure: a preliminary report.  Raposeiras -Roub\u00edn S, Rodi\u00f1o -ianeiro \nBK, Paradela -Dobarro B, Grigorian -\nShamagian L, Garc\u00eda -Acu\u00f1a iM, Aguiar -\nSouto P, iacquet -Hervet M, R eino -\nMaceiras MV, Alvarez E, Gonz\u00e1lez -\niuanatey iR.  Cardiovasc \nDiabetol  2012 Aug \n21;11:102.  Original  Q2 3,346  1475 -2840   \n \n66 Histological and molecular features \nof lipomatous and nonlipomatous \nadipose tissue in familial partial \nlipodystrophy caused by LMNA \nmut ations.  Ara\u00faio -Vilar D, Victoria B, Gonz\u00e1lez -\nM\u00e9ndez B, Barreiro F, Fern\u00e1ndez -\nRodr\u00edguez B, Cereiio R, Gallego -\nEscuredo iM, Villarroya F, Pa\u00f1eda -\nMen\u00e9ndez A  Clinical \nEndocrinology  2012 \niun;76(6):816 -\n24. Original  Q2 3,320  1365 -2265  \nGenetic epistasis in femal e suicide \nattempters  Fern\u00e1ndez -Navarro P, Vaquero -\nLorenzo C, Blasco -Fontecilla H, D\u00edaz -\nHern\u00e1ndez M, Gratac\u00f2s M, Estivill X, \nCostas i, Carracedo \u00c1, Fern\u00e1ndez -\nPiqueras i, Saiz -Ruiz i, Baca -Garcia E.  Prog Neuro -\nPsychoph  2012 Aug \n7;38(2):294 -\n301..  Original  Q1 3,247  0278 -5846  \nNosema ceranae (Microsporidia), a \ncontroversial 21st century honey \nbee pathogen  Mariano Higes, Ar\u00e1nzazu Meana, \nCarolina Bartolom\u00e9, Cristina Bot\u00edas and \nRaquel Mart\u00edn -Hern\u00e1ndez  Environmental \nmicrobioloby \nreports  Feb 2012; 5 (1): \n17-29 Origin al Q1 3,232  1758 -2229  \nCOGENT (COlorectal cancer \nGENeTics) revisited  Houlston RS; members of COGENT \n(Carracedo A, Ruiz -Ponte C)  Mutagenesis  2012 \nMar;27(2):143 -\n51.  Review  Q2 3,183  0267 -8357  \nSeeking genetic susceptibility \nvariants for colorectal cancer: th e \nEPICOLON consortium experience  Castellv\u00ed -Bel S, Ruiz -Ponte C, \nFern\u00e1ndez -Rozadilla C, Abul\u00ed A, Mu\u00f1oz \ni, Bessa X, Brea -Fern\u00e1ndez A, Ferro M, \nGir\u00e1ldez MD, Xicola RM, Llor X, iover R, \nPiqu\u00e9 iM, Andreu M, Castells A, \nCarracedo A; Gastrointestinal \nOncology Gro up of the Spanish \nGastroenterological Association (Salas, \nA.). Mutagenesis  2012 \nMar;27(2):153 -\n9. Original  Q2 3,183  0267 -8357  \nCoronary artery disease is \nassociated with higher epicardial \nretinol -binding protein 4 (RBP4) and \nlower glucose transporter (GLUT)  4 \nlevels in epicardial and \nsubcutaneous adipose tissue.  Salgado -Somoza A, Teiieira -Fern\u00e1ndez \nE, Rubio i, Couso E, Gonz\u00e1lez -iuanatey \niR, Eiras S.  Clin Endocrinol \n(Oxf)  2012 ian; \n76(1):51 -8.  Original  Q2 3,168  0300 -0664  \n8-Substituted 3 -arylcoumarins as \npotent and selective MAO -B \ninhibitors: synthesis, Dolores Vi\u00f1a, Mar\u00eda ioao Matos, Giulio \nFerino, Enzo Cadoni, Reyes Laguna, \nFernanda Borges, Eugenio Uriarte, ChemMedChem \n7, 464 -470 2012 Mar \n5;7(3):464 -70 Original  Q2 3,151  1860 -7187   \n \n67 pharmacological evaluation, and \ndocking studies.  Lourdes Santana.  \nBMPR1A mutations in early -onset \ncolorectal cancer with mismatch \nrepair proficiency  Fernandez -Rozadilla C, Brea -Fern\u00e1ndez \nA, Bessa X, Alvarez -Urturi C, Abul\u00ed A, \nClofent i, Pay\u00e1 A; The EPICOLON \nConsortium, iover R, Xic ola R, Llor X, \nAndreu M, Castells A, Carracedo A, \nCastellv\u00ed -Bel S, Ruiz -Ponte C.  Clin Genet  2012 Oct 12.  Letter  Q2 3,128  0009 -9163  \nA cautionary note on switching \nmitochondrial DNA reference \nsequences in forensic genetics  Salas A, Coble M, Desmyter S, \nGrzybowski T, Gusm\u00e3o L, Hohoff C, \nHolland MM, Irwin iA, Kupiec T, Lee \nHY, Ludes B, Lutz -Bonengel S, Melton \nT, Parsons Ti, Pfeiffer H, Prieto L, \nTagliabracci A, Parson W  FORENSIC SCI INT \n-GENET  2012 \nDec;6(6):e182 -\n4. Original  Q1 3,082  1872 -4973  \nA new SNP assay  for identification \nof highly degraded human DNA  Freire -Aradas A, Fondevila M, Kriegel \nAK, Phillips C, Gill P, Prieto L, Schneider \nPM, Carracedo A, Lareu MV.  Forensic Sci Int \nGenet  2012 \nMay;6(3):341 -9 Original  Q1 3,082  1872 -4973  \nAllele frequencies of 20 S TRs from \nNorthwest Spain (Galicia)  Fernandez -Formoso L, Phillips C, \nRodriguez A, Calvo R, Barbaro A, Lareu \nMV, Carracedo \u00c1.  Forensic Sci Int \nGenet  2012 \nSep;6(5):e149 -\n50.  Letter  Q1 3,082  1872 -4973  \nAnalysis of a claimed distant \nrelationship in a deficient pedigree \nusing high density SNP data  Lareu MV, Garc\u00eda -Magari\u00f1os M, \nPhillips C, Quintela I, Carracedo A, \nSalas A.  Forensic Sci Int \nGenet  2012 \nMay;6(3):350 -3. \nEpub 2011 Aug \n24. Original  Q1 3,082  1872 -4973  \nAnalysis of the SNPforID 52 -plex \nmarkers in four Nat ive American \npopulations from Venezuela  Ruiz Y, Chiurillo MA, Borias L, Phillips C, \nLareu MV, Carracedo \u00c1.  Forensic Sci Int \nGenet  2012 \nSep;6(5):e142 -5. Original  Q1 3,082  1872 -4973  \nCurrent Next Generation \nSequencing technology may not \nmeet forensic standar ds Bandelt Hi, Salas A  FORENSIC SCI INT \n-GENET  2012 \nian;6(1):143 -5. Original  Q1 3,082  1872 -4973  \nDistribution of allele frequencies of \n20 STRs loci in a population sample \nfrom Calabria, Southern Italy  Barbaro A, Phillips C, Formoso LF, \nLareu MV, Carracedo \u00c1. Forensic Sci Int \nGenet  2012 \nSep;6(5):e137 -\n8.. Letter  Q1 3,082  1872 -4973   \n \n68 Focus issue -Analysis and \nbiostatistical interpretation of \ncomplex and low template DNA \nsamples  Carracedo A, Schneider PM, Butler i, \nPrinz M.  Forensic Sci Int \nGenet.  2012 \nDec;6(6):6 77-8.  Editorial  Q1 3,082  1872 -4973  \nGenetic variability of the SNPforID \n52-plex identification SNP panel in \nItalian population samples  Barbaro A, Phillips C, Fondevila M, \nLareu M, Carracedo A.  Forensic Sci Int \nGenet.  2012 \nDec;6(6):e185 -\n6.. Letter  Q1 3,082  1872 -4973  \nPatterns of Y -STR variation in Italy  Brisighelli F, Blanco -Verea A, Boschi I, \nGaragnani P, Pascali VL, Carracedo A, \nCapelli C, Salas A.  Forensic Sci Int \nGenet  2012 \nDec;6(6):834 -9  Original  Q1 3,082  1872 -4973  \nRNA/DNA co -analysis from blood \nstains--results of a second \ncollaborative EDNAP exercise  Haas C, Hanson E, Anios Mi, B\u00e4r W, \nBanemann R, Berti A, Borges E, \nBouakaze C, Carracedo A, Carvalho M, \nCastella V, Choma A, De Cock G, \nD\u00f6tsch M, Hoff -Olsen P, iohansen P, \nKohlmeier F, Lindenbergh PA, Lud es B, \nMaro\u00f1as O, Moore D, Morerod ML, \nMorling N, Niederst\u00e4tter H, Noel F, \nParson W, Patel G, Popielarz C, Salata \nE, Schneider PM, Siien T, Svie\u017eena B, \nTuransk\u00e1 M, Zatkal\u00edkov\u00e1 L, Ballantyne \ni. Forensic Sci Int \nGenet  2012 \nian;6(1):70 -80 Original  Q1 3,082  1872-4973  \nThe recombination landscape \naround forensic STRs: Accurate \nmeasurement of genetic distances \nbetween syntenic STR pairs using \nHapMap high density SNP data  Phillips C, Ballard D, Gill P, Court DS, \nCarracedo A, Lareu MV.  Forensic Sci Int \nGenet  2012 \nMay;6(3):354 -\n65.  Original  Q1 3,082  1872 -4973  \nTyping short amplicon binary \npolymorphisms: supplementary \nSNP and Indel genetic information \nin the analysis of highly degraded \nskeletal remains.  Romanini C, Catelli ML, Borosky A, \nPereira R, Romero M, Salado Pue rto \nM, Phillips C, Fondevila M, Freire A, \nSantos C, Carracedo A, Lareu MV, \nGusmao L, Vullo CM.  Forensic Sci Int \nGenet  2012 \niul;6(4):469 -76.  Original  Q1 3,082  1872 -4973  \nBaseline epicardial adipose tissue \nadiponectin levels predict Teiieira -Fernandez E, Eiras S, Salgado \nSomoza A, Gonzalez -iuanatey iR.  Cytokine  2012 \nDec;60(3):674 -Original  Q2 3,019  1043 -4666   \n \n69 cardiovascular outcomes:  a long -\nterm follow -up study.  80 \nTerena Amerindian group \nautosomal STR data: comparison \nstudies with other Brazilian \npopulations . Manta FS, Silva DA, S\u00e1nchez -Diz P, \nAguiar iI, Cabello PH, Carvalho EF.  MOL BIOL REP  2012 \nApr;39(4):4455 -\n9 Original  Q2 2,929  0301 -4851  \nRegulation of lipin1 by nutritional \nstatus, adiponectin, sex and \npituitary function in rat white \nadipose tissue.  Gonz\u00e1l ez CR,  Novelle MG,  Caminos \niE, V\u00e1zquez Mi,  Luque RM,  L\u00f3pez \nM, Nogueiras R,  Di\u00e9guez C.  Physiol Behav  2012 Feb \n1;105(3):777 -83 Original  Q2 2,869  0031 -9384  \nThe HPA axis modulates the CNS \nmelanocortin control of liver \ntriacylglyceride metabolism.  Wiedmer P,  Chaudhary N,  Rath M,  Yi \nCX, Ananthakrishnan G,  Nogueiras \nR, Wirth EK,  Kirchner H,  Schweizer \nU, Jonas W,  Veyrat -Durebex C,  Rohner -\nJeanrenaud F,  Sch\u00fcrmann A,  Joost \nHG, Tsch\u00f6p MH,  Perez -Tilve D.  Physiol Behav  2012 Feb \n1;105(3):791 -9 Original  Q2 2,869  0031 -9384  \nProcyanidins from grape pomace \nare suitable inhibitors of human \nendothelial NADPH oxidase.  \u00c1lvarez E, Rodi\u00f1o -ianeiro BK, ierez M, \nUcieda -Somoza R, N\u00fa\u00f1ez Mi, Gonz\u00e1lez -\niuanatey iR.  i Cell Biochem  2012 \nApr;113(4):1386\n-96. Original  Q2 2,868  0730 -2312  \nThe ro le of the adenomatous \npolyposis coli (APC) in oral \nsquamous cell carcinoma  P\u00e9rez -Say\u00e1ns M, Su\u00e1rez -Pe\u00f1aranda iM, \nHerranz -Carnero M, Gayoso -Diz P, \nBarros -Angueira F, G\u00e1ndara -Rey iM, \nGarc\u00eda -Garc\u00eda A.  ORAL ONCOL  2012 \nian;48(1):56 -60 Original  Q1/D1  2,857  1368 -8375 \nPrions, proteinase K and infectivity.  Sainani G, Requena iR.  Prion  2012 Nov -\nDec;6(5):430 -2 Review  Q3 2,850  1933 -6896  \nThe value of genetic polymorphisms \nto predict toxicity in metastatic \ncolorectal patients with irinotecan -\nbased regimens  Lamas Mi, Dur an G, Balboa E, \nBernardez B, Candamio S, Vidal Y, \nMosquera A, Giraldez iM, Lopez R, \nCarracedo A, Barros F.  Cancer \nChemother \nPharmacol  2012 \niun;69(6):1591 -\n9.  Original  Q2 2,833  0344 -5704  \nA melting pot of multicontinental \nmtDNA lineages in admixed \nVenezuela ns G\u00f3mez -Carballa A, Ignacio -Veiga A, \nAlvarez -Iglesias V, Pastoriza -Mourelle \nA, Ru\u00edz Y, Pineda L, Carracedo A, Salas \nA. Am i Phys \nAnthropol  \n 2012 \nJan;147(1):78 -\n87 Original  Q3 2,824  0002 -9483   \n \n70 3-Substituted coumarins as dual \ninhibitors of AChE and MAO for t he \ntreatment of Alzheimer\u2019s disease  Dolores Vi\u00f1a, Maria ioao Matos, \nMatilde Ya\u00f1ez, Lourdes Santana, \nEugenio Uriarte  MedChemComm \n3, 213 -218 2012 Feb;  3, \n213-218 Original  Q2 2,800  2040 -2503  \nPutamen neurons process both \nsensory and motor information \nduring a complex task.  Vicente AF, Bermudez MA, Romero \nMC, Perez R, Gonzalez F  Brain Research  2012 iul \n23;1466:70 -8 Original  Q2 2,728  0006 -8993  \nHyperthyroidism differentially \nregulates neuropeptide S system in \nthe rat brain  Gonz\u00e1lez CR,  Mart\u00ednez de Morentin \nPB, Mart\u00ednez -S\u00e1nchez N,  G\u00f3mez -D\u00edaz \nC, Lage R,  Varela L,  Di\u00e9guez \nC, Nogueiras R,  Casta\u00f1o iP,  L\u00f3pez M.  Brain Res.  2012 Apr \n23;1450:40 -8.  Original  Q3 2,728  0006 -8993  \nPersistent lipid abnormalities in \nstatin -treated patients and \npredictors of LDL -cholesterol go al \nachievement in clinical practice in \nEurope and Canada.  Gitt AK, Drexel H, Feely i, Ferri\u00e8res \ni, Gonzalez -iuanatey iR, Thomsen KK, \nLeiter LA, Lundman P, da Silva PM, \nPedersen T, Wood D, i\u00fcnger C, Dellea \nPS, Sazonov V, Chazelle F, Kastelein ii; \nDYSIS Inve stigators.  Eur i Prev Cardiol.  2012 \nApr;19(2):221 -\n30  Q2 2,634  1741 -8267  \nA method for the analysis of 32 X \nchromosome insertion deletion \npolymorphisms in a single PCR  Pereira R, Pereira V, Gomes I, Tomas C, \nMorling N, Amorim A, Prata Mi, \nCarracedo A, Gusm \u00e3o L.  Int i Legal Med  2012 \nian;126(1):97 -\n105. Epub 2011 \niun 30.  Original  Q1 2,587  0937 -9827  \nForensic performance of two \ninsertion -deletion marker assays  Fondevila M, Phillips C, Santos C, \nPereira R, Gusm\u00e3o L, Carracedo A, \nButler iM, Lareu MV, Vallone PM.  Int i Legal Med  2012 \nSep;126(5):725 -\n37. Original  Q1 2,587  0937 -9827  \nHaplogrouping mitochondrial DNA \nsequences in Legal \nMedicine/Forensic Genetics  Bandelt Hi, van Oven M, Salas A  INT i LEGAL MED  2012 \nNov;126(6):901 -\n16 Original  Q1 2,587  0937 -9827  \nHydroxyco umarins as selective \nMAO -B inhibitors  Silvia Serra, Giulio Ferino, Mar\u00eda ioao \nMatos, Saleta V\u00e1zquez -Rodr\u00edguez, \nGiovanna Delogu, Dolores Vi\u00f1a, Enzo \nCadoni, Lourdes Santana, Eugenio \nUriarte  Bioorganic & \nMedicinal \nChemistry Letters \n22, 258 -261 2012 ian \n1;22(1 ):258 -61 Original  Q2 2,554  0960 -894X  \nIncreased clopidogrel response is \nassociated with ABCC3 expression: \na pilot study  Luchessi AD, Silbiger VN, Cerda A, \nHirata RD, Carracedo A, Brion M, \nI\u00f1iguez A, Bravo M, Bastos G, Sousa Clin Chim Acta  2012 Feb \n18;413(3 -\n4):417 -21. Original  Q1 2,535  0009 -8981   \n \n71 AG, Hirata MH.  \n[Advances in arterial hypertension \nand diabetes mellitus].  Cordero A, Lekuona I, Galve E, Maz\u00f3n \nP; Secci\u00f3n de Hipertensi\u00f3n Arterial, \nGrupo de Trabaio Coraz\u00f3n y Diabetes, \nGrupo de Trabaio Cardio -Renal,  \nSociedad Espa\u00f1ola de Cardiolog\u00eda, \nEspa\u00f1a.  Rev Esp Cardiol  2012 ian; 65 \nSuppl 1:12 -23. Original  Q2 2,530  0300 -8932  \nAn opportunity to know about \nresistant hypertension in our area.  Vidal -P\u00e9rez R, Otero -Ravi\u00f1a F, Gesto \nRB, Gonz\u00e1lez -iuanatey iR.  Rev Esp Card iol 2012 ian; \n65(1):109.  Letter  Q2 2,530  0300 -8932  \nAttitude and efficacy of \ncardiologists with respect to \nsmoking in patients after acute \ncoronary syndromes.  Cordero A, Bertomeu -Mart\u00ednez V, \nMaz\u00f3n P, Cos\u00edn i, Galve E, Lekuona I, \nde la Gu\u00eda F, Gonzalez -iuanatey iR.  Rev Esp Cardiol  2012 \nAug;65(8):719 -\n725.  Original  Q2 2,530  0300 -8932  \nCardiopat\u00eda isqu\u00e9mica y muier: son \nnecesarias m\u00e1s respuestas. \nRespuesta  Vidal -P\u00e9rez R, Otero -Ravi\u00f1a F, de Blas \nAbad P, Gonz\u00e1lez -iuanatey iR; en \nrepresentaci\u00f3n de los componente s \ndel grupo Barbanza.  Rev Esp Cardiol  2012 \nNov;65(11):106\n7. Letter  Q2 2,530  0300 -8932  \nChange in atrial fibrillation status, \ncomments to Val -FAAP registry.  Vidal -P\u00e9rez R, Otero -Ravi\u00f1a F, Turrado \nTurrado V, Gonz\u00e1lez -iuanatey iR.  Rev Esp Cardiol  2012 \nMay;65( 5):490 -\n1; author reply \n491-2.. Letter  Q2 2,530  0300 -8932  \nComments on the ESC Guidelines \nfor the diagnosis and treatment of \nacute and chronic heart failure \n2012. A report of the Task Force of \nthe Clinical Practice Guidelines \nCommittee of the Spanish Societ y \nof Cardiology.  Anguita M, Comin i, Almenar L, Crespo \nM, Delgado i, Gonzalez -Costello i, \nHernandez -Madrid A, Manito N, Perez \nde la Sota E, Segovia i, Segura C, \nAlonso -Gomez AM, Anguita M, \nCequier A, Comin i, Diaz -Buschmann I, \nFernandez -Lozano I, Fernandez -Ortiz \nA, Gomez de Diego ii, Pan M, Worner \nF, Alonso -Pulpon L, Bover R, Castro A, \nDiaz -Molina B, Gomez -Bueno M, \nGonzalez -iuanatey iR, Lage E, Lopez -\nGranados A, Lupon i, Martinez -Dolz L, Rev Esp Cardiol  2012 \nOct;65(10):874 -\n878.  Editorial  Q2 2,530  0300 -8932   \n \n72 Munoz R, Pascual D, Ridocci F, Roig E, \nVarela A, Vazquez de Prada iA.  \nComments on the ESC guidelines on \ncardiovascular disease prevention \n(version 2012). A report of the Task \nForce of the Clinical Practice \nGuidelines Committee of the \nSpanish Society of Ca rdiology.  Diaz -Buschmann I, Castro A, Galve E, \nCalero Mi, Dalmau R, Guzm\u00e1n G, \nCordero A, F\u00e1cila L, Quiles i, Arrarte V, \nDiaz -Buschmann I, Alonso G\u00f3mez \u00c1M, \nCequier \u00c1, Com\u00edn i, Fern\u00e1ndez -Ortiz A, \nPan M, Fern\u00e1ndez Lozano FW, \nFern\u00e1ndez -Ortiz A, Sanmart\u00edn M, \nFerreira I, Brotons C, L\u00f3pez Send\u00f3n iL, \nMaz\u00f3n P, Alonso i, Abeytua M, \nGonz\u00e1lez iuanatey iR, de Pablo C, \nWorner F, Castro -Beiras A.  Rev Esp Cardiol \n(Engl Ed)  2012 \nOct;65(10):901 -\n10  Q2 2,530  1885 -5857   \nComments on the ESC guidelines on \nthe management of card iovascular \ndiseases during pregnancy. A critical \nvision of Spanish cardiology.  Alonso G\u00f3mez AM, Com\u00edn i, Borr\u00e1s X, \ndel Castillo S, Elvira Gonz\u00e1lez A, Maz\u00f3n \nP, Monserrat L, Piiuan A, Salvador Sanz \nA; Grupo de Trabaio de Sociedad \nEspa\u00f1ola de Cardiolog\u00eda de G u\u00eda de \nPr\u00e1ctica Cl\u00ednica sobre embarazo; \nComit\u00e9 de Gu\u00edas de Pr\u00e1ctica Cl\u00ednica de \nSEC, Anguita M, Cequier A, Fern\u00e1ndez -\nOrtiz A, Pan M, Worner F, Alonso \nG\u00f3mez AM, Com\u00edn i, Alonso C, Bardai\u00ed \nA, Cobo M, Garc\u00eda -Pav\u00eda P, Gonz\u00e1lez \nCostello i, Oliver iM, Pedreira M,  \nSerrano iM, Subirana M, Tornos P.  Rev Esp Cardiol  2012 Feb; \n65(2):113 -8. Editorial  Q2 2,530  0300 -8932  \nCost -effectiveness of dabigatran for \nstroke prevention in non -valvular \natrial fibrillation in Spain.  Gonz\u00e1lez -iuanatey iR, Alvarez -Sabin i, \nLobos iM, Ma rt\u00ednez -Rubio A, Reverter \niC, Oyag\u00fcez I, Gonz\u00e1lez -Roias N, \nBecerra V.  Rev Esp Cardiol  2012 \nOct;65(10):901 -\n910.  Original  Q2 2,530  0300 -8932  \nDiagnostic accuracy of computer -\nassisted electrocardiography in the \ndiagnosis of left ventricular \nhypertrophy in lef t bundle branch Rodr\u00edguez -Padial L, Rodr\u00edguez -Pic\u00f3n B, \nierez -Valero M, Casares -Medrano i, \nAkerstr\u00f6m FO, Calderon A, Barrios V, \nSarr\u00eda -Santamera A, Gonz\u00e1lez -iuanatey Rev Esp Cardiol  2012 ian; \n65(1):38 -46.  Original  Q2 2,530  0300 -8932   \n \n73 block.  iR, Coca A, Andr\u00e9s i, Ruiz -Baena i.  \nIschemic heart disease in women. \nData from BARIHD study.  Vidal -P\u00e9rez R, Otero -Ravi\u00f1a F, G\u00f3mez \nV\u00e1zquez iL, Santos Rodr\u00edguez iA, De \nFrutos De Marcos C, Gonz\u00e1lez -iuanatey \niR; en representaci\u00f3n de los \ninvestigadores del grupo Barbanza.  Rev Esp Cardiol  2012 \nNov;65(11):105\n6-8.  Letter  Q2 2,530  0300 -8932  \nSafety and efficacy of endothelial \nprogenitor cell capture stent in ST -\nelevation acute myocardial \ninfarction. GENIA Study.  Santas -Alvarez M, Lopez -Otero D, Cid -\nAlvarez AB, Souto -Castro P, Tri llo-\nNouche R, Gonzalez -iuanatey iR.  Rev Esp Cardiol  2012 \niul;65(7):670 -\n671.  Letter  Q2 2,530  0300 -8932  \nSructural and functional inverse \ncardiac remodeling after \ncavotricuspid isthmus ablation in \npatients with typical atrial flutter.  Garc\u00eda -Seara i, Gude F , Cabanas -\nGrand\u00edo P, Mart\u00ednez -Sande iL, \nFern\u00e1ndez -L\u00f3pez X, Elices -Teia i, \nRaposeiras Roubin S, Gonz\u00e1lez -\niuanatey iR.  Rev Esp Cardiol.  2012 \nNov;65(11):100\n3-9.  Original  Q2 2,530  0300 -8932  \nTranscatheter aortic valve \nimplantation: safety and \neffectiveness of  the treatment of \ndegenerated aortic homograft.  L\u00f3pez -Otero D, Teles R, G\u00f3mez -\nHospital iA, Balestrini CS, Romaguera \nR, Saaibi -Solano iF, Neves i, Cid -Alvarez \nB, Brito i, Cequier -Fillat A, Trillo -\nNouche R.  Rev Esp Cardiol  2012 Apr; \n65(4):350 -5.  Original  Q2 2,530  0300 -8932  \nDiagnostic accuracy of computer -\nassisted electrocardiography in the \ndiagnosis of left ventricular \nhypertrophy in left bundle branch \nblock.  Rodr\u00edguez -Padial L, Rodr\u00edguez -Pic\u00f3n B, \nierez -Valero M, Casares -Medrano i, \nAkerstr\u00f6m FO, Calderon A,  Barrios V, \nSarr\u00eda -Santamera A, Gonz\u00e1lez -iuanatey \niR, Coca A, Andr\u00e9s i, Ruiz -Baena i  Rev Esp Cardiol \n(Engl Ed).  2012 \nian;65(1):38 -46.  Q3 2,530  1885 -5857   \nImpact of a health safety warning \nand prior authorisation on the use \nof piroxicam: a time -series stu dy Carracedo -Mart\u00ednez E, Pia -Morandeira \nA, Figueiras A.  Pharmacoepidemi\nol Drug Saf  2012 \nMar;21(3):281 -\n4.  Original  Q2 2,528  1053 -8569  \nInfluence of heart failure on \nnucleolar organization and protein \nexpression in human hearts.  Rosell\u00f3 -Llet\u00ed E, Rivera M, C ort\u00e9s R, \nAzor\u00edn I, Sirera R, Mart\u00ednez -Dolz L, \nHove L, Cinca i, Lago F, Gonz\u00e1lez -\niuanatey iR, Salvador A, Portol\u00e9s M.  Biochem Bioph \nRes Co  2012 Feb \n10;418(2):222 -\n8.  Original  Q3 2,484  0006 -291X  \nMolecular modelling of G Protein - Rodr\u00edguez, D.; Bello, X.; Guti\u00e9rrez -de- MOL INFORM  2012 May; 31(5) Original  Q1 2,390  1868 -1743   \n \n74 Coupled Receptors through the  \nWeb  Ter\u00e1n, H  334-41 \nAxonal neuropathy, long limbs and \nbumpy tongue: Think of MEN2B  Ramos -Lev\u00ed AM, D\u00edaz -P\u00e9rez A, Sobrido \nMi, Pi\u00f1eiro -Hermida S, Blanco -Arias P, \nCabezas -Agr\u00edcola iM, Pascual -Pascual \nSI, Ara\u00faio -Vilar D  Muscle &Nerve  2012 \nDec;46(6):961 -4 Case report  Q2 2,367  1097 -4598  \nGrowth hormone treatment \nenhances the functional recovery of \nsciatic nerves after transection and \nrepair.  Devesa P, Gelabert M, Gon\u017alez -\nMosquera T, Gallego R, Relova iL, \nDevesa i, Arce VM.  Muscle & Nerve  2012 \nMar;45(3):385 -\n92. Original  Q2 2,367  0148 -639X  \nSarcomeric gene mutations in \nsudden infant death syndrome \n(SIDS)  Brion M, Allegue C, Santori M, Gil R, \nBlanco-Verea A, Haas C, Bartsch C, \nPoster S, Madea B, Campuzano O, \nBrugada R, Carracedo A.  Forensic Sci Int  2012 iun \n10;219(1 -\n3):278 -81.  Original  Q2 2,301  0379 -0738  \nThe ant genomes have been \ninvaded by several types of mariner \ntransposable elements  Lorite, P. Maside, X., Sanllorente, O., \nTorres, M.I., Periquet, G., Palomeque, \nT. Die \nNaturwissenschaf\nten 2012 \nDec;99(12):100\n7-20 Original  Q1 2,278  0028 -1042  \nSerum markers of apoptosis in the \nearly period of heart \ntransplantation.  S\u00e1nchez -L\u00e1zaro Ii, Almenar -Bonet  L, \nRomero -Pelechano A, Portoles -Sanz M, \nMart\u00ednez -Dolz L, Rosell\u00f3 -Lleti E, Ram\u00f3n \nGonz\u00e1lez -iuanatey i, Rivera -Otero M, \nSalvador -Sanz A.  Biomarkers  2012 May; \n17(3):254 -60.  Original  Q2 2,215  1354 -750X  \nCognitive functioning in children \nand adults with Smith -Magenis \nsyndrome  Os\u00f3rio A, Cruz R, Sampaio A, \nGarayz\u00e1bal E, Carracedo A, Fern\u00e1ndez -\nPrieto M.  Eur i Med Genet  2012 iun;55(6 -\n7):394 -9.  Original  Q3 2,178  1769 -7212  \nExtending induced ROC \nmethodology to the functional \ncontext  In\u00e1cio, V.; Gonz\u00e1lez -Manteiga, W. ; \nFebrero -Bande, M.; F Gude; Alonzo, \nT.A., and Cadarso Su\u00e1rez, C.  Biostatistics  2012 \nSep;13(4):594 -\n608 Original  Q1/D1  2,145  1465 -4644  \nThe prevalence of Acarapis woodi in \nSpanish honey bee (Apis mellifera) \ncolonies  Encarna Garrido -Bail\u00f3n a, Carolina \nBartol om\u00e9 b, Lourdes Prieto c, Cristina \nBot\u00edas a, Amparo Mart\u00ednez -Salvador d, \nAr\u00e1nzazu Meana e, Raquel Mart\u00edn -\nHern\u00e1ndez a,f, Mariano Higes  Experimental \nParasitology  2012 \nDec;132(4):530 -\n6 Original  Q3 2,122  0014 -4894   \n \n75 Health -related quality of life in \ndifferent cl inical subgroups with \ntypical AFL who have undergone \ncavo -tricuspid isthmus ablation.  Garc\u00eda Seara i, Gude F, Cabanas P, \nMart\u00ednez Sande iL, Fern\u00e1ndez L\u00f3pez X, \nHern\u00e1ndez Madrid A, Moro C, \nGonz\u00e1lez iuanatey iR.  Health Qual Life \nOut 2012 Aug \n6;10:90.  Research  Q2 2,112  1477 -7525  \nPlatelet proteomics in transfusion \nmedicine: a reality with a \nchallenging but promising future.  Pargui\u00f1a AF, Garc\u00eda A.  Blood Transfusion  Blood Transfus. \n2012;10 Suppl \n2:s113 -114.  Letter  Q3 2,099  1723 -2007  \nThe Opioid System and Food In take: \nHomeostatic and Hedonic \nMechanisms  Nogueiras R,  Romero -Pic\u00f3 A,  Vazquez \nMi, Novelle MG,  L\u00f3pez M,  Di\u00e9guez C.  Obes Facts  2012 Apr \n19;5(2):196 -207 Review  Q3 1,856  1662 -4025  \nDiscovery and preliminary SAR of 5 -\narylidene -2,2-dimethyl -1,3-dioxane - \n4,6-dione s as platelet aggregation \ninhibitors  El Maatougui A,  Azuaie i,  Coelho \nA, Cano E,  Ya\u00f1ez M,  L\u00f3pez C,  Yaziii \nV, Carbaiales C,  Sotelo E.  Comb Chem High \nThroughput \nScreen.  2012 \nAug;15(7):551 -4 Original  Q2 1,785  1386 -2073  \n2-Benzazepine nitrones protect \ndopamine rgic neurons against 6 -\nhydroxydopamine -induced \noxidative toxicity.  Soto -Otero R, M\u00e9ndez -\u00c1lvarez E, \nS\u00e1nchez -Iglesias S, Labandeira -Garc\u00eda \niL, Rodr\u00edguez -Pallares i, Zubkov FI, \nZaytsev VP, Voskressensky LG, \nVarlamov AV, de Candia M, Fiorella F, \nAltomare C.  Arch Pharm \n(Weinheim)  2012 \nAug;345(8):598 -\n609.  Original  Q2 1,708  0365 -6233  \nRaising Doubts about the \nPathogenicity of Mitochondrial DNA \nMutation m.3308T>C in Left \nVentricular \nHypertraveculation/Noncompactio\nn Salas A, Elson iL  Cardiology  2012;122(2):113\n-5 Original  Q3 1,705  0008 -6312  \nCurrent trends in miRNAs and their \nrelationship with oral squamous cell \ncarcinoma  P\u00e9rez -Say\u00e1ns M, Pilar GD, Barros -\nAngueira F, Su\u00e1rez -Pe\u00f1aranda iM, \nFern\u00e1ndez AC, G\u00e1ndara -Rey iM, \nGarc\u00eda -Garc\u00eda A.  i ORAL PATHOL \nMED  2012 \niul;41(6):43 3-43 Original  Q2 1,628  0904 -2512  \nComparison of the Cytobrush(\u00ae) , \ndermatological curette and oral \nCDx(\u00ae) brush test as methods for Reboiras -L\u00f3pez MD, P\u00e9rez -Say\u00e1ns M, \nSomoza -Mart\u00edn iM, Gayoso -Diz P, \nBarros -Angueira F, G\u00e1ndara -Rey iM, CYTOPHAT  2012 \niun;23(3):192 -7 Original  Q3 1,588  0956 -5507   \n \n76 obtaining samples of RNA for \nmolecular analysis of oral cytology  Garc\u00eda -Garc\u00eda A.  \nRadiographic evaluation of marginal \nbone maintenance around tissue \nlevel implant and bone level \nimplant: a randomised controlled \ntrial. A  1-year follow -up Fern\u00e1ndez -Formoso N; Rilo Pousa, \nBenito; Mora, Mi; Isabel Mart\u00ednez -Silva \nand D\u00edaz -Afonso AM  iournal of Oral \nRehabilitation  2012, Vol. 39, \npp. 830 -7 Original  Q2 1,530  0305 -182X  \nHigh -sensitivity C -reactive protein is \nam predictor of in -hospital cardiac \nevents in acute myocardial \ninfarction independently of GRACE \nrisk score  Raposeiras -Roub\u00edn S, Barreiro Pardal C, \nRodi\u00f1o ianeiro B, Abu -Assi E, Garc\u00eda -\nAcu\u00f1a iM, Gonz\u00e1lez -iuanatey iR.  Angiology  2012 ian; \n63(1):30 -4. Original  Q3 1,511  0003 -3197  \nQuerying phenotype -genotype \nrelationships on patient datasets \nusing semantic web technology: the \nexample of cerebrotendinous \nxanthomatosis  Taboada M, Mart\u00ednez D, Pilo B, \niim\u00e9nez -Escrig A, Robinson PN, Sobrido \nMi BMC Med Inform \nDecis Mak  2012 iul \n31;12:78.  Original  Q3 1,477  1472 -6947  \n[Arterial hypertension and \nperipheral artery disease. A \ndangerous relationship].  Gonz\u00e1lez -iuanatey iR.  Med Clin -\nBarcelona  2012 iun \n16;139(2):67 -9.  Editorial  Q2 1,385  0025 -7753  \n[Clinical features and hospital \ncomplications of patients with \nacute coronary syndromes \naccording to smoking habits].  Cordero A, Bertomeu -Mart\u00ednez V, \nMaz\u00f3n P, Galve E, Lekuona I, de la Gu\u00eda \nF, Cos\u00edn i, Garc\u00eda G\u00f3mez i, Roncales F, \nGonz\u00e1lez -iuanatey iR.  Med Clin -\nBarcelona  2012 Apr 21; \n138(10):422 -8.  Origi nal Q2 1,385  0025 -7753  \n[Relationship between the degree \nof glycemic control and diabetes \ncharacteristics and hyperglycemia \ntreatment in type 2 diabetes. \nDIABES Study].  P\u00e9rez A, Franch i, Cases A, Gonz\u00e1lez \niuanatey iR, Conthe P, Gimeno E, \nMatali A.  Med Cl in-\nBarcelona  2012 May \n5;138(12):505 -\n11. Original  Q2 1,385  0025 -7753  \nNucleofection of whole murine \nretinas  Gomez -Touri\u00f1o IM, Senra A, Gonzalez \nF Cytotechnology  2012 Nov 7  Original  Q3 1,207  0920 -9069  \nSNPs as Supplements in Simple \nKinship Analysis or as Cor e Markers \nin Distant Pairwise Relationship Phillips C, Garc\u00eda -Magari\u00f1os M, Salas \nA, Carracedo A, Lareu MV.  Transfus Med \nHemother  2012 \niun;39(3):202 -\n210.  Original  Q4 1,164  1660-3796   \n \n77 Tests: When Do SNPs Add Value or \nReplace Well -Established and \nPowerful STR Tests?  \nCharacterization of TGM1 \nc.984+1G>A mutation identified in a \nhomozygous carrier of lamellar \nichthyosis  Fachal L, Rodr\u00edguez -Pazos L, Ginarte M, \nBeiras A, Su\u00e1rez -Pe\u00f1aranda iM, Toribio \ni, Carracedo \u00c1, Vega A.  Int i Dermatol  2012 \nApr;51(4):427 -\n30. Original  Q3 1,142  0011 -9059  \nDifferentiation of African \ncomponents of ancestry to stratify \ngroups in a case -control study of a \nBrazilian urban population  Silbiger VN, Hirata MH, Luchessi AD, \nGenvigir FD, Cerda A, Rodrigues AC, \nWillrich MA, Arazi SS, Dorea EL,  Bernik \nMM, Faludi AA, Bertolami MC, Santos \nC, Carracedo A, Salas A, Freire A, Lareu \nMV, Phillips C, Porras -Hurtado L, \nFondevila M, Hirata RD  Genet Test Mol \nBiomarkers  2012 \niun;16(6):524 -\n30.  Original  Q4 1,110  1945 -0265  \nActivity of \u03b22-adrenergic receptor in \noral squamous cell carcinoma is \nmediated by overexpression of the \nADRBK2 gene: a pilot study  P\u00e9rez -Say\u00e1ns M, Somoza -Mart\u00edn i, \nBarros -Angueira F, Gayoso -Diz P, \nOtero -Rey E, G\u00e1ndra -Rey i, Garc\u00eda -\nGarc\u00eda A.  BIOTECH \nHISTOCHEM  2012 \nApr; 87(3):179 -\n86 Original  Q4 1,100  1052 -0295  \nCalcium binding proteins  Y\u00e1\u00f1ez M,  Gil-Longo i,  Campos -Toimil M  Adv Exp Med Biol.  2012;740:461 -\n82. Original  Q3 1,093  0065 -2598  \nCardiac troponin I and creatine \nkinase MB isoenzyme in patients \nwith chronic renal fail ure. Flores -Sol\u00eds LM, Hern\u00e1ndez -Dom\u00ednguez \niL, Otero -Gonz\u00e1lez A, Gonz\u00e1lez -\niuanatey iR.  Nefrologia  2012 Nov \n21;32(6):809 -\n818.  Original  Q4 1,000  0211 -6995  \n2013         \nTranscriptome and genome \nsequencing uncovers functional \nvariation in humans  Lappalainen T,  Sammeth M, \nFriedl\u00e4nder MR, 't Hoen PA, Monlong \nJ, Rivas MA, Gonz\u00e0lez -Porta M, \nKurbatova N, Griebel T, Ferreira PG, \nBarann M, Wieland T, Greger L, van \nIterson M, Alml\u00f6f J, Ribeca P, \nPulyakhina I, Esser D, Giger T, Tikhonov \nA, Sultan M, Bertier G, MacArthur  DG, \nLek M, Lizano E, Buermans HP, Nature  2013 Sep \n26;501(7468):50\n6-11. doi: \n10.1038/nature\n12531. Epub \n2013 Sep 15.  Original  Q1/D1  38,597  0028 -0836   \n \n78 Padioleau I, Schwarzmayr T, Karlberg \nO, Ongen H, Kilpinen H, Beltran S, Gut \nM, Kahlem K, Amstislavskiy V, Stegle O, \nPirinen M, Montgomery SB, Donnelly \nP, McCarthy MI, Flicek P, Strom TM; \nGeuvadis Consortium, Lehrach H, \nSchreiber S, Sudbrak R, Carracedo A, \nAntonarakis SE, H\u00e4sler R, Syv\u00e4nen AC, \nvan Ommen GJ, Brazma A, Meitinger T, \nRosenstiel P, Guig\u00f3 R, Gut IG, Estivill X, \nDermitzakis ET, Palotie A, Deleuze JF, \nGyllensten U, Brunner H, Veltman J, \nCambon -Thomsen A, Mangion J,  \nBentley D, Hamosh A.  \nGenome -wide association study \nidentifies multiple risk loci for \nchronic lymphocytic leukemia  Berndt SI, Skibola CF, Jose ph V, Camp \nNJ, Nieters A, Wang Z, Cozen W, \nMonnereau A, Wang SS, Kelly RS, Lan \nQ, Teras LR, Chatterjee N, Chung CC, \nYeager M, Brooks -Wilson AR, Hartge P, \nPurdue MP, Birmann BM, Armstrong \nBK, Cocco P, Zhang Y, Severi G, \nZeleniuch -Jacquotte A, Lawrence C, \nBurdette L, Yuenger J, Hutchinson A, \nJacobs KB, Call TG, Shanafelt TD, Novak \nAJ, Kay NE, Liebow M, Wang AH, \nSmedby KE, Adami HO, Melbye M, \nGlimelius B, Chang ET, Glenn M, Curtin \nK, Cannon -Albright LA, Jones B, Diver \nWR, Link BK, Weiner GJ, Conde L, \nBracci PM , Riby J, Holly EA, Smith MT, \nJackson RD, Tinker LF, Benavente Y, \nBecker N, Boffetta P, Brennan P, \nForetova L, Maynadie M, McKay J, \nStaines A, Rabe KG, Achenbach SJ, Nat Genet  2013 \nAug;45(8):868 -\n76. doi: \n10.1038/ng.265\n2. Epub 2013 \nJun 16.  Original  Q1/D1  35,209  1061 -4036   \n \n79 Vachon CM, Goldin LR, Strom SS, \nLanasa MC, Spector LG, Leis JF, \nCunningham JM, Weinberg JB , \nMorrison VA, Caporaso NE, Norman \nAD, Linet MS, De Roos AJ, Morton LM, \nSeverson RK, Riboli E, Vineis P, Kaaks \nR, Trichopoulos D, Masala G, \nWeiderpass E, Chirlaque MD, \nVermeulen RC, Travis RC, Giles GG, \nAlbanes D, Virtamo J, Weinstein S, \nClavel J, Zheng T,  Holford TR, Offit K, \nZelenetz A, Klein RJ, Spinelli JJ, \nBertrand KA, Laden F, Giovannucci E, \nKraft P, Kricker A, Turner J, Vajdic CM, \nEnnas MG, Ferri GM, Miligi L, Liang L, \nSampson J, Crouch S, Park JH, North \nKE, Cox A, Snowden JA, Wright J, \nCarracedo A, Lopez -Otin C, Bea S, \nSalaverria I, Martin -Garcia D, Campo E, \nFraumeni JF Jr, de Sanjose S, Hjalgrim \nH, Cerhan JR, Chanock SJ, Rothman N, \nSlager SL.  \nMutations in the gene encoding \nPDGF -B cause brain calcifications in \nhumans and mice  Keller A, Westenberger A, Sobrido MJ, \nGarc\u00eda -Murias M, Domingo A, Sears RL, \nLemos RR, Ordo\u00f1ez -Ugalde A, Nicolas \nG, da Cunha JE, Rushing EJ, \nHugelshofer M, Wurnig MC, Kaech A,  \nReimann R, Lohmann K, Dobri\u010di\u0107 V, \nCarracedo A, Petrovi\u0107 I, Miyasaki JM, \nAbakumova I, M\u00e4e MA, Raschperger E, \nZatz M, Zschiedrich K, Klepper J, Spiteri \nE, Prieto JM, Navas I, Preuss M, Dering \nC, Jankovi\u0107 M, Paucar M, Svenningsson \nP, Saliminejad K, Khorshid HR, Nat Genet  2013 Aug \n28;45(9):1077 -\n82. doi: \n10.1038/ng.272\n3. Epub 2013 \nAug 4.  Letter  Q1/D1  35,209  1061 -4036   \n \n80 Novakovi\u0107 I, Aguzzi A, Boss A, Le Ber I, \nDefer G, Hannequin D, Kosti\u0107 VS, \nCampion D, Geschwind DH, Coppola G, \nBetsholtz C, Klein C, Oliveira JR.  \nReproducibility of high -throughput \nmRNA and small RNA sequencing \nacross laboratories  t Hoen PA, Friedl\u00e4nder MR, Alml\u00f6f J, \nSammeth M, Pulyakhina I, Anvar SY, \nLaros JF, Buermans HP, Karlberg O, \nBr\u00e4nnvall M; The GEUVADIS \nConsortium, van Ommen GJ, Estivill X, \nGuig\u00f3 R, Syv\u00e4nen AC, Gut IG, \nDermitzakis ET, Antonorakis SE, \nBrazma A, Flicek P, Schreiber S, \nRosenstiel P, Meitinger T, Strom TM, \nLehrach H, Sudbrak R, Carracedo A, 't \nHoen PA, Pulyakhina I, Anvar SY, Laros \nJF, Buermans HP, van Iterson M, \nFriedl\u00e4nder MR, Monlong J, Lizano E, \nBertier G, Ferreira PG, Sammeth M, \nAlml\u00f6f J, Karlberg O, Br\u00e4nnvall M, \nRibeca P, Griebel T, Beltran S, Gut M, \nKahlem K, Lappalainen T, Giger T, \nOngen H, Padioleau I, Kilpinen H, \nGonz\u00e0lez -Porta M, Kurbatova N, \nTikhonov A, Greger L, Baran n M, Esser \nD, H\u00e4sler R, Wieland T, Schwarzmayr T, \nSultan M, Amstislavskiy V, den Dunnen \nJT, van Ommen GJ, Gut IG, Guig\u00f3 R, \nEstivill X, Syv\u00e4nen AC, Dermitzakis ET, \nLappalainen T.  Nat Biotechnol  2013 \nNov;31(11):101\n5-22. doi: \n10.1038/nbt.27\n02. Epub 2013 \nSep 1 5. Original  Q1/D1  32,438  1087 -0156  \nMitofusin 2 in POMC neurons \nconnects ER stress with leptin \nresistance and energy imbalance  Schneeberger M, Dietrich MO, \nSebasti\u00e1n D, Imbern\u00f3n M, Casta\u00f1o C, \nGarcia A, Esteban Y, Gonzalez -\nFranquesa A, Rodr\u00edguez IC, Bortolo zzi \nA, Garcia -Roves PM, Gomis R, Cell 2013 Sep \n26;155(1):172 -\n87. doi: \n10.1016/j.cell.2\n013.09.003.  Original  Q1/D1  31,957  0092 -8674   \n \n81 Nogueiras R, Horvath TL, Zorzano A, \nClaret M.  \nSupercomplex assembly determines \nelectron flux in the mitochondrial \nelectron tr ansport chain  Lapuente -Brun E, Moreno -Loshuertos \nR, Ac\u00edn -P\u00e9rez R, Latorre -Pellicer A, \nCol\u00e1s C, Balsa E, Perales -Clemente E, \nQuir\u00f3s PM, Calvo E, Rodr\u00edguez -\nHern\u00e1ndez MA, Navas P, Cruz R, \nCarracedo \u00c1, L\u00f3pez -Ot\u00edn C, P\u00e9rez -\nMartos A, Fern\u00e1ndez -Silva P, \nFern\u00e1ndez -Vizarra E, Enr\u00edquez JA.  Science  2013 Jun \n28;340(6140):15\n67-70. doi: \n10.1126/science\n.1230381.  Original  Q1/D1  31,027  0036 -8075  \nEffect of aliskiren on postdischarge \nmortality and heart failure \nreadmissions among patients \nhospitalized for heart failure: The \nASTRONAUT randomized trial  Gheorghiade M, B\u00f6hm M, Greene SJ, \nFonarow GC, Lewis EF, Zannad F, \nSolomon SD, Baschiera F, Botha J, Hua \nTA, Gimpelewicz CR, Jaumont X, \nLesogor A, Maggioni AP; ASTRONAUT \nInvestigators and Coordinators \n(Gonzalez Juanatey JR).  Jama -J Am Med \nAssoc  2013 Mar \n20;309(11):1125\n-35. doi: \n10.1001/jama.2\n013.1954.  Original  Q1/D1  29,978  0098 -7484  \nCyclin -dependent kinase inhibitor \np21 controls adult neural stem cell \nexpansion by regulating Sox2 gene \nexpression.  Marqu\u00e9s -Torrej\u00f3n M\u00c1, Porlan E, \nBanito A, G\u00f3mez -Ibarlucea E, Lopez -\nContreras AJ, Fern\u00e1ndez -Capetillo O, \nVidal A, Gil J, Torres J, Fari\u00f1as I.  Cell Stem Cell  2013 Jan \n3;12(1):88 -100. \ndoi: \n10.1016/j.stem.\n2012.12.001. \nEpub 2012 Dec \n20. Original  Q1/D1  25,315  1934 -5909  \nTranscriptional repression  of Bmp2 \nby p21Waf1/Cip1 links quiescence \nto neural stem cell maintenance  Porlan E, Morante -Redolat JM, \nMarqu\u00e9s -Torrej\u00f3n MA, Andreu -Agull\u00f3 \nC, Carneiro C, G\u00f3mez -Ibarlucea E, Soto \nA, Vidal A, Ferr\u00f3n SR, Fari\u00f1as I.  Nat Neurosci  2013 \nNov;16(11):156\n7-75. doi: \n10.1038/nn.354\n5. Epub 2013 \nOct 6.  Original  Q1/D1  15,251  1097 -6256  \nThe global cardiovascular risk \ntransition : Associations of four \nmetabolic risk factors with national \nincome, urbanization, and western Danaei G, Singh GM, Paciorek CJ,  Lin \nJK, Cowan MJ, Finucane MM, Farzadfar \nF, Stevens GA, Riley LM, Lu Y, Rao M, \nEzzati M; Global Burden of Metabolic Circulation  2013 Apr \n9;127(14):1493 -\n502, 1502e1 -8. \ndoi: Original  Q1/D1  15,202  0009 -7322   \n \n82 diet in 1980 and 2008  Risk Factors of Chronic Diseases \nCollaborating Group (P\u00e9rez -Fern\u00e1ndez \nR). 10.1161/C IRCUL\nATIONAHA.113.\n001470. Epub \n2013 Mar 12.  \nK(ATP) -channel -dependent \nregulation of catecholaminergic \nneurons controls BAT sympathetic \nnerve activity and energy \nhomeostasis  Tovar S, Paeger L, Hess S, Morgan DA, \nHausen AC, Br \u00f6nneke HS, Hampel B, \nAckermann PJ, Evers N, B\u00fcning H, \nWunderlich FT, Rahmouni K, \nKloppenburg P, Br\u00fcning JC.  Cell Metab  2013 Sep \n3;18(3):445 -55. \ndoi: \n10.1016/j.cmet.\n2013.08.006.  Original  Q1/D1  14,619  1550 -4131  \nChronic sympathoexcitation \nthrough loss of vav 3, a rac1 \nactivator, results in divergent \neffects on metabolic syndrome and \nobesity depending on diet  Menacho -M\u00e1rquez M, Nogueiras R, \nFabbiano S, Sauzeau V, Al -Massadi O, \nDi\u00e9guez C, Bustelo XR.  Cell Metab  2013 Aug \n6;18(2):199 -\n211. doi: \n10.1016/j.cmet.\n2013. 07.001.  Original  Q1/D1  14,619  1550 -4131  \nEffect of aliskiren on post -discharge \noutcomes among diabetic and non -\ndiabetic patients hospitalized for \nheart failure: insights from the \nASTRONAUT trial  Maggioni AP, Greene SJ, Fonarow GC, \nB\u00f6hm M, Zannad F, Solomon  SD, Lewis \nEF, Baschiera F, Hua TA, Gimpelewicz \nCR, Lesogor A, Gheorghiade M; \nASTRONAUT Investigators and \nCoordinators (Gonzalez Juanatey JR).  Eur Heart J  2013 \nOct;34(40):3117\n-27. doi: \n10.1093/eurhea\nrtj/eht342. \nEpub 2013 Sep \n2. Original  Q1/D1  14,097  0195 -668X \n2013 ESC guidelines on the \nmanagement of stable coronary \nartery disease: the Task Force on \nthe management of stable coronary \nartery disease of the European \nSociety of Cardiology  Task Force Members, Montalescot G, \nSechtem U, Achenbach S, Andreotti F, \nArden C, Budaj A, Bugiardini R, Crea F, \nCuisset T, Di Mario C, Ferreira JR, \nGersh BJ, Gitt AK, Hulot JS, Marx N, \nOpie LH, Pfisterer M, Prescott E, \nRuschitzka F, Sabat\u00e9 M, Senior R, \nTaggart DP, van der Wall EE, Vrints CJ; \nESC Committee for Practice Guideline s, \nZamorano JL, Achenbach S, \nBaumgartner H, Bax JJ, Bueno H, Dean \nV, Deaton C, Erol C, Fagard R, Ferrari R, \nHasdai D, Hoes AW, Kirchhof P, Knuuti Eur Heart J  2013 \nOct;34(38):2949\n-3003. doi: \n10.1093/eurhea\nrtj/eht296. \nEpub 2013 Aug \n30. Original  Q1/D1  14,097  0195 -668X   \n \n83 J, Kolh P, Lancellotti P, Linhart A, \nNihoyannopoulos P, Piepoli MF, \nPonikowski P, Sirnes PA, Tamargo JL, \nTende ra M, Torbicki A, Wijns W, \nWindecker S; Document Reviewers, \nKnuuti J, Valgimigli M, Bueno H, Claeys \nMJ, Donner -Banzhoff N, Erol C, Frank \nH, Funck -Brentano C, Gaemperli O, \nGonzalez -Juanatey JR, Hamilos M, \nHasdai D, Husted S, James SK, Kervinen \nK, Kolh P, Kr istensen SD, Lancellotti P, \nMaggioni AP, Piepoli MF, Pries AR, \nRomeo F, Ryd\u00e9n L, Simoons ML, Sirnes \nPA, Steg PG, Timmis A, Wijns W, \nWindecker S, Yildirir A, Zamorano JL.  \nESC Core curriculum for the general \ncardiologist (2013)  European Society of Cardiology; \nCommittee for Education; \nAuthors/Task Force Members:, \nGillebert TC, Brooks N, Fontes -\nCarvalho R, Fras Z, Gueret P, Lopez -\nSendon J, Sa lvador MJ, van den Brink \nRB, Smiseth OA; Observer on behalf of \nthe UEMS (Cardiology Section):, \nGriebenow R; Review Coordinators:, \nKearney P, Vahanian A; Contributors \nand reviewers:, Bauersachs J, Bax J, \nBurri H, Caforio AL, Calvo F, Charron P, \nErtl G, Flac hskampf F, Giannuzzi P, \nGibbs S, Gon\u00e7alves L, Gonz\u00e1lez -\nJuanatey JR, Hall J, Herpin D, Iaccarino \nG, Iung B, Kitsiou A, Lancellotti P, \nMcDonough T, Monsuez JJ, Nu\u00f1ez IJ, \nPlein S, Porta -S\u00e1nchez A, Priori S, Price \nS, Regitz -Zagrosek V, Reiner Z, Ruilope Eur Heart J  2013 \nAug;34(30):238\n1-411. doi: \n10.1093/eurhea\nrtj/eht234. \nEpub 2013 Jul \n11. Original  Q1/D 1 14,097  0195 -668X   \n \n84 LM, Sc hmid JP, Sirnes PA, Sousa -Ouva \nM, Stepinska J, Szymanski C, Taggart D, \nTendera M, Tokg\u00f6zoglu L, Trindade P, \nZeppenfeld K; ESC staff:, Joubert L, \nCarrera C.  \nDiscovery of neuritogenic \ncompound classes inspired by \nnatural products  Dakas PY, Parga JA, H\u00f6ing S, Sch\u00f6ler \nHR, Sterneckert J, Kumar K, Waldmann \nH. Angew Chem Int \nEdit 2013 Sep \n2;52(36):9576 -\n81. doi: \n10.1002/anie.20\n1302045. Epub \n2013 J un 3.  Original  Q1/D1  13,734  1433 -7851  \nRisk of cancer in cases of suspected \nlynch syndrome without germline \nmutation  Rodr\u00edguez -Soler M, P\u00e9rez -Carbonell L, \nGuarinos C, Zapater P, Castillejo A, \nBarber\u00e1 VM, Ju\u00e1rez M, Bessa X, Xicola \nRM, Clofent J, Bujanda L, Balaguer F, \nRe\u00f1\u00e9 JM, de -Castro L, Mar\u00edn -Gabriel \nJC, Lanas A, Cubiella J, Nicol\u00e1s -P\u00e9rez D, \nBrea -Fern\u00e1ndez A, Castellv\u00ed -Bel S, \nAlenda C, Ruiz -Ponte C, Carracedo A, \nCastells A, Andreu M, Llor X, Soto JL, \nPay\u00e1 A, Jover R.  Gastroenterology  2013 \nMay;144(5):926\n-932.e1; quiz \ne13-4. doi: \n10.1053/j.gastro\n.2013.01.044. \nEpub 2013 Jan \n24. Original  Q1/D1  12,821  0016 -5085  \nCentral melanin -concentrating \nhormone influences liver and \nadipose metabolism via specific \nhypothalamic nuclei and efferent \nautonomic/JNK1 pathways  Imbernon M, Beiroa D, V\u00e1zquez MJ, \nMorgan DA, Veyrat -Durebex C, \nPorteiro B, D\u00edaz -Arteaga A, Senra A, \nBusquets S, Vel\u00e1squez DA, Al -Massadi \nO, Varela L, G\u00e1ndara M, L\u00f3pez -Soriano \nFJ, Gallego R, Seoane LM, Argiles JM, \nL\u00f3pez M, Davis RJ, Sabio G, Rohner -\nJeanrenaud F, Rahmouni K, Dieguez C, \nNogueiras R.  Gastroenterology  2013 \nMar;144(3):636 -\n649.e6. doi: \n10.1053/j.gastro\n.2012.10.051. \nEpub 2012 Nov \n6. Original  Q1/D1  12,821  0016 -5085  \nAssociation of thromboxane A1 \nsynthase (TBXAS1) gene \npolymorphism with acute urticaria \ninduced by nonsteroidal anti -Vidal C, Porras -Hurtado L, Cruz R, \nQuiralte J, Cardona V, Col\u00e1s C, Castillo \nLF, Marcos C, Soto T, Lopez -Abad R, \nHern\u00e1ndez D, Teresa Audicana M, J Allergy Clin \nImmun  2013 \nOct;132(4):989 -\n91. doi: \n10.1016/j.jaci.2Letter  Q1/D1  12,047  0091 -6749   \n \n85 inflammatory drugs  Armis\u00e9n M, Rodr\u00edguez V, Perez -Carral \nC, Moreno E, Caba\u00f1es R, Cor ominas M, \nParra A, Lobera T, Qui\u00f1ones D, Ojeda \nP, Luna I, Torres M, Carracedo A.  013.04.045. \nEpub 2013 Jun \n12. \nEnhanced localization of genetic \nsamples through  linkage -\ndisequilibrium correction  Baran Y, Quintela I, Carracedo A, \nPasaniuc B, Halperin E.  Am J Hum Genet  2013 Jun \n6;92(6):882 -94. \ndoi: \n10.1016/j.ajhg.2\n013.04.023. \nEpub 2013 May \n30. Original  Q1/D1  11,202  0002 -9297  \nCerebral cavernous malformations: \nfrom CCM genes to endothelial cell \nhomeostasis  Fischer A, Zalvide J, Faurobert E, \nAlbiges -Rizo C, Tournier -Lasserve E.  Trends Mol Med  2013 \nMay;19(5):302 -\n8. doi: \n10.1016/j.molm\ned.2013.02.004. \nEpub 2013 Mar \n15. Revisi\u00f3n  Q1/D1  9,571  1471 -4914  \nEnergy balance regul ation by \nthyroid hormones at central level  L\u00f3pez M, Alvarez CV, Nogueiras R, \nDi\u00e9guez C.  Trends Mol Med  2013 \nJul;19(7):418 -\n27. doi: \n10.1016/j.molm\ned.2013.04.004. \nEpub 2013 May \n23. Revisi\u00f3n  Q1/D1  9,571  1471 -4914  \nHypothalamic \u03ba-opioid receptor \nmodulates the orexigenic effect of \nghrelin  Romero -Pic\u00f3 A, V\u00e1zquez MJ, Gonz\u00e1lez -\nTouceda D, Folgueira C, Skibicka KP, \nAlvarez -Crespo M, Van Gestel MA, \nVel\u00e1squez DA, Schwarzer C, Herzog H, \nL\u00f3pez M, Adan RA, Dickson SL, Di\u00e9guez \nC, Nogueiras R.  Neuropsychophar\nmacol  2013 \nJun;38(7):1296 -\n307. doi: \n10.1038/npp.20\n13.28. Epub \n2013 Jan 24.  Original  Q1/D1  8,678  0893 -133X  \nAMPK activation by oncogenesis is \nrequired to maintain cancer cell \nproliferation in astrocytic tumors  R\u00edos M, Foretz M, Viollet B, Prieto A, \nFraga M, Costoya JA, Se \u00f1ar\u00eds R.  Cancer Res  2013 Apr \n15;73(8):2628 -\n38. doi: Original  Q1/D1  8,650  0008 -5472   \n \n86 10.1158/0008 -\n5472.CAN -12-\n0861. Epub \n2013 Jan 31.  \nHuman spermatogenic failure \npurges deleterious mutation load \nfrom the autosomes and both sex \nchromosomes, including the gen e \nDMRT1  Lopes AM, Aston KI, Thompson E, \nCarvalho F, Gon\u00e7alves J, Huang N, \nMatthiesen R, Noordam MJ, Quintela I, \nRamu A, Seabra C, Wilfert AB, Dai J, \nDownie JM, Fernandes S, Guo X, Sha J, \nAmorim A, Barros A, Carracedo A, Hu \nZ, Hurles ME, Moskovtsev S, Ober C, \nPaduch DA, Schiffman JD, Schlegel PN, \nSousa M, Carrell DT, Conrad DF.  PLoS Genet  2013 \nMar;9(3):e1003\n349. doi: \n10.1371/journal\n.pgen.1003349. \nEpub 2013 Mar \n21. Original  Q1/D1  8,517  1553 -7390  \nAdaptive changes of the \nInsig1/SREBP1/SCD1 set point help \nadipo se tissue to cope with \nincreased storage demands of \nobesity  Carobbio S, Hagen RM, Lelliott CJ, \nSlawik M, Medina -Gomez G, Tan CY, \nSicard A, Atherton HJ, Barbarroja N, \nBjursell M, Bohlooly -Y M, Virtue S, \nTuthill A, Lefai E, Laville M, Wu T, \nConsidine RV, Vid al H, Langin D, Oresic \nM, Tinahones FJ, Fernandez -Real JM, \nGriffin JL, Sethi JK, L\u00f3pez M, Vidal -Puig \nA. Diabetes  2013 \nNov;62(11):369\n7-708. doi: \n10.2337/db12 -\n1748. Epub \n2013 Aug 6.  Original  Q1/D1  7,895  0012 -1797  \nHypothalamic ceramide levels \nregulated by CP T1C mediate the \norexigenic effect of ghrelin  Ram\u00edrez S, Martins L, Jacas J, Carrasco \nP, Pozo M, Clotet J, Serra D, Hegardt \nFG, Di\u00e9guez C, L\u00f3pez M, Casals N.  Diabetes  2013 \nJul;62(7):2329 -\n37. doi: \n10.2337/db12 -\n1451. Epub \n2013 Mar 14.  Original  Q1/D1  7,895  0012-1797  \nExpression of angiotensinogen and \nreceptors for angiotensin and \nprorenin in the monkey and human \nsubstantia nigra: an intracellular \nrenin -angiotensin system in the \nnigra.  Garrido -Gil P, Valenzuela R, Villar -\nCheda B, Lanciego JL, Labandeira -\nGarcia J L. Brain Struct Funct  2013 \nMar;218(2):373 -\n88. doi: \n10.1007/s00429\n-012-0402 -9. \nEpub 2012 Mar Original  Q1/D1  7,837  1863 -2653   \n \n87 11. \nA new potential nano -oncological \ntherapy based on polyamino acid \nnanocapsules  Gonzalo T, Lollo G, Garcia -Fuentes M, \nTorres D, Co rrea J, Riguera R, \nFernandez -Megia E, Calvo P, Avil\u00e9s P, \nGuill\u00e9n MJ, Alonso MJ.  J Control Release  2013 Jul \n10;169(1 -2):10 -\n6. Original  Q1/D1  7,633  0168 -3659  \nCo-delivery of viral proteins and a \ntlr7 agonist from polysaccharide \nnanocapsules: A needle -free \nvaccination strategy  Vicente S, Peleteiro M, D\u00edaz -Freitas B, \nSanchez A, Gonz\u00e1lez -Fern\u00e1ndez A, \nAlonso MJ.  J Control Release  2013 Dec \n28;172(3):773 -\n81. doi: \n10.1016/j.jconr\nel.2013.09.012. \nEpub 2013 Sep \n25. Original  Q1/D1  7,633  0168 -3659  \nPoly(styrene oxide) -poly(ethylene \noxide) block copolymers: From \n\"classical\" chemotherapeutic \nnanocarriers to active cell -response \ninducers  Camb\u00f3n A, Rey -Rico A, Barbosa S, \nSoltero JF, Yeates SG, Brea J, Loza MI, \nAlvarez -Lorenzo C, Concheiro A, \nTaboada P, Mosquera V.  J Control R elease  2013 Apr \n10;167(1):68 -\n75. doi: \n10.1016/j.jconr\nel.2013.01.010. \nEpub 2013 Jan \n23. Original  Q1/D1  7,633  0168 -3659  \nPercutaneous coronary intervention \nfor control of post -operative \nbleeding in patients with cardiac \nangiosarcoma  Gonz\u00e1lez -Cambeiro MC, L\u00f3p ez-Otero \nD, Rubio -Garc\u00eda J, Virg\u00f3s -Lamela A, \nVega -Fern\u00e1ndez M, Trillo -Nouche R, \nGonz\u00e1lez -Juanatey JR.  JACC -Cardiovasc \nInte 2013 \nJun;6(6):e35 -7. \ndoi: \n10.1016/j.jcin.2\n013.02.011.  Editorial  Q1/D1  6,552  1936 -8798  \nScientific competency questions as \nthe basis f or semantically enriched \nopen pharmacological space \ndevelopment  Azzaoui K, Jacoby E, Senger S, \nRodr\u00edguez EC, Loza M, Zdrazil B, Pinto \nM, Williams AJ, de la Torre V, Mestres \nJ, Pastor M, Taboureau O, Rarey M, \nChichester C, Pettifer S, Blomberg N, \nHarland L,  Williams -Jones B, Ecker GF.  Drug Discov \nToday  2013 Sep;18(17 -\n18):843 -52. doi: \n10.1016/j.drudis\n.2013.05.008. \nEpub 2013 May \n20. Revisi\u00f3n  Q1/D1  6,551  1359 -6446  \nHumanized medium (h7H) allows \nlong -term primary follicular thyroid \ncultures from human normal Bravo SB, Garcia -Rendueles ME, \nGarcia -Rendueles AR, Rodrigues JS, \nPerez -Romero S, Garcia -Lavandeira M, J Clin Endocrinol \nMetab  2013 \nJun;98(6):2431 -\n41. doi: Original  Q1 6,430  0021 -972X   \n \n88 thyroid, benign neoplasm, and \ncancer  Suarez -Fari\u00f1a M, Barreiro F, Czarnocka \nB, Senra A, Lareu MV, Rodriguez -\nGarcia J, Cameselle -Teijeiro J, Alvarez \nCV. 10.1210/jc.2012\n-3812. Epub \n2013 Mar 28.  \nMultilocus patterns of genetic \nvariation across Cryptosporidium \nspecies suggest balancing selection \nat the gp60 locus  Abal -Fabeiro JL, Mas ide X, Bello X, \nLlovo J, Bartolom\u00e9 C.  Mol Ecol  2013 \nSep;22(18):4723\n-32. doi: \n10.1111/mec.12\n425. Epub 2013 \nAug 5.  Original  Q1/D1  6,275  0962 -1083  \nNeuroprotective and reparative \neffects of carotid body grafts in a \nchronic MPTP model of Parkinson's \ndisease  Mu\u00f1oz-Manchado AB, Villadiego J, \nSu\u00e1rez -Luna N, Bermejo -Navas A, \nGarrido -Gil P, Labandeira -Garc\u00eda JL, \nEchevarr\u00eda M, L\u00f3pez -Barneo J, Toledo -\nAral JJ.  Neurobiol Aging  2013 \nMar;34(3):902 -\n15. doi: \n10.1016/j.neuro\nbiolaging.2012.\n06.001. Epub \n2012 Jun 27.  Original  Q1/D1  6,166  0197 -4580  \nHighly enantioselective catalytic \nsynthesis of neurite growth -\npromoting secoyohimbane  Antonchick AP, L\u00f3pez -Tosco S, Parga J, \nSievers S, Sch\u00fcrmann M, Preut H, \nH\u00f6ing S, Sch\u00f6ler HR, Sterneckert J, \nRauh D, Waldmann H.  Chem Biol  2013 Apr \n18;20(4):500 -9. \ndoi: \n10.1016/j.chem\nbiol.2013.03.01\n1. Original  Q1 6,157  1074 -5521  \nThe role of a sodium ion binding \nsite in the allosteric modulation of \nthe A2A adenosine G protein -\ncoupled receptor  Guti\u00e9rrez -de-Ter\u00e1n H, Massink A, \nRodr\u00edguez D, Liu W, Han GW,  Joseph \nJS, Katritch I, Heitman LH, Xia L, \nIjzerman AP, Cherezov V, Katritch V, \nStevens RC.  Structure  2013 Dec \n3;21(12):2175 -\n85. doi: \n10.1016/j.str.20\n13.09.020. Epub \n2013 Nov 7.  Original  Q1 5,994  0969 -2126  \nSirt1 inhibits the transcription \nfactor CREB to r egulate pituitary \ngrowth hormone synthesis  Monteserin -Garcia J, Al -Massadi O, \nSeoane LM, Alvarez CV, Shan B, Stalla \nJ, Paez -Pereda M, Casanueva FF, Stalla \nGK, Theodoropoulou M.  FASEB J  2013 \nApr;27(4):1561 -\n71. doi: \n10.1096/fj.12 -\n220129. Epub Original  Q1/D1  5,704  0892 -6638   \n \n89 2013 Jan 4.  \nA new seipin -associated \nneurodegenerative syndrome  Guill\u00e9n -Navarro E, S\u00e1nchez -Iglesias S, \nDomingo -Jim\u00e9nez R, Victoria B, Ruiz -\nRiquelme A, R\u00e1bano A, Loidi L, Beiras \nA, Gonz\u00e1lez -M\u00e9ndez B, Ramos A, \nL\u00f3pez -Gonz\u00e1lez V, Ballesta -Mart\u00ed nez \nMJ, Garrido -Pumar M, Aguiar P, Ruibal \nA, Requena JR, Ara\u00fajo -Vilar D.  J Med Genet  2013 \nJun;50(6):401 -9. \ndoi: \n10.1136/jmedge\nnet-2013 -\n101525. Epub \n2013 Apr 6.  Original  Q1 5,703  0022 -2593  \nGenetic susceptibility variants \nassociated with colorectal cancer \nprognosis  Abul\u00ed A, Lozano JJ, Rodr\u00edguez -Soler M, \nJover R, Bessa X, Mu\u00f1oz J, Esteban -\nJurado C, Fern\u00e1ndez -Rozadilla C, \nCarracedo A, Ruiz -Ponte C, Cubiella J, \nBalaguer F, Bujanda L, Re\u00f1\u00e9 JM, \nClofent J, Morillas JD, Nicol\u00e1s -P\u00e9rez D, \nXicola RM, Llor X, Piqu\u00e9 JM,  Andreu M, \nCastells A, Castellv\u00ed -Bel S; for the \nGastrointestinal Oncology Group of \nthe Spanish Gastroenterological \nAssociation. (Salas A)  Carcinogenesis  2013 \nOct;34(10):2286\n-2291. Epub \n2013 May 27.  Original  Q1 5,635  0143 -3334  \nBMP2/BMP4 colorectal cancer \nsusceptibility loci in northern and \nsouthern European populations.  Fernandez -Rozadilla C, Palles C, \nCarvajal -Carmona L, Peterlongo P, Nici \nC, Veneroni S, Pinheiro M, Teixeira MR, \nMoreno V, Lamas MJ, Baiget M, Lopez \nJL, Gonzalez D, Brea -Fernandez A, \nClofent J, Bujanda L, Bessa X, Andreu \nM, Xicola R, Llor X, Jover R; The \nEPICOLON Consortium, Castells A, \nCastellvi -Bel S, Carracedo A, Tomlinson \nI, Ruiz -Ponte C (Salas A).  Carcinogenesis  2013 \nFeb;34(2):314 -\n318. Epub 2012 \nNov 16.  Original  Q1 5,635  0143 -3334  \nInhibi tion of Rho kinase mediates \nthe neuroprotective effects of \nestrogen in the MPTP model of \nParkinson's disease  Rodriguez -Perez AI, Dominguez -\nMeijide A, Lanciego JL, Guerra MJ, \nLabandeira -Garcia JL.  Neurobiol Dis  2013 \nOct;58:209 -19. \ndoi: \n10.1016/j.nbd.2\n013.06 .004. Original  Q1 5,624  0969 -9961   \n \n90 Epub 2013 Jun \n14. \nSerotonin skews human \nmacrophage polarization through \nHTR2B and HTR7  de las Casas -Engel M, Dom\u00ednguez -Soto \nA, Sierra -Filardi E, Bragado R, Nieto C, \nPuig -Kroger A, Samaniego R, Loza M, \nCorcuera MT, G\u00f3mez -Aguado F, Bustos \nM, S\u00e1nchez -Mateos P, Corb\u00ed AL.  J Immunol  2013 Mar \n1;190(5):2301 -\n10. doi: \n10.4049/jimmu\nnol.1201133. \nEpub 2013 Jan \n25. Original  Q1 5,520  0022 -1767  \nIncidence and prognostic value of \ninfections during an acute coronary \nsyndrome: A single cente r \nexperience  Raposeiras -Roub\u00edn S, Abu -Assi E, \nAlvarez -\u00c1lvarez B, Cambeiro -Gonz\u00e1lez \nC, Fandi\u00f1o -Vaquero R, Garc\u00eda -Castelo \nA, Garc\u00eda -Acu\u00f1a JM, Gonz\u00e1lez -\nJuanatey JR.  Int J Cardiol  2013 Sep \n30;168(2):1609. \ndoi: \n10.1016/j.ijcard.\n2013.01.033. \nEpub 2013 Feb \n17. Letter Q1 5,509  0167 -5273  \nPro B -type natriuretic peptide \nplasma value: A new criterion for \nthe prediction of short - and long -\nterm outcomes after transcatheter \naortic valve implantation  L\u00f3pez -Otero D, Trillo -Nouche R, Gude \nF, Cid -\u00c1lvarez B, Ocaranza -Sanchez R, \nAlvarez MS, Lear PV, Gonzalez -\nJuanatey JR.  Int J Cardiol  2013 Sep \n30;168(2):1264 -\n1268. doi: \n10.1016/j.ijcard.\n2012.11.116. \nEpub 2012 Dec \n30. Original  Q1 5,509  0167 -5273  \nA comparison of the CKD -EPI, \nMDRD -4, and Cockcroft -Gault \nequations to assess renal f unction \nin predicting all -cause mortality in \nacute coronary syndrome patients  Abu-Assi E, Lear P, Cabanas -Grand\u00edo P, \nRodr\u00edguez -Girondo M, Raposeiras -\nRoubin S, Pereira -L\u00f3pez E, Roman\u00ed SG, \nGil CP, Garc\u00eda -Acu\u00f1a JM, Gonz\u00e1lez -\nJuanatey JR.  Int J Cardiol  2013 Sep  \n1;167(5):2325 -\n6. doi: \n10.1016/j.ijcard.\n2012.11.014. \nEpub 2012 Dec \n4. Letter  Q1 5,509  0167 -5273  \nSpironolactone in mild chronic \nheart failure: Insights from a \npropensity -matched analysis of the \nMUSIC study cohort  Pascual -Figal DA, Caballero L, Bayes -\nGenis A, Gonzalez -Juanatey JR, \nVazquez R, Bayes de Luna A, Cinca J; \non behalf of MUSIC Investigators.  Int J Cardiol  2013 Oct \n9;168(4):4525 -\n7. doi: \n10.1016/j.ijcard.Letter  Q1 5,509  0167 -5273   \n \n91 2013.06.103. \nEpub 2013 Jul \n25. \nCreatinine -or cystatin C -based \nequations  to estimate glomerular \nfiltration rate in acute myocardial \ninfarction: A disparity in estimating \nrenal function and in mortality risk \nprediction  Abu-Assi E, Raposeiras -Roubin S, \nRiveiro -Cruz A, Rodr\u00edguez -Girondo M, \nGonz\u00e1lez -Cambeiro C, Alvarez -Alvarez \nB, Gestal -Roman\u00ed S, Pereira -L\u00f3pez E, \nCabanas -Grand\u00edo P, Garc\u00eda -Acu\u00f1a JM, \nVirg\u00f3s -Lamela A, Gonz\u00e1lez -Juanatey \nJR. Int J Cardiol  2013 Oct \n9;168(4):4300 -\n1. doi: \n10.1016/j.ijcard.\n2013.04.194. \nEpub 2013 May \n25. Letter  Q1 5,509  0167 -5273  \nHeart failure entails signi ficant \nchanges in human \nnucleocytoplasmic transport gene \nexpression  Molina -Navarro MM, Rosell\u00f3 -Llet\u00ed E, \nTaraz\u00f3n E, Ortega A, S\u00e1nchez -\nIzquierdo D, Lago F, Gonz\u00e1lez -Juanatey \nJR, Garc\u00eda -Pav\u00eda P, Salvador A, \nMontero JA, Portol\u00e9s M, Rivera M.  Int J Cardiol  2013  Oct \n3;168(3):2837 -\n2843. doi: \n10.1016/j.ijcard.\n2013.03.192. \nEpub 2013 May \n4. Original  Q1 5,509  0167 -5273  \nThe change in the atrial fibrillation \ntype as a prognosis marker in a \ncommunity study: long -term data \nfrom AFBAR (Atrial Fibrillation in \nthe BARbanza)  study  Vidal -Perez R, Otero -Ravi\u00f1a F, Lado -\nL\u00f3pez M, Turrado -Turrado V, \nRodr\u00edguez -Moldes E, G\u00f3mez -V\u00e1zquez \nJL, de Frutos -de Marcos C, de Blas -\nAbad P, Besada -Gesto R, Gonzalez -\nJuanatey JR; BARBANZA Investigators.  Int J Cardiol  2013 Oct \n3;168(3):2146 -\n52. doi: \n10.1016/j.ijcard.\n2013.01.261. \nEpub 2013 Feb \n26. Original  Q1 5,509  0167 -5273  \nLeft bundle branch block in atrial \nfibrillation patients without heart \nfailure  Rodr\u00edguez -Ma\u00f1ero M, Abu -Assi E, \nL\u00f3pez MJ, de Blas Abad P, Fern\u00e1ndez \nGG, Alcalde CC, Loureiro MS, Gar c\u00eda-\nSeara J, P\u00e9rez RC, Gonz\u00e1lez -Juanatey \nJR; Grupo Barbanza investigators.  Int J Cardiol  2013 Oct \n15;168(6):5460 -\n2. doi: \n10.1016/j.ijcard.\n2013.07.250. \nEpub 2013 Aug \n3. No abstract \navailable.  Letter  Q1 5,509  0167 -5273  \nPrognostic influence of prior \nischemi c heart disease in in -hospital Raposeiras -Roub\u00edn S, Abu -Assi E, \nGonz\u00e1lez -Cambeiro C, Alvarez -\u00c1lvarez Int J Cardiol  2013 Oct \n12;168(5):5063 -Letter  Q1 5,509  0167 -5273   \n \n92 mortality of acute coronary \nsyndromes  B, Pereira -L\u00f3pez E, Gestal -Roman\u00ed S, \nRodr\u00edguez -Cordero M, Garc\u00eda -Castelo \nA, Garc\u00eda -Acu\u00f1a JM, Gonz\u00e1lez -\nJuanatey JR.  4. doi: \n10.1016/j.ijcard.\n2013.07.203. \nEpub 2013 Jul \n30. \nThe ibero -american transcatheter \naortic valve implantation registry \nwith the corevalve prosthesis. Early \nand long -term results  Mu\u00f1oz -Garc \u00eda AJ, del Valle R, Trillo -\nNouche R, El\u00edzaga J, Gimeno F, \nHern\u00e1ndez -Antol\u00edn R, Teles R, de Gama \nRibeiro V, Molina E, Cequier A, \nUrbano -Carrillo C, Cruz -Gonz\u00e1lez I, \nPayaslian M, Patricio L, Sztejfman M, \nI\u00f1iguez A, Rodr\u00edguez V, Scuteri A, \nCaorsi C, L\u00f3pez -Otero D, Avanzas P, \nAlonso -Briales JH, Hern\u00e1ndez -Garc\u00eda \nJM, Mor\u00eds C; Ibero -American registry \ninvestigators.  Int J Cardiol  2013 Nov \n20;169(5):359 -\n65. doi: \n10.1016/j.ijcard.\n2013.09.006. \nEpub 2013 Oct \n4. Original  Q1 5,509  0167 -5273  \nDrug -eluting stents for off -label \nindications in real clinical world: \nevidence based or 'intuition' based \nclinical practice?  Ribera A, Ferreira -Gonz\u00e1lez I, Del \nBlanco BG, Marsal JR, Cascant P, Mart\u00ed \nG, Cequier AR, G\u00f3mez -Hospital JA, \nFernandez -Nofrer\u00edas E, Carrillo X, \nL\u00f3pez -P\u00e9rez MC, N avarro J, Raso R, \nGarc\u00eda -Dorado D, Permanyer -Miralda \nG; ACDC study investigators (Trillo -\nNouche R).  Int J Cardiol  2013 Mar \n20;164(1):116 -\n22. doi: \n10.1016/j.ijcard.\n2011.06.096. \nEpub 2011 Jul \n13. Original  Q1 5,509  0167 -5273  \nComparison of the reliability and  \nvalidity of four contemporary risk \nstratification schemes to predict \nthromboembolism in non -\nanticoagulated patients with atrial \nfibrillation  Abu-Assi E, Otero -Ravi\u00f1a F, Allut Vidal \nG, Coutado M\u00e9ndez A, Vaamonde \nMosquera L, S\u00e1nchez Loureiro M, \nCaneda Villa r MC, Fern\u00e1ndez \nVillaverde JM, Maestro Saavedra FJ, \nGonz\u00e1lez -Juanatey JR; Grupo Barbanza \nresearchers.  Int J Cardiol  2013 Jun \n5;166(1):205 -9. \ndoi: \n10.1016/j.ijcard.\n2011.10.096. \nEpub 2011 Nov \n21. Original  Q1 5,509  0167 -5273  \nDeterminants of cardiovascular \nmortality in a cohort of primary \ncare patients with chronic ischemic Vidal -Perez R, Otero -Ravi\u00f1a F, Franco \nM, Rodr\u00edguez Garcia JM, Stolle RL, \nAlvarez RE, D\u00edaz CI, L\u00f3pez EO, V\u00e1zquez Int J Cardiol  2013 Jul \n31;167(2):442 -\n50. doi: Original  Q1 5,509  0167 -5273   \n \n93 heart disease. BARBANZA Ischemic \nHeart Disease (BARIHD) study  L\u00f3pez MJ, Gonza lez-Juanatey JR; on \nbehalf of the BARBANZA investigators.  10.1016/j.ijcard.\n2012.01.014. \nEpub 2012 Feb \n2. \nDevelopment of PLGA -\nmannosamine nanoparticles as oral \nprotein carriers  Alons o-Sande M, des Rieux A, Fievez V, \nSarmento B, Delgado A, Evora C, \nRemu\u00f1\u00e1n -L\u00f3pez C, Pr\u00e9at V, Alonso MJ.  Biomacromolecul\nes 2013 Nov \n11;14(11):4046 -\n52. doi: \n10.1021/bm401\n141u. Epub \n2013 Oct 30.  Original  Q1/D1  5,371  1525 -7797  \nSUMOylation of p53 mediates \ninter feron activities  Marcos -Villar L, P\u00e9rez -Gir\u00f3n JV, Vilas \nJM, Soto A, de la Cruz -Hererra CF, Lang \nV, Collado M, Vidal A, Rodr\u00edguez MS, \nMu\u00f1oz -Fontela C, Rivas C.  Cell Cycle  2013 Sep \n1;12(17):2809 -\n16. doi: \n10.4161/cc.258\n68. Epub 2013 \nAug 5.  Original  Q1 5,321  1538-4101  \nKnown and missing left ventricular \nejection fraction and survival in \npatients with heart failure: a \nMAGGIC meta -analysis report  Poppe KK, Squire IB, Whalley GA, \nK\u00f8ber L, McAlister FA, McMurray JJ, \nPocock S, Earle NJ, Berry C, Doughty \nRN; Meta -Analysis Global Group in \nChronic Heart Failure (Gonzalez -\nJuanatey J, Grigorian -Shamagian \nLVarela -Roman A, Maz\u00f3n -Ramos P, \nTrillo R, Garcia -Seara J, Gude F).  Eur J Heart Fail  2013 \nNov;15(11):122\n0-7. doi: \n10.1093/eurjhf/\nhft101. Epub \n2013 Jun 26.  Original  Q1 5,24 7 1388 -9842  \nDifferential clinical characteristics \nand prognosis of intraventricular \nconduction defects in patients with \nchronic heart failure  Cinca J, Mendez A, Puig T, Ferrero A, \nRoig E, Vazquez R, Gonzalez -Juanatey \nJR, Alonso -Pulpon L, Delgado J, \nBrugad a J, Pascual -Figal D; \ninvestigators of the Spanish Heart \nFailure Network (REDINSCOR). \n(Gonz\u00e1lez -Juanatey JR, Band\u00edn M, Eiras \nS, Garc\u00eda -Acu\u00f1a J, Grigorian -Shamagian \nL, Lago F, Manz\u00f3n P, Otero -Ravi\u00f1a F, \nOtero -Santiago F, Rodino Janeiro BK, Eur J Hea rt Fail  2013 \nAug;15(8):877 -\n84. doi: \n10.1093/eurjhf/\nhft042. Epub \n2013 Mar 19.  Original  Q1 5,247  1388 -9842   \n \n94 Lear PV)  \nAnalysis of the C9orf72 Gene in \nPatients with Amyotrophic Lateral \nSclerosis in Spain and Different \nPopulations Worldwide  Garc\u00eda -Redondo A, Dols -Icardo  O, \nRojas -Garc\u00eda R, Esteban -P\u00e9rez J, \nCordero -V\u00e1zquez P, Mu\u00f1oz -Blanco JL, \nCatalina I, Gonz\u00e1lez -Mu\u00f1oz M, Varona \nL, Sarasola E, Povedano M, Sevilla T, \nGuerrero A, Pardo J, de Munain AL, \nM\u00e1rquez -Infante C, de Rivera FJ, \nPastor P, Jeric\u00f3 I, de Arcaya AA, Mora \nJS, Clarim\u00f3n J; The C9ORF72 Spanish \nStudy Group, Gonzalo -Mart\u00ednez JF, \nJu\u00e1rez -Rufi\u00e1n A, Atencia G, Jim\u00e9nez -\nBautista R, Mor\u00e1n Y, Masc\u00edas J, \nHern\u00e1ndez -Barral M, Kapetanovic S, \nGarc\u00eda -Barcina M, Alcal\u00e1 C, Vela A, \nRam\u00edrez -Ramos C, Gal\u00e1n L, P\u00e9rez -Tur J, \nQuint\u00e1ns B, Sobrido MJ, Fern\u00e1ndez -\nTorr\u00f3n R, Poza JJ, Gorostidi A, Paradas \nC, Villoslada P, Larrod\u00e9 P, Capablo JL, \nPascual -Calvet J, Go\u00f1i M, Morgado Y, \nGuitart M, Moreno -Laguna S, Rueda A, \nMart\u00edn -Estefan\u00eda C, Cemill\u00e1n C, Blesa \nR, Lle\u00f3 A.  Hum Mutat  2013 \nJan;34(1):79 -82. \ndoi: \n10.1002/humu.\n22211. Epub \n2012 Oct 11.  Original  Q1 5,213  1059 -7794  \nPharmacogenomics in colorectal \ncancer: A genome -wide association \nstudy to predict toxicity after 5 -\nfluorouracil or FOLFOX \nadministration  Fernandez -Rozadilla C, Cazier JB, \nMoreno V , Crous -Bou M, Guin\u00f3 E, \nDur\u00e1n G, Lamas MJ, L\u00f3pez R, \nCandamio S, Gallardo E, Par\u00e9 L, Baiget \nM, P\u00e1ez D, L\u00f3pez -Fern\u00e1ndez LA, \nCortejoso L, Garc\u00eda MI, Bujanda L, \nGonz\u00e1lez D, Gonzalo V, Rodrigo L, \nRe\u00f1\u00e9 JM, Jover R, Brea -Fern\u00e1ndez A, \nAndreu M, Bessa X, Llor X, Xi cola R, \nPalles C, Tomlinson I, Castellv\u00ed -Bel S, \nCastells A, Ruiz -Ponte C, Carracedo A. Pharmacogenomi\ncs J 2013 \nJun;13(3):209 -\n217. doi: \n10.1038/tpj.201\n2.2. Epub 2012 \nFeb 7.  Original  Q1/D1  5,134  1470 -269X   \n \n95 (Salas A)  \nRotavirus viroplasm proteins \ninteract with  the cellular \nSUMOylation system: Implications \nfor viroplasm -like structure \nformation  Campagna M, Marcos -Villar L, Arnoldi \nF, de la Cruz -Herrera CF, Gallego P, \nGonz\u00e1lez -Santamar\u00eda J, Gonz\u00e1lez D, \nLopitz -Otsoa F, Rodriguez MS, Burrone \nOR, Rivas C.  J Virol  2013 \nJan;87(2):807 -\n17. doi: \n10.1128/JVI.015\n78-12. Epub \n2012 Oct 31.  Original  Q1 5,076  0022 -538X  \nPrediction of metastatic breast \ncancer in non -sentinel lymph nodes \nbased on metalloprotease -1 \nexpression by the sentinel lymph \nnode  Eir\u00f3 N, Gonz\u00e1lez LO, Atienza S, \nGonz\u00e1lez -Quintana JM, Beridze N, \nFernandez -Garcia B, P\u00e9rez -Fern\u00e1ndez \nR, Garc\u00eda -Caballero T, Schneider J, \nVizoso FJ.  Eur J Cancer  2013 \nMar;49(5):1009 -\n17. doi: \n10.1016/j.ejca.2\n012.09.019. \nEpub 2012 Oct \n11. Original  Q1 5,061  0959 -8049  \nDefining hypoxic \nmicroenvironments by non -invasive \nfunctional optical imaging  Iglesias P, Fraga M, Costoya JA.  Eur J Cancer  2013 \nJan;49(1):264 -\n71. doi: \n10.1016/j.ejca.2\n012.06.001. \nEpub 2012 Jul 3.  Original  Q1 5,061  0959 -8049  \nMetabolic programming of puberty: \nSexually dimorp hic responses to \nearly nutritional challenges  S\u00e1nchez -Garrido MA, Castellano JM, \nRuiz -Pino F, Garcia -Galiano D, \nManfredi -Lozano M, Leon S, Romero -\nRuiz A, Di\u00e9guez C, Pinilla L, Tena -\nSempere M.  Endocrinology  2013 \nSep;154(9):3387\n-400. doi: \n10.1210/en.201\n2-2157. Epub \n2013 Jun 10.  Original  Q1 4,717  0013 -7227  \nGhrelin requires p53 to stimulate \nlipid storage in fat and liver  Porteiro B, D\u00edaz -Ru\u00edz A, Mart\u00ednez G, \nSenra A, Vidal A, Serrano M, Gualillo O, \nL\u00f3pez M, Malag\u00f3n MM, Di\u00e9guez C, \nNogueiras R.  Endocrinology  2013  \nOct;154(10):367\n1-9. doi: \n10.1210/en.201\n3-1176. Epub \n2013 Jul 5.  Original  Q1 4,717  0013 -7227  \nThe orexigenic effect of orexin -A Alvarez -Crespo M, Mart\u00ednez -S\u00e1nchez Endocrinology  2013 Original  Q1 4,717  0013 -7227   \n \n96 revisited: Dependence of an intact \ngrowth hormone axis  N, Ru\u00edz -Pino F, Garcia -Lavandeira M, \nAlvarez CV, Tena -Sempere M, \nNogueiras R, Di\u00e9guez C, L\u00f3pez M.  Oct;154(10):358\n9-98. doi: \n10.1210/en.201\n3-1251. Epub \n2013 Jul 16.  \nFiring up brown fat with brain \namylin  L\u00f3pez M, Nogueiras R.  Endocrinology  2013 \nJul;154(7):2263 -\n5. doi: \n10.1210/en.201\n3-1445.  Editorial  Q1 4,717  0013 -7227  \nChanges in hypothalamic \nexpression of the Lin28/let -7 \nsystem and related microRNAs \nduring postnatal maturation and \nafter experimental manipulations of \npuberty  Sangiao -Alvarellos S, Ma nfredi -Lozano \nM, Ruiz -Pino F, Navarro VM, S\u00e1nchez -\nGarrido MA, Leon S, Dieguez C, \nCordido F, Matagne V, Dissen GA, \nOjeda SR, Pinilla L, Tena -Sempere M.  Endocrinology  2013 \nFeb;154(2):942 -\n55. doi: \n10.1210/en.201\n2-2006. Epub \n2013 Jan 4.  Original  Q1 4,717  0013 -7227  \nNesfatin -1 in human and murine \ncardiomyocytes: Synthesis, \nsecretion, and mobilization of glut -4 Feij\u00f3o -Band\u00edn S, Rodr\u00edguez -Penas D, \nGarc\u00eda -R\u00faa V, Mosquera -Leal A, Otero \nMF, Pereira E, Rubio J, Mart\u00ednez I, \nSeoane LM, Gualillo O, Calaza M, \nGarc\u00eda -Cabal lero T, Portol\u00e9s M, \nRosell\u00f3 -Llet\u00ed E, Di\u00e9guez C, Rivera M, \nGonz\u00e1lez -Juanatey JR, Lago F.  Endocrinology  2013 \nDec;154(12):47\n57-67. doi: \n10.1210/en.201\n3-1497. Epub \n2013 Sep 24.  Original  Q1 4,717  0013 -7227  \nBrain angiotensin regulates iron \nhomeostasis in dopami nergic \nneurons and microglial cells  Garrido -Gil P, Rodriguez -Pallares J, \nDominguez -Meijide A, Guerra MJ, \nLabandeira -Garcia JL.  Exp Neurol  2013 \nDec;250:384 -96. \ndoi: \n10.1016/j.expne\nurol.2013.10.01\n3. Epub 2013 \nOct 30.  Original  Q1 4,645  0014 -4886  \nCytocompatib ility and p -\nglycoprotein inhibition of block \ncopolymers: Structure -activity \nrelationship  Camb\u00f3n A, Brea J, Loza MI, Alvarez -\nLorenzo C, Concheiro A, Barbosa S, \nTaboada P, Mosquera V.  Mol Pharmaceut  2013 Aug \n5;10(8):3232 -\n41. doi: \n10.1021/mp400Original  Q1 4,570  1543 -8384   \n \n97 2848. Epub \n2013  Jun 25.  \nElevated 4 -aminobiphenyl and 2,6 -\ndimethylaniline hemoglobin \nadducts and increased risk of \nbladder cancer among lifelong \nnonsmokers --The Shanghai Bladder \nCancer Study  Tao L, Day BW, Hu B, Xiang YB, Wang \nR, Stern MC, Gag o-Dominguez M, \nCortessis VK, Conti DV, Van Den Berg \nD, Pike MC, Gao YT, Yu MC, Yuan JM.  Cancer Epidem \nBiomar  2013 \nMay;22(5):937 -\n45. doi: \n10.1158/1055 -\n9965.EPI -12-\n1447. Epub \n2013 Mar 28.  Original  Q1/D1  4,559  1055 -9965  \nDopamine -Angiotensin interactions \nin the basal ganglia and their \nrelevance for Parkinson's disease  Labandeira -Garcia JL, Rodriguez -\nPallares J, Dominguez -Meijide A, \nValenzuela R, Villar -Cheda B, \nRodr\u00edguez -Perez AI.  Movement Disord  2013 \nSep;28(10):1337\n-42. doi: \n10.1002/mds.25\n614. Epub 2013 \nAug 7 . Revisi\u00f3n  Q1 4,558  0885 -3185  \nHypothesized role of pregnancy \nhormones on HER2+ breast tumor \ndevelopment  Cruz GI, Mart\u00ednez ME, Natarajan L, \nWertheim BC, Gago -Dominguez M, \nBondy M, Daneri -Navarro A, Meza -\nMontenegro MM, Gutierrez -Millan LE, \nBrewster A, Sched in P, Komenaka IK, \nCastelao JE, Carracedo A, Redondo \nCM, Thompson PA.  Breast Cancer Res \nTreat  2013 \nJan;137(1):237 -\n46. doi: \n10.1007/s10549\n-012-2313 -0. \nEpub 2012 Nov \n8. Original  Q1 4,469  0167 -6806  \nPharmacogenetic analysis of SNPs \nin genes involved in the \npharmacokinetics and response to \nlopinavir/ritonavir therapy  L\u00f3pez Aspiroz E, Figueroa SE, Hurtado \nGL, Guerrero RC, Hurl\u00e9 AD, Carracedo \nA; Tormes Team.  Curr Drug Metab  2013 \nSep;14(7):729 -\n37. Original  Q1 4,405  1389 -2002  \nA colorectal cancer genome -wide \nassoci ation study in a Spanish \ncohort identifies two variants \nassociated with colorectal cancer \nrisk at 1p33 and 8p12  Fernandez -Rozadilla C, Cazier JB, \nTomlinson IP, Carvajal -Carmona LG, \nPalles C, Lamas MJ, Baiget M, L\u00f3pez -\nFern\u00e1ndez LA, Brea -Fern\u00e1ndez A, Abul\u00ed \nA, Bujanda L, Clofent J, Gonzalez D, \nXicola R, Andreu M, Bessa X, Jover R, \nLlor X; EPICOLON Consortium, Moreno \nV, Castells A, Carracedo \u00c1, Castellvi -Bel BMC Genomics  2013 Jan \n26;14:55. doi: \n10.1186/1471 -\n2164 -14-55. Original  Q1 4,397  1471 -2164  \n \n98 S, Ruiz -Ponte C.  \nThe genetic landscape of Equatorial \nGuinea and the origin and migration \nroutes of the Y chromosome \nhaplogroup R -V88 Gonz\u00e1lez M, Gomes V, L\u00f3pez -Parra \nAM, Amorim A, Carracedo A, S\u00e1nchez -\nDiz P, Arroyo -Pardo E, Gusm\u00e3o L.  Eur J Hum Genet  2013 \nMar;21(3):324 -\n31. doi: \n10.1038/ejhg.20\n12.167. Epub \n2012 Aug 15.  Original  Q1 4,319  1018 -4813  \nBMPR1A mutations in early -onset \ncolorectal cancer with mismatch \nrepair proficiency  Fernandez -Rozadilla C, Brea -Fern\u00e1ndez \nA, Bessa X, Alvarez -Urturi C, Abul\u00ed A, \nClofent J, Pay\u00e1 A ; The EPICOLON \nConsortium, Jover R, Xicola R, Llor X, \nAndreu M, Castells A, Carracedo A, \nCastellv\u00ed -Bel S, Ruiz -Ponte C. (Salas A)  Clin Genet  2013 \nJul;84(1):94 -6. \ndoi: \n10.1111/cge.12\n023. Epub 2012 \nOct 12.  Letter  Q1 4,247  0009 -9163  \nDopaminergic degeneration  is \nenhanced by chronic brain \nhypoperfusion and inhibited by \nangiotensin receptor blockage  Rodriguez -Perez AI, Dominguez -\nMeijide A, Lanciego JL, Guerra MJ, \nLabandeira -Garcia JL.  Age 2013 \nOct;35(5):1675 -\n90. doi: \n10.1007/s11357\n-012-9470 -2. \nEpub 2012 Sep \n18. Original  Q1 4,084  0161 -9152  \nCentral manipulation of dopamine \nreceptors attenuates the orexigenic \naction of ghrelin  Romero -Pic\u00f3 A, Novelle MG, Folgueira \nC, L\u00f3pez M, Nogueiras R, Di\u00e9guez C.  Psychopharmacol\nogy 2013 \nSep;229(2):275 -\n83. doi: \n10.1007/s00213\n-013-3096 -7. \nEpub 2013 Apr \n28. Original  Q1 4,061  0033 -3158  \nResistin regulates pituitary lipid \nmetabolism and inflammation in \nvivo and in vitro  Rodriguez -Pacheco F, Novelle MG, \nVazquez MJ, Garcia -Escobar E, \nSoriguer F, Rojo -Martinez G, Garc\u00eda -\nFuentes E, Malagon  MM, Dieguez C.  Mediat Inflamm  2013;2013:4797\n39. doi: \n10.1155/2013/4\n79739. Epub \n2013 Apr 18.  Original  Q2 3,882  0962 -9351  \nAncestry analysis reveals a Heinz T, Alvarez -Igles ias V, Pardo -Seco Forensic Sci Int 2013 Original  Q1/D1  3,861  1872 -4973   \n \n99 predominant Native American \ncomponent with moderate \nEuropean admixture in Bolivians  J, Taboada -Echalar P, G\u00f3mez -Carballa \nA, Torres -Balanza A, Rocabado O, \nCarracedo A, Vullo C, Salas A.  Genet  Sep;7(5):537 -\n42. doi: \n10.1016/j.fsigen\n.2013.05.012. \nEpub 2013 Jul \n11. \nPopulat ion genetics of 17 Y -STR \nmarkers in West Libya (Tripoli \nregion)  Triki -Fendri S, S\u00e1nchez -Diz P, Rey -\nGonz\u00e1lez D, Ayadi I, Alfadhli S, Rebai A, \nCarracedo A.  Forensic Sci Int \nGenet  2013 \nMay;7(3):e59 -\n61. doi: \n10.1016/j.fsigen\n.2013.02.002. \nEpub 2013 Mar \n7. Origi nal Q1/D1  3,861  1872 -4973  \nEurasiaplex: A forensic SNP assay \nfor differentiating European and \nSouth Asian ancestries  Phillips C, Aradas AF, Kriegel AK, \nFondevila M, Bulbul O, Santos C, Rech \nFS, Carceles MD, Carracedo A, \nSchneider PM, Lareu MV.  Forensic Sci  Int \nGenet  2013 \nMay;7(3):359 -\n66. doi: \n10.1016/j.fsigen\n.2013.02.010. \nEpub 2013 Mar \n26. Original  Q1/D1  3,861  1872 -4973  \nRevision of the SNPforID 34 -plex \nforensic ancestry test: Assay \nenhancements, standard reference \nsample genotypes and extended \npopulation s tudies  Fondevila M, Phillips C, Santos C, \nFreire Aradas A, Vallone PM, Butler \nJM, Lareu MV, Carracedo A.  Forensic Sci Int \nGenet  2013 \nJan;7(1):63 -74. \ndoi: \n10.1016/j.fsigen\n.2012.06.007. \nEpub 2012 Jun \n29. Original  Q1/D1  3,861  1872 -4973  \nFurther development of  forensic \neye color predictive tests  Ruiz Y, Phillips C, Gomez -Tato A, \nAlvarez -Dios J, Casares de Cal M, Cruz \nR, Maro\u00f1as O, S\u00f6chtig J, Fondevila M, \nRodriguez -Cid MJ, Carracedo A, Lareu \nMV. Forensic Sci Int \nGenet  2013 \nJan;7(1):28 -40. \ndoi: \n10.1016/j.fsigen\n.2012.05.009. \nEpub 2012 Jun \n17. Original  Q1/D1  3,861  1872 -4973   \n \n100 RNA/DNA co -analysis from human \nsaliva and semen stains --results of a \nthird collaborative EDNAP exercise  Haas C, Hanson E, Anjos MJ, \nBanemann R, Berti A, Borges E, \nCarracedo A, Carvalho M, Courts  C, De \nCock G, D\u00f6tsch M, Flynn S, Gomes I, \nHollard C, Hjort B, Hoff -Olsen P, \nHr\u00edbikov\u00e1 K, Lindenbergh A, Ludes B, \nMaro\u00f1as O, McCallum N, Moore D, \nMorling N, Niederst\u00e4tter H, Noel F, \nParson W, Popielarz C, Rapone C, \nRoeder AD, Ruiz Y, Sauer E, Schneider \nPM, Sijen T, Court DS, Svie\u017een\u00e1 B, \nTuransk\u00e1 M, Vidaki A, Zatkal\u00edkov\u00e1 L, \nBallantyne J.  Forensic Sci Int \nGenet  2013 \nFeb;7(2):230 -9. \ndoi: \n10.1016/j.fsigen\n.2012.10.011. \nEpub 2012 Nov \n17. Original  Q1/D1  3,861  1872 -4973  \nNew guidelines for the publication \nof geneti c population data  Carracedo A, Butler JM, Gusm\u00e3o L, \nLinacre A, Parson W, Roewer L, \nSchneider PM.  Forensic Sci Int \nGenet  2013 \nFeb;7(2):217 -\n20. doi: \n10.1016/j.fsigen\n.2013.01.001. \nEpub 2013 Feb \n1. No abstract \navailable.  Editorial  Q1/D1  3,861  1872 -4973  \nImpac t of pharmacogenetics on CNS \nside effects related to efavirenz  S\u00e1nchez Mart\u00edn A, Cabrera Figueroa S, \nCruz Guerrero R, Hurtado LP, Hurl\u00e9 AD, \nCarracedo \u00c1lvarez A.  Pharmacogenomi\ncs 2013 \nJul;14(10):1167 -\n78. doi: \n10.2217/pgs.13.\n111.  Original  Q1 3,857  1462 -2416  \nNew genetic associations in \nthiopurine -related bone marrow \ntoxicity among inflammatory bowel \ndisease patients  Zabala W, Cruz R, Barreiro -de Acosta \nM, Chaparro M, Panes J, Echarri A, \nEsteve M, Carpio D, Andreu M, Garc\u00eda -\nPlanella E, Domenech E, Carracedo A,  \nGisbert JP, Barros F; EIGA & ENEIDA \ninvestigators.  Pharmacogenomi\ncs 2013 \nApr;14(6):631 -\n40. doi: \n10.2217/pgs.13.\n38. Original  Q1 3,857  1462 -2416  \nPoly -l-asparagine nanocapsules as \nanticancer drug delivery vehicles  Rivera -Rodr\u00edguez GR, Alonso MJ, \nTorres D.  Eur J Pharm \nBiopharm  2013 \nNov;85(3):481 -Original  Q1 3,826  0939 -6411   \n \n101 7. doi: \n10.1016/j.ejpb.2\n013.08.001. \nEpub 2013 Aug \n13. \nAdministration of the optimized \u03b2-\nLapachone \u2013poloxamer \u2013cyclodextrin \nternary system induces apoptosis, \nDNA damage and reduces tumor \ngrow th in a human breast \nadenocarcinoma xenograft mouse \nmodel  Seoane S, D\u00edaz -Rodr\u00edguez P, Sendon -\nLago J, Gallego R, P\u00e9rez -Fern\u00e1ndez R, \nLandin M.  Eur J Pharm \nBiopharm  2013 \nAug;84(3):497 -\n504. doi: \n10.1016/j.ejpb.2\n012.12.019. \nEpub 2013 Jan \n18. Original  Q1 3,826  0939-6411  \nAnti -tumor efficacy of chitosan -g-\npoly(ethylene glycol) nanocapsules \ncontaining docetaxel: Anti -TMEFF -2 \nfunctionalized nanocapsules vs. \nnon-functionalized nanocapsules  Torrecilla D, Lozano MV, Lallana E, \nNeissa JI, Novoa -Carballal R, Vidal A, \nFernandez -Megia E, Torres D, Riguera \nR, Alonso MJ, Dominguez F.  Eur J Pharm \nBiopharm  2013 \nApr;83(3):330 -7. \ndoi: \n10.1016/j.ejpb.2\n012.10.017. \nEpub 2012 Dec \n20. Original  Q1 3,826  0939 -6411  \nGenetic variations in SMAD7 are \nassociated with colorectal cancer \nrisk i n the colon cancer family \nregistry  Jiang X, Castelao JE, Vandenberg D, \nCarracedo A, Redondo CM, Conti DV, \nParedes Cotor\u00e9 JP, Potter JD, \nNewcomb PA, Passarelli MN, Jenkins \nMA, Hopper JL, Gallinger S, Le \nMarchand L, Mart\u00ednez ME, Ahnen DJ, \nBaron JA, Lindor NM , Haile RW, Gago -\nDominguez M.  PLoS One  2013;8(4):e6046\n4. doi: \n10.1371/journal\n.pone.0060464. \nEpub 2013 Apr \n3. Original  Q1 3,730  1932 -6203  \nElectrophysiological study of \nsupraspinal input and spinal output \nof cat's subnucleus reticularis \ndorsalis (SRD) neuro ns Velo P, Leiras R, Canedo A.  PLoS One  2013;8(3):e6068\n6. doi: \n10.1371/journal\n.pone.0060686. \nEpub 2013 Mar \n27. Original  Q1 3,730  1932 -6203  \nDerivation and expansion using Reinhardt P, Glatza M, Hemmer K, PLoS One  2013;8(3):e5925 Original  Q1 3,730  1932 -6203   \n \n102 only small molecules of human \nneural progenitors for \nneurodegenerative disease \nmodeli ng. Tsytsyura Y, Thiel CS, H\u00f6ing S, Moritz S, \nParga JA, Wagner L, Bruder JM, Wu G, \nSchmid B, R\u00f6pke A, Klingauf J, \nSchwamborn JC, Gasser T, Sch\u00f6ler HR, \nSterneckert J.  2. doi: \n10.1371/journal\n.pone.0059 252. \nEpub 2013 Mar \n22. \nThe genetic legacy of the pre -\ncolonial period in contemporary \nBolivians  Taboada -Echalar P, Alvarez -Iglesias V, \nHeinz T, Vidal -Bralo L, G\u00f3mez -Carballa \nA, Catelli L, Pardo -Seco J, Pastoriza A, \nCarracedo A, Torres -Balanza A, \nRocabado O, Vullo C, Salas A.  PLoS One  2013;8(3):e5898\n0. doi: \n10.1371/journal\n.pone.0058980. \nEpub 2013 Mar \n20. Original  Q1 3,730  1932 -6203  \nDeterminants of serum \nconcentrations of \nlipopolysaccharide -binding protein \n(LBP) in the adult popul ation: the \nrole of obesity  Gonzalez -Quintela A, Alonso M, \nCampos J, Vizcaino L, Loidi L, Gude F.  PLoS One  2013;8(1):e5460\n0. doi: \n10.1371/journal\n.pone.0054600. \nEpub 2013 Jan \n22. Original  Q1 3,730  1932 -6203  \nHeterozygous deficiency of endoglin \ndecreases insu lin and hepatic \ntriglyceride levels during high fat \ndiet Beiroa D, Romero -Pic\u00f3 A, Langa C, \nBernabeu C, L\u00f3pez M, L\u00f3pez -Novoa \nJM, Nogueiras R, Di\u00e9guez C.  PLoS One  2013;8(1):e5459\n1. doi: \n10.1371/journal\n.pone.0054591. \nEpub 2013 Jan \n15. Original  Q1 3,730  1932 -6203 \nFemale Nur77 -deficient mice show \nincreased susceptibility to diet -\ninduced obesity  Perez -Sieira S, Martinez G, Porteiro B, \nLopez M, Vidal A, Nogueiras R, Dieguez \nC. PLoS One  2013;8(1):e5383\n6. doi: \n10.1371/journal\n.pone.0053836. \nEpub 2013 Jan \n14. Origina l Q1 3,730  1932 -6203  \nMeta -analysis of mismatch repair \npolymorphisms within the cogent \nconsortium for colorectal cancer \nsusceptibility  Picelli S, Lorenzo Bermejo J, Chang -\nClaude J, Hoffmeister M, Fern\u00e1ndez -\nRozadilla C, Carracedo A, Castells A, \nCastellv\u00ed -Bel S; Members of the \nEPICOLON Consortium PLoS One  2013 Sep \n6;8(9):e72091.  Original  Q1 3,730  1932 -6203   \n \n103 (Gastrointestinal Oncology Group of \nthe Spanish Gastroenterological \nAssociation):, Naccarati A, Pardini B, \nVodickova L, M\u00fcller H, Talseth -Palmer \nBA, Stibbard G, Peterlongo P, Nici C, \nVeneroni S, Li L, Casey G, Tenesa  A, \nFarrington SM, Tomlinson I, Moreno V, \nvan Wezel T, Wijnen J, Dunlop M, \nRadice P, Scott RJ, Vodicka P, Ruiz -\nPonte C, Brenner H, Buch S, V\u00f6lzke H, \nHampe J, Schafmayer C, Lindblom A. \n(Salas A)  \nA generalized model to estimate \nthe statistical power in \nmitochondrial disease studies \ninvolving 2\u00d7k tables  Pardo -Seco J, Amigo J, Gonz\u00e1lez -\nManteiga W, Salas A.  PLoS One  2013 Sep \n27;8(9):e73567. \ndoi: \n10.1371/journal\n.pone.0073567.  Original  Q1 3,730  1932 -6203 \nFluorescent advanced glycation end \nproducts and their soluble receptor: \nthe birth of new plasmatic \nbiomarkers for risk stratification of \nacute coronary syndrome  Raposeiras -Roub\u00edn S, Rodi\u00f1o -Janeiro \nBK, Paradela -Dobarro B, Grigorian -\nShamagian L, Garc\u00eda -Acu\u00f1a JM, Aguiar -\nSouto P, Jacquet -Hervet M, Reino -\nMaceiras MV, Gonz\u00e1lez -Juanatey JR, \nAlvarez E.  PLoS One  2013 Sep \n13;8(9):e74302. \ndoi: \n10.1371/journal\n.pone.0074302.  Original  Q1 3,730  1932 -6203  \nThe gastric CB1 receptor modulates \nghrelin production through th e \nmTOR pathway to regulate food \nintake  Senin LL, Al -Massadi O, Folgueira C, \nCastelao C, Pardo M, Barja -Fernandez \nS, Roca -Rivada A, Amil M, Crujeiras AB, \nGarcia -Caballero T, Gabellieri E, Leis R, \nDieguez C, Pagotto U, Casanueva FF, \nSeoane LM.  PLoS One  2013 Nov \n26;8(11):e80339\n. doi: \n10.1371/journal\n.pone.0080339.  Original  Q1 3,730  1932 -6203  \nAnalysis of PALB2 gene in \nBRCA1/BRCA2 negative spanish \nhereditary breast/ovarian cancer \nfamilies with pancreatic cancer \ncases  Blanco A, de la Hoya M, Osorio A, Diez \nO, Mir amar MD, Infante M, Martinez -\nBouzas C, Torres A, Lasa A, Llort G, \nBrunet J, Gra\u00f1a B, Perez Segura P, \nGarcia MJ, Guti\u00e9rrez -Enr\u00edquez S, PLoS One  2013 Jul \n23;8(7):e67538. \ndoi: \n10.1371/journal\n.pone.0067538. Original  Q1 3,730  1932 -6203   \n \n104 Carracedo A, Tejada MI, Velasco EA, \nCalvo MT, Balma\u00f1a J, Benitez J, Cald\u00e9s \nT, Vega A.  Print 2013.  \nDifferential gene expression of \ncardiac ion channels in human \ndilated cardiomyopathy  Molina -Navarro MM, Rosell\u00f3 -Llet\u00ed E, \nOrtega A, Taraz\u00f3n E, Otero M, \nMart\u00ednez -Dolz L, Lago F, Gonz\u00e1l ez-\nJuanatey JR, Espa\u00f1a F, Garc\u00eda -Pav\u00eda P, \nMontero JA, Portol\u00e9s M, Rivera M.  PLoS One  2013 Dec \n5;8(12):e79792. \ndoi: \n10.1371/journal\n.pone.0079792.  Original  Q1 3,730  1932 -6203  \nInterleukin 6 deficiency modulates \nthe hypothalamic expression of \nenergy balance r egulating peptides \nduring pregnancy in mice  Pazos P, Lima L, Casanueva FF, Di\u00e9guez \nC, Garc\u00eda MC.  PLoS One  2013 Aug \n28;8(8):e72339. \ndoi: \n10.1371/journal\n.pone.0072339.  Original  Q1 3,730  1932 -6203  \nTemporomandibular disorders: the \nhabitual chewing side syndro me Santana -Mora U, L\u00f3pez -Cedr\u00fan J, \nMora MJ, Otero XL, Santana -Pen\u00edn U.  PLoS One  2013 Apr \n8;8(4):e59980. \ndoi: \n10.1371/journal\n.pone.0059980.  Original  Q1 3,730  1932 -6203  \nA polymer/oil based nanovaccine as \na single -dose immunization \napproach  Vicente S, Diaz -Freitas B, Peleteiro M, \nSanchez A, Pascual DW, Gonzalez -\nFernandez A, Alonso MJ.  PLoS One  2013 Apr \n22;8(4):e62500. \ndoi: \n10.1371/journal\n.pone.0062500.  Original  Q1 3,730  1932 -6203  \nHeart rate at baseline influences \nthe effect of ivabradine on \ncardiovascular ou tcomes in chronic \nheart failure: analysis from the \nSHIFT study  B\u00f6hm M, Borer J, Ford I, Gonzalez -\nJuanatey JR, Komajda M, Lopez -\nSendon J, Reil JC, Swedberg K, Tavazzi \nL. Clin Res Cardiol  2013 \nJan;102(1):11 -\n22. doi: \n10.1007/s00392\n-012-0467 -8. \nEpub 2012 May \n11. Original  Q2 3,667  1861 -0684  \nSeptic shock non -thyroidal illness \nsyndrome causes hypothyroidism \nand conditions for reduced \nsensitivity to thyroid hormone  Castro I, Quisenberry L, Calvo RM, \nObregon MJ, Lado -Abeal J.  J Mol Endocrinol  2013 Mar \n18;50(2):255 -\n66. doi: \n10.1530/JME -Original  Q2 3,577  0952 -5041   \n \n105 12-0188.  \nMutations in SLC20A2 are a major \ncause of familial idiopathic basal \nganglia calcification  Hsu SC, Sears RL, Lemos RR, Quint\u00e1ns \nB, Huang A, Spiteri E, Nevarez L, \nMamah C, Zatz M, Pierce KD, Fullerto n \nJM, Adair JC, Berner JE, Bower M, \nBrodaty H, Carmona O, Dobrici\u0107 V, \nFogel BL, Garc\u00eda -Estevez D, Goldman J, \nGoudreau JL, Hopfer S, Jankovi\u0107 M, \nJaum\u00e0 S, Jen JC, Kirdlarp S, Klepper J, \nKosti\u0107 V, Lang AE, Linglart A, \nMaisenbacher MK, Manyam BV, \nMazzoni P, Mi edzybrodzka Z, Mitarnun \nW, Mitchell PB, Mueller J, Novakovi\u0107 I, \nPaucar M, Paulson H, Simpson SA, \nSvenningsson P, Tuite P, Vitek J, \nWetchaphanphesat S, Williams C, Yang \nM, Schofield PR, de Oliveira JR, Sobrido \nMJ, Geschwind DH, Coppola G.  Neurogenetics  2013  \nFeb;14(1):11 -\n22. doi: \n10.1007/s10048\n-012-0349 -2. \nEpub 2013 Jan \n20. Original  Q1 3,575  1364 -6745  \nSynthesis and allosteric modulation \nof the dopamine receptor by \npeptide analogs of l -prolyl -l-leucyl -\nglycinamide (PLG) modified in the l -\nproline or l -proline a nd l-leucine \nscaffolds  Ferreira da Costa J, Caama\u00f1o O, \nFern\u00e1ndez F, Garc\u00eda -Mera X, Sampaio -\nDias IE, Brea JM, Cadavid MI.  Eur J Med Chem  2013 \nNov;69:146 -58. \ndoi: \n10.1016/j.ejmec\nh.2013.08.001. \nEpub 2013 Aug \n22. Original  Q1 3,499  0223 -5234  \nSelective and pote nt adenosine A(3) \nreceptor antagonists by \nmethoxyaryl substitution on the N -\n(2,6-diarylpyrimidin -4-yl)acetamide \nscaffold  Yaziji V, Rodr\u00edguez D, Coelho A, Garc\u00eda -\nMera X, El Maatougui A, Brea J, Loza \nMI, Cadavid MI, Guti\u00e9rrez -de-Ter\u00e1n H, \nSotelo E.  Eur J Med Chem  2013 \nJan;59:235 -42. \ndoi: \n10.1016/j.ejmec\nh.2012.11.010. \nEpub 2012 Nov \n24. Original  Q1 3,499  0223 -5234  \nUnraveling phosphodiesterase \nsurfaces. Identification of Redondo M, Soteras I, Brea J, \nGonz\u00e1lez -Garc\u00eda A, Cadavid MI, Loza Eur J Med Chem  2013 \nDec;70:781 -8. Original  Q1 3,499  0223 -5234   \n \n106 phosphodiesterase 7 allosteric \nmodulation cavities  MI, Martinez A, Gil C, Campillo NE.  doi: \n10.1016/j.ejmec\nh.2013.10.035. \nEpub 2013 Oct \n22. \nNovel (coumarin -3-yl)carbamates as \nselective MAO -B inhibitors: \nsynthesis, in vi tro and in vivo \nassays, theoretical evaluation of \nADME properties and docking study  Matos MJ, Vilar S, Gonzalez -Franco \nRM, Uriarte E, Santana L, Friedman C, \nTatonetti NP, Vi\u00f1a D, Fontenla JA.  Eur J Med Chem.  2013 \nMay;63:151 -61.  Original  Q1 3,499  0223 -5234 \nCombining QSAR classification \nmodels for predictive modeling of \nhuman monoamine oxidase \ninhibitors  Helguera AM, P\u00e9rez -Garrido A, Gaspar \nA, Reis J, Cagide F, Vina D, Cordeiro \nMN, Borges F.  Eur J Med Chem.  2013 Jan;59:75 -\n90 Original  Q1 3,499  0223 -5234  \nPredictive value of thromboembolic \nrisk scores before an atrial \nfibrillation ablation procedure: time \nfor a consensus?  Rodr\u00edguez -Ma\u00f1ero M, Mart\u00ednez -Sande \nL, Gonz\u00e1lez -Juanatey JR.  J Cardiovasc \nElectr  2013 \nMay;24(5):E8. \ndoi: \n10.1111/jce.121\n37. Epub 2013 \nApr 9 . Letter  Q2 3,475  1045 -3873  \nEffects of sevoflurane \npostconditioning on cell death, \ninflammation and TLR expression in \nhuman endothelial cells exposed to \nLPS Rodr\u00edguez -Gonz\u00e1lez R, Baluja A, Veiras \nDel R\u00edo S, Rodr\u00edguez A, Rodr\u00edguez J, \nTaboada M, Brea D, \u00c1lv arez J.  J Transl Med  2013 Apr \n3;11:87. doi: \n10.1186/1479 -\n5876 -11-87. Original  Q2 3,459  1479 -5876  \nDoxorubicin -loaded micelles of \nreverse poly(butylene oxide) -\npoly(ethylene oxide) -poly(butylene \noxide) block copolymers as efficient \n\"active\" chemotherapeutic agents  Camb\u00f3n A, Rey -Rico A, Mistry D, Brea \nJ, Loza MI, Attwood D, Barbosa S, \nAlvarez -Lorenzo C, Concheiro A, \nTaboada P, Mosquera V.  Int J Pharmaceut  2013 Mar \n10;445(1 -2):47 -\n57. doi: \n10.1016/j.ijphar\nm.2013.01.056. \nEpub 2013 Feb \n1. Original  Q1 3,458  0378 -5173 \nVaccine delivery carriers: Insights \nand future perspectives  Correia -Pinto JF, Csaba N, Alonso MJ.  Int J Pharmaceut  2013 Jan \n2;440(1):27 -38. Revisi\u00f3n  Q1 3,458  0378 -5173   \n \n107 doi: \n10.1016/j.ijphar\nm.2012.04.047. \nEpub 2012 Apr \n23. \nIn vivo evaluation of poly -l-\nasparagine nanocapsules as carriers \nfor anti -cancer drug delivery  Rivera -Rodriguez GR, Lollo G, Montier \nT, Benoit JP, Passirani C, Alonso MJ, \nTorres D.  Int J Pharmaceut  2013 Dec \n15;458(1):83 -9. \ndoi: \n10.1016/j.ijphar\nm.2013.09.038. \nEpub 2013 Oct \n17. Original  Q1 3,458  0378 -5173  \nSystemic heparin delivery by the \npulmonary route using chitosan and \nglycol chitosan nanoparticles  Trapani A, Di Gioia S, Ditaranto N, \nCioffi N, Goycoolea FM, Carbone A, \nGarcia -Fuentes M, Conese M, Alonso \nMJ. Int J Pharmaceut  2013 Apr \n15;447(1 -\n2):115 -23. doi: \n10.1016/j.ijphar\nm.2013.02.035. \nEpub 2013 Feb \n20. Original  Q1 3,458  0378 -5173  \nA genetic case -control study \nconfirms the implication of SMAD7 \nand TNF locus in the development \nof proliferative vitreoretinopathy  Rojas J, Fernandez I, P astor JC, \nMaclaren RE, Ramkissoon Y, Harsum S, \nCharteris DG, Van Meurs JC, \nAmarakoon S, Ruiz -Moreno JM, Rocha -\nSousa A, Brion M, Carracedo A.  Invest \nOphthalmol Vis \nSci 2013 Mar \n5;54(3):1665 -\n78. doi: \n10.1167/iovs.12\n-10931.  Original  Q1/D1  3,441  0146 -0404  \nFas/CD95 ligation induces \nproliferation of primary fetal \nastrocytes through a mechanism \ninvolving caspase 8 -mediated ERK \nactivation  Barca O, Seoane M, Se\u00f1ar\u00eds RM, Arce \nVM. Cell Physiol \nBiochem  2013;32(1):111 -\n20. doi: \n10.1159/000350\n129. Epub 2013 \nJul 12.  Origi nal Q2 3,414  1015 -8987  \nDual inhibitors of monoamine \noxidase and cholinesterase for the \ntreatment of Alzheimer disease  Y\u00e1\u00f1ez M, Vi\u00f1a D.  Curr Top Med \nChem  2013;13(14):169\n2-706.  Original  Q1 3,41  1568 -0266  \nEpidemiology, mortality rate \nandsurvival in a homog eneous Fernandez -Rodriguez E, Lopez -Raton \nM, Andujar P, Martinez -Silva I, Clin Endocrinol \n(Oxf)  2013 \nFeb;78(2):278 -Original  Q2 3,396  0300 -0664   \n \n108 population of hypopituitary \npatients  Cadarso -Suarez C, Casanueva F, \nBernabeu I.  84. doi: \n10.1111/j.1365 -\n2265.2012.0451\n6.x. \nMutagenesis and computational \nmodeling of the human G protein -\ncoupled receptor Y2 for \nneuropeptide Y and peptide YY  Xu B, F\u00e4llmar H, Boukharta L, Pruner J, \nLundell I, Mohell N, Guti\u00e9rrez -de-Ter\u00e1n \nH, Aqvist J, Larhammar D.  Biochemistry -US 2013 No v \n12;52(45):7987 -\n98. doi: \n10.1021/bi4008\n30c. Epub 2013 \nOct 31.  Original  Q2 3,377  0006 -2960  \nOxidation of methionine 216 in \nsheep and elk prion protein is \nhighly dependent upon the amino \nacid at position 218 but is not \nimportant for prion propagation  Silva CJ, Dynin I, Erickson ML, Requena \nJR, Balachandran A, Hui C, Onisko BC, \nCarter JM.  Biochemistry -US 2013 Mar \n26;52(12):2139 -\n47. doi: \n10.1021/bi3016\n795. Epub 2013 \nMar 15.  Original  Q2 3,377  0006 -2960  \nComputational approaches for \nligand discovery and design i n class -\nA G protein -coupled receptors  Rodr\u00edguez D, Guti\u00e9rrez -de-Ter\u00e1n H.  Curr Pharm Des  2013;19(12):221\n6-36. Original  Q1 3,311  1381 -6128  \nDevelopment of a novel forensic \nSTR multiplex for ancestry analysis \nand extended identity testin  Phillips C, Fernande z-Formoso L, \nGelabert -Besada M, Garcia -Magari\u00f1os \nM, Santos C, Fondevila M, Carracedo \nA, Lareu MV.  Electrophoresis  2013 \nApr;34(8):1151 -\n62. doi: \n10.1002/elps.20\n1200621. Epub \n2013 Mar 18.  Original  Q1 3,261  0173 -0835  \nCyclic AMP relaxation of rat aortic \nsmooth  muscle is mediated in part \nby decrease of depletion of \nintracellular Ca(2+) stores and \ninhibition of capacitative calcium \nentry.  Cu\u00ed\u00f1as A, El\u00edes J, Orallo F, Campos -\nToimil M  Vascul Pharmacol  2013 Jan;58(1 -\n2):98 -104 Original  Q2 3,212  1537 -1891  \nPercutaneou s implantation of the \ncoreValve\u00ae self -expanding valve \nprosthesis in patients with severe Pascual I, Avanzas P, Mu\u00f1oz -Garc\u00eda AJ, \nL\u00f3pez -Otero D, Jimenez -Navarro MF, \nCid-Alvarez B, Del Valle R, Alonso -Rev Esp Cardiol  2013 \nOct;66(10):775 -\n781. doi: Original  Q2 3,204  0300 -8932   \n \n109 aortic stenosis and porcelain aorta: \nMedium -term lollow -up Briales JH, Ocaranza -Sanchez R, \nAlfonso F, Hern\u00e1ndez JM, Trillo -\nNouche R, Mor\u00eds C.  10.1016/j.reces\np.2013.03.002. \nEpub 2013 Jun \n3. \nRadial vs femoral access after \npercutaneous corona ry intervention \nfor ST -segment elevation \nmyocardial infarction. Thirty -day \nand one -year mortality results  Ruano -Ravina A, Aldama -L\u00f3pez G, Cid -\n\u00c1lvarez B, Pi\u00f1\u00f3n -Esteban P, L\u00f3pez -\nOtero D, Calvi\u00f1o -Santos R, Ocaranza -\nS\u00e1nchez R, V\u00e1zquez -Gonz\u00e1lez N, Trillo -\nNouche  R, L\u00f3pez -Pardo E.  Rev Esp Cardiol  2013 \nNov;66(11):871 -\n878. doi: \n10.1016/j.reces\np.2013.05.029. \nEpub 2013 Sep \n14. Original  Q2 3,204  0300 -8932  \nA first case of totally percutaneous \ntransaxillary aortic valve \nimplantation  Oteo JF, Trillo R, Garc\u00eda -Touchard A,  \nFern\u00e1ndez -D\u00edaz JA, Cavero MA, \nGoicolea J.  Rev Esp Cardiol  2013 \nMar;66(3):220 -\n2. doi: \n10.1016/j.reces\np.2012.06.022. \nEpub 2012 Oct \n3. Letter  Q2 3,204  0300 -8932  \nTAVI through the left subclavian \nartery with a LIMA graft  Cruz -Gonz\u00e1lez I, Mart\u00edn -Moreiras J, \nTrillo R.  Rev Esp Cardiol  2013 \nMar;66(3):219. \ndoi: \n10.1016/j.reces\np.2011.03.013. \nEpub 2011 Jun \n12. Original  Q2 3,204  0300 -8932  \nOn the Cost -effectiveness of \nDabigatran. Response.  Gonz\u00e1lez -Juanatey JR, Mart\u00ednez -Rubio \nA, Gonz\u00e1lez -Rojas N.  Rev Esp Cardiol  2013 \nJun;66(6):513. \ndoi: \n10.1016/j.reces\np.2013.02.007. \nEpub 2013 Apr \n22. Letter  Q2 3,204  0300 -8932  \nSelf-management of Vitamin K \nAntagonists Is More Cost -effective Gonz \u00e1lez-Juanatey JR, Lobos JM, \nReverter JC, Becerra V; en Rev Esp Cardiol  2013 \nJun;66(6):511. Letter  Q2 3,204  0300 -8932   \n \n110 Than Dabigatran for Stroke \nPrevention in Non -valvular Atrial \nFibrillation in Spain. Response  representaci\u00f3n de todos los autores \ndel art\u00edculo.  doi: \n10.1016/j.reces\np.2012.12.004. \nEpub 2013 Feb \n27. \nResults of intra -aortic balloon \ncounterpulsation in patients with \nST-elevation myocardial infarction \nwith cardiogenic shock undergoing \npercutaneous coronary \nintervention: Is there a benefit?  Raposeiras -Roub\u00edn S, Abu -Assi E, \nGarc\u00eda -Acu\u00f1a JM, Gonz\u00e1lez -Juanatey \nJR. Rev Esp Cardiol  2013 \nJul;66( 7):590 -1. \ndoi: \n10.1016/j.reces\np.2013.01.011. \nEpub 2013 Apr \n6. Letter  Q2 3,204  0300 -8932  \nDry pericarditis, diagnosis with \ncardiac magnetic resonance imaging  Raposeiras Roub\u00edn S, Maceira Gonz\u00e1lez \nA. Rev Esp Cardiol  2013 \nJul;66(7):584. \ndoi: \n10.1016/j.reces\np.2011.09.025. \nEpub 2012 Feb \n2. Original  Q2 3,204  0300 -8932  \nUpdate in cardiology: Vascular risk \nand cardiac rehabilitation  Galve E, Castro A, Cordero A, Dalmau \nR, F\u00e1cila L, Garc\u00eda -Romero A, Maz\u00f3n P, \nSanmart\u00edn M, Alonso Garc\u00eda A; en \nrepresentaci\u00f3n de la Secc i\u00f3n de Riesgo \nVascular y Rehabilitaci\u00f3n Cardiaca de \nla Sociedad Espa\u00f1ola de Cardiolog\u00eda.  Rev Esp Cardiol  2013 \nFeb;66(2):124 -\n30. doi: \n10.1016/j.reces\np.2012.10.009. \nEpub 2012 Dec \n23. Editorial  Q2 3,204  0300 -8932  \nStatins modulate feedback \nregulation mechanis ms between \nadvanced glycation end -products \nand C -reactive protein: Evidence in \npatients with acute myocardial \ninfarction  Paradela -Dobarro B, Raposeiras -\nRoub\u00edn S, Rodi\u00f1o -Janeiro BK, \nGrigorian -Shamagian L, Garc\u00eda -Acu\u00f1a \nJM, Aguiar -Souto P, Jacquet -Hervet M, \nReino -Maceiras MV, Gonz\u00e1lez -\nJuanatey JR, Alvarez E.  Eur J Pharm Sci  2013 Jul \n16;49(4):512 -8. \ndoi: \n10.1016/j.ejps.2\n013.05.001. \nEpub 2013 May \n9. Original  Q2 2,987  0928 -0987  \nHyaluronan nanocapsules as a new Oyarzun -Ampu ero FA, Rivera - Eur J Pharm Sci  2013 Jul Original  Q2 2,987  0928 -0987   \n \n111 vehicle for intracellular drug \ndelivery  Rodr\u00edguez GR, Alonso MJ, Torres D.  16;49(4):483 -\n90. doi: \n10.1016/j.ejps.2\n013.05.008. \nEpub 2013 May \n15. \nAnalysis of SUMOylated proteins \nusing SUMO -trap  Da Silva -Ferrada E, Xolalpa W, Lang V, \nAillet F, Martin -Ruiz I, de la Cruz -\nHerrera CF, Lopitz -Otsoa F, Carracedo \nA, Goldenberg SJ, Rivas C, England P, \nRodr\u00edguez MS.  Sci Rep -UK 2013;3:1690. \ndoi: \n10.1038/srep01\n690.  Original  Q1 2,927  2045 -2322  \nPharmacogenomics of anti -platelet \ntherapy focused on peripheral \nblood cells of coronary arterial \ndisease patients  Luchessi AD, Silbiger VN, Hirata RD, \nLima -Neto LG, Cavichioli D, I\u00f1iguez A, \nBravo M, Bastos G, Sousa AG, Bri\u00f3n M, \nCarracedo A, Hirata MH.  Clin Chim Acta  2013 Oct \n21;425C:9 -17. \ndoi: \n10.1016/j.c ca.2\n013.06.021. \nEpub 2013 Jul 4.  Original  Q1 2,850  0009 -8981  \nNovel genes detected by \ntranscriptional profiling from \nwhole -blood cells in patients with \nearly onset of acute coronary \nsyndrome  Silbiger VN, Luchessi AD, Hirata RD, \nLima -Neto LG, Cavichioli D, Carracedo \nA, Bri\u00f3n M, Dopazo J, Garc\u00eda -Garc\u00eda F, \nDos Santos ES, Ramos RF, Sampaio MF, \nArmaganijan D, Sousa AG, Hirata MH.  Clin Chim Acta  2013 Jun \n5;421:184 -90. \ndoi: \n10.1016/j.cca.2\n013.03.011. \nEpub 2013 Mar \n25. Original  Q1 2,850  0009 -8981  \nGenetic variants in genes related to \nlipid metabolism and \natherosclerosis, dyslipidemia and \natorvastatin response  Rodrigues AC, Sobrino B, Genvigir FD, \nWillrich MA, Arazi SS, Dorea EL, Bernik \nMM, Bertolami M, Faludi AA, Brion MJ, \nCarracedo A, Hirata MH, Hi rata RD.  Clin Chim Acta  2013 Feb \n18;417:8 -11. \ndoi: \n10.1016/j.cca.2\n012.11.028. \nEpub 2012 Dec \n13. Original  Q1 2,850  0009 -8981  \nMAO inhibitory activity of 2 -\narylbenzofurans versus 3 -\narylcoumarins: synthesis, in vitro Ferino G,  Cadoni E, Matos MJ, \nQuezada E, Uriarte E, Santana L, Vilar \nS, Tatonetti NP, Y\u00e1\u00f1ez M, Vi\u00f1a D, ChemMedChem.  2013 \nJun;8(6):956 -66 Original  Q2 2,835  1860 -7179   \n \n112 study, and docking calculations.  Picciau C, Serra S, Delogu G  \nA glimpse into past, present, and \nfuture DNA sequencing.  Morey M, Fer n\u00e1ndez -Marmiesse A, \nCasti\u00f1eiras D, Fraga JM, Couce ML, \nCocho JA.  Mol Genet Metab  2013 Sep -\nOct;110(1 -2):3-\n24. doi: \n10.1016/j.ymgm\ne.2013.04.024. \nEpub 2013 May \n11. Revisi\u00f3n  Q2 2,834  1096 -7192  \nNosema ceranae (Microsporidia), a \ncontroversial 21st century honey  \nbee pathogen  Higes M, Meana A, Bartolom\u00e9 C, Bot\u00edas \nC, Mart\u00edn -Hern\u00e1ndez R.  Environ Microbiol \nRep 2013 \nFeb;5(1):17 -29. \ndoi: \n10.1111/1758 -\n2229.12024. \nEpub 2013 Jan \n18. Revisi\u00f3n  Q2 2,708  1758 -2229  \nGlobal population variability in \nPromega PowerPlex CS7, D6S10 43, \nand Penta B STRs  Phillips C, Kind S, Fernandez -Formoso \nL, Gelabert -Besada M, Carracedo A, \nLareu MV.  Int J Legal Med  2013 \nSep;127(5):901 -\n6. doi: \n10.1007/s00414\n-013-0888 -6. \nEpub 2013 Jul \n11. Original  Q1 2,686  0937 -9827  \nCharacterization of the dynamic \nevents of GPCRs by automated \ncomputational simulations  Guti\u00e9rrez -de-Ter\u00e1n H, Bello X, \nRodr\u00edguez D.  Biochem Soc T  2013 Feb \n1;41(1):205 -12. \ndoi: \n10.1042/BST201\n20287.  Original  Q3 2,587  0300 -5127  \nSerum chemerin levels during \nnormal human pregnancy  Garces MF, Sa nchez E, Ru\u00edz -Parra AI, \nRubio -Romero JA, Angel -M\u00fcller E, \nSuarez MA, Boh\u00f3rquez LF, Bravo SB, \nNogueiras R, Di\u00e9guez C, Caminos JE.  Peptides  2013 \nApr;42:138 -43. \ndoi: \n10.1016/j.pepti\ndes.2013.01.00\n3. Epub 2013 \nJan 8.  Original  Q2 2,522  0196 -9781   \n \n113 Irisin, two year s later  Novelle MG, Contreras C, Romero -Pic\u00f3 \nA, L\u00f3pez M, Di\u00e9guez C.  Int J Endocrinol  2013;2013:7462\n81. Epub 2013 \nNov 5.  Revisi\u00f3n  Q3 2,518  1687 -8337  \nDosing of iodinated contrast \nvolume: A new simple algorithm to \nstratify the risk of contrast -induced \nnephro pathy in patients with acute \ncoronary syndrome: A New Simple \nAlgorithm to Stratify the Risk of \nContrast -Induced Nephropathy in \nPatients With Acute Coronary \nSyndrome  Raposeiras -Roub\u00edn S, Abu -Assi E, \nOcaranza -S\u00e1nchez R, Alvarez -\u00c1lvarez \nB, Cambeiro -Gonz\u00e1lez C , Fandi\u00f1o -\nVaquero R, Garc\u00eda -Castelo A, Garc\u00eda -\nAcu\u00f1a JM, Gonz\u00e1lez -Juanatey JR.  Catheter Cardio \nInte 2013 Nov \n15;82(6):888 -\n97. doi: \n10.1002/ccd.24\n847. Epub 2013 \nJul 17.  Original  Q2 2,514  1522 -1946  \nThe CYP1A2 -163C>A polymorphism \nis associated with clozapine -\ninduced generalized tonic -clonic \nseizures in Brazilian schizophrenia \npatients  Kohlrausch FB, Severino -Gama C, \nLobato MI, Belmonte -de-Abreu P, \nCarracedo A, Hutz MH.  Psychiat Res  2013 Sep \n30;209(2):242 -\n5. doi: \n10.1016/j.psych\nres.2013.02.030\n. Epub 2013 Apr \n18. Original  Q2 2,456  0165 -1781  \nSynthesis and binding affinity of \nnew 1,4 -disubstituted triazoles as \npotential dopamine D(3) receptor \nligands  Insua I, Alvarado M, Masaguer CF, \nIglesias A, Brea J, Loza MI, Carro L.  Bioorg Med Chem \nLett 2013 Oct \n15;23(20):55 86-\n91. doi: \n10.1016/j.bmcl.\n2013.08.047. \nEpub 2013 Aug \n16. Original  Q2 2,338  0960 -894X  \nThe CCM3 -GCKIII partnership  Zalvide J, Fidalgo M, Fraile M, Guerrero \nA, Iglesias C, Floridia E, Pombo CM.  Histol Histopathol  2013 \nOct;28(10):1265\n-1272. Epub \n2013 Jun 7.  Revisi\u00f3n  Q2 2,281  0213 -3911  \nA Xq21.31 duplication without \nfeatures of Prader -Willi syndrome  Castro -Gago M, P\u00e9rez -Gay L, G\u00f3mez -\nLado C, Barros -Angueira F.  Endocrine  2013 \nFeb;43(1):238. \ndoi: \n10.1007/s12020Letter  Q3 2,250  1355 -008X   \n \n114 -012-9738 -4. \nAnti -dyskinet ic effect of anpirtoline \nin animal models of L -DOPA -\ninduced dyskinesia  B\u00e9zard E, Mu\u00f1oz A, Tronci E, Pioli EY, Li \nQ, Porras G, Bj\u00f6rklund A, Carta M.  Neurosci Res  2013 \nDec;77(4):242 -\n6. doi: \n10.1016/j.neure\ns.2013.10.002. \nEpub 2013 Oct \n14. Original  Q3 2,204  0168-0102  \nPolyarginine nanocapsules: A new \nplatform for intracellular drug \ndelivery  Lozano MV, Lollo G, Alonso -Nocelo M, \nBrea J, Vidal A, Torres D, Alonso MJ.   J Nanopart Res  2013 Mar; \nVolume: 15, \nIssue: 3, Article \nNumber: 1515, \nDOI: \n10.1007/s11051\n-013-1515-7 Original  Q1 2,175  1388 -0764  \nThe brain: A new organ for the \nmetabolic actions of SIRT1  Al Massadi O, Qui\u00f1ones M, Lear P, \nDieguez C, Nogueiras R.  Horm Metab Res  2013 \nDec;45(13):960 -\n6. doi: \n10.1055/s -0033 -\n1351322. Epub \n2013 Aug 15.  Revisi\u00f3n  Q3 2,145  0018-5043  \nEffects of neonatal programming on \nhypothalamic mechanisms \ncontrolling energy balance  Contreras C, Novelle MG, Leis R, \nDi\u00e9guez C, Skrede S, L\u00f3pez M.  Horm Metab Res  2013 \nDec;45(13):935 -\n44. doi: \n10.1055/s -0033 -\n1351281. Epub \n2013 Aug 2.  Revisi\u00f3n  Q3 2,145  0018 -5043  \nSNOMED CT module -driven clinical \narchetype management  Allones JL, Taboada M, Martinez D, \nLozano R, Sobrido MJ.  J Biomed Inform  2013 \nJun;46(3):388 -\n400. doi: \n10.1016/j.jbi.20\n13.01.003. Epub \n2013 Feb 9.  Original  Q1 2,131  1532 -0464   \n \n115 A simple me thod for isolating rat \nbrain mitochondria with high \nmetabolic activity: effects of EDTA \nand EGTA  Iglesias -Gonz\u00e1lez J, S\u00e1nchez -Iglesias S, \nBeiras -Iglesias A, Soto -Otero R, \nM\u00e9ndez -\u00c1lvarez E.  J Neurosci \nMethods  2013 Feb \n15;213(1):39 -\n42. doi: \n10.1016/j.jneu\nmeth.2012.12.0\n05. Epub 2012 \nDec 20.  Original  Q3 2,114  0165 -0270  \nThe role of carbonic anhydrase IX in \nhypoxia control in OSCC  P\u00e9rez -Say\u00e1ns M, Supuran CT, \nPastorekova S, Su\u00e1rez -Pe\u00f1aranda JM, \nPilar GD, Barros -Angueira F, G\u00e1ndara -\nRey JM, Garc\u00eda -Garc\u00eda A.  J Oral Pathol Med  2013 \nJan;42(1):1 -8. \ndoi: \n10.1111/j.1600 -\n0714.2012.0114\n4.x. Epub 2012 \nMar 14.  Revisi\u00f3n  Q1 2,055  0904 -2512  \nModel building in nonproportional \nhazard regression  Rodr\u00edguez -Girondo M, Kneib T, \nCadarso -Su\u00e1rez C, Abu -Assi E.  Stat Med  2013 Dec \n30;32(30) :5301 -\n14. doi: \n10.1002/sim.59\n61. Epub 2013 \nSep 6.  Original  Q1 2,044  0277 -6715  \nMyostatin expression is regulated \nby underfeeding and neonatal \nprogramming in rats  Carneiro I, Gonz\u00e1lez T, L\u00f3pez M, \nSe\u00f1ar\u00eds R, Devesa J, Arce VM.  J Physiol Biochem  2013 \nMar;69(1 ):15-\n23. doi: \n10.1007/s13105\n-012-0183 -x. \nEpub 2012 Jun \n9. Original  Q3 1,654  1138 -7548  \nGRACE risk score predicts contrast -\ninduced nephropathy in patients \nwith acute coronary syndrome and \nnormal renal function  Raposeiras -Roub\u00edn S, Aguiar -Souto P, \nBarreiro -Pardal C, L\u00f3pez Otero D, \nElices Teja J, Ocaranza Sanchez R Md, \nCid \u00c1lvarez B, Trillo Nouche R, Reino \nMaceiras MV, Abu -Assi E, Garc\u00eda -\nAcu\u00f1a JM, Gonz\u00e1lez -Juanatey JR.  Angiology  2013 \nJan;64(1):31 -9. \ndoi: \n10.1177/000331\n9711434800. \nEpub 2012 Feb \n1. Original  Q3 1,647  0003 -3197   \n \n116 Intracellular delivery of docetaxel \nusing freeze -dried polysaccharide \nnanocapsules  Lozano MV, Esteban H, Brea J, Loza MI, \nTorres D, Alonso MJ.  J Microencapsul  2013;30(2):181 -\n8. doi: \n10.3109/026520\n48.2012.714411\n. Epub 2012 Oct \n22. Original  Q2 1,571  0265 -2048  \nMolecular characterization of \nCryptosporidium spp. isolated in \nhumans in two different locations \nin Spain  Navarro -I-Martinez L, da Silva AJ, Llovo \nTaboada J, Del \u00c1guila C, Pieniazek NJ, \nBornay -Llinares FJ.  Enferm Infecc \nMicrobiol Clin  2013 \nOct;31(8):506 -\n510. doi: \n10.1016/j.eimc.\n2012.11.005. \nEpub 2012 Dec \n27. Original  Q4 1,478  0213 -005X  \nApplying a simulation model to \nmanage waiting lists for hospital \ninpatient activity in an EU region  Reyes -Santias, F; Cadarso -Suaarez, C; \nMartinez -Calvo, A.  Math Comput \nModel  2013 Apr; 57(7 -\n8): 1840 -1846.  Original  Q1 1,420  0895 -7177  \nDyslipemia in diabetics treated with \nstatins. Results of the Dyslipidemia \nInternational Study in Spain  Mill\u00e1n J, Alegr\u00eda E, Guijarro C, Lozano \nJV, Vitale GC, Gonz\u00e1lez -Tim\u00f3n B,  \nGonz\u00e1lez -Juanatey JR.  Med Clin -\nBarcelona  2013 Nov \n16;141(10):430 -\n6. doi: \n10.1016/j.medcl\ni.2012.09.030. \nEpub 2012 Dec \n12. Original  Q2 1,399  0025 -7753  \nPocket echography performed by a \nfamily physician: yes to \ndemocratization, no to revolution  Gonz\u00e1lez -Juan atey JR, Abu -Assi E.  Med Clin -\nBarcelona  2013 Jul \n7;141(1):24 -6. \ndoi: \n10.1016/j.medcl\ni.2012.12.012. \nEpub 2013 Feb \n26. Editorial  Q2 1,399  0025 -7753  \nEducational intervention for the \nprevention of osteoporosis in a \nrural Primary Healthcare service  P\u00e9rez Fern\u00e1 ndez MR, Almaz\u00e1n Ortega \nR, Mart\u00ednez Portela JM, Alves P\u00e9rez \nMT, Segura Iglesias MC, P\u00e9rez \nFern\u00e1ndez R.  Med Clin -\nBarcelona  2013 Dec \n21;141(12):519 -\n21. doi: \n10.1016/j.medclOriginal  Q2 1,399  0025 -7753   \n \n117 i.2013.02.041. \nEpub 2013 Sep \n7. \nRadiological infrabony de fects after \nimpacted mandibular third molar \nextractions in young adults  Inoc\u00eancio Faria A, Gallas -Torreira M, \nL\u00f3pez -Rat\u00f3n M, Crespo -V\u00e1zquez E, \nRodr\u00edguez -N\u00fa\u00f1ez I, L\u00f3pez -Castro G.  J Oral Maxillofac \nSurg  2013 \nDec;71(12):202\n0-8. doi: \n10.1016/j.joms.\n2013.07.029 . \nEpub 2013 Sep \n24. Original  Q2 1,333  0278 -2391  \nErratum to: Nucleofection of whole \nmurine retinas  Gomez -Touri\u00f1o IM, Senra A, Gonzalez \nF. Cytotechnology  2013 \nAug;65(4):671. \ndoi: \n10.1007/s10616\n-013-9535 -9. Correcci\u00f3n  Q3 1,315  0920 -9069  \nNucleofection of who le murine \nretinas  Gomez -Touri\u00f1o IM, Senra A, Garcia F.  Cytotechnology  2013 \nAug;65(4):523 -\n32. doi: \n10.1007/s10616\n-012-9509 -3. \nEpub 2012 Nov \n7. Original  Q3 1,315  0920 -9069  \nCHEK2 c.1100delC mutation among \nnon-BRCA1/2 Spanish hereditary \nbreast cancer families  Fachal L, Santamari\u00f1a M, Blanco A, \nCarracedo A, Vega A.  Clin Transl Oncol  2013 \nFeb;15(2):164 -\n5. doi: \n10.1007/s12094\n-012-0967 -z. \nEpub 2012 Nov \n13. Letter  Q4 1,276  1699 -048X  \nResponse to the comment on: \nCardiac troponin I and creatine \nkinase MB isoenzyme in  patients \nwith chronic renal failure  Flores -Sol\u00eds LM, Hern\u00e1ndez -Dom\u00ednguez \nJL, Otero -Gonz\u00e1lez A, Gonz\u00e1lez -\nJuanatey JR.  Nefrologia  2013 Nov \n13;33(6):852 -\n853. doi: \n10.3265/Nefrol\nogia.pre2013.OcLetter  Q4 1,274  0211 -6995   \n \n118 t.12321.  \nMicrodeletion 2q23.1 and \nsyndr omic findings  Perez -Gay L, Gomez -Lado C, Eiris -Punal \nJ, Dacruz D, Quintela I, Barros -\nAngueira F, Castro -Gago M.  Rev Neurologia  2013 Nov \n1;57(9):430 -1. Letter  Q4 1,179  0210 -0010  \nIs necessary to perform a \ntransthoracic echocardiogram in all \nthe patients wit h cryptogenic stroke \nduring hospitalization?  Arias -Rivas S, Rodr\u00edguez -Y\u00e1\u00f1ez M, \nL\u00f3pez -Ferreiro A, Santamar\u00eda -Cadavid \nM, Fern\u00e1ndez -Pajar\u00edn G, Gonz\u00e1lez -\nJuanatey JR, Castillo J, Blanco M.  Rev Neurologia  2013 May \n16;56(10):510 -\n4. Original  Q4 1,179  0210 -0010  \n16p11.2 microdeletion associated \nto early onset benign childhood \nseizures  Castro -Gago M, P\u00e9rez -Gay L, G\u00f3mez -\nLado C, Dacruz D, Barros -Angueira F.  Rev Neurologia  2013 Jan \n16;56(2):125 -7. Letter  Q4 1,179  0210 -0010  \nRepeatability and accuracy of a \nparalleling te chnique for \nradiographic evaluation of distal \nbone healing after impacted third \nmolar surgery  Inoc\u00eancio Faria A, Gallas Torreira M, \nL\u00f3pez Rat\u00f3n M.  Dentomaxillofac \nRad 2013;42(1):7802\n2535. doi: \n10.1259/dmfr/7\n8022535. Epub \n2012 Jun 29.  Original  Q3 1,148  0250 -832X  \nCasework application of a stand -\nalone pentaplex assay of extended -\nESS STRs  Barbaro A, Fernandez -Formoso L, \nPhillips C, Carracedo A, Lareu MV.  Legal Med -Tokio  2013 \nJul;15(4):217 -\n21. doi: \n10.1016/j.legal\nmed.2012.12.00\n1. Epub 2013 \nFeb 4.  Original  Q3 1,080 1344 -6223  \nVariable expressivity familial \ncherubism: Woman transmitting \ncherubism without suffering the \ndisease  P\u00e9rez -Say\u00e1ns M, Barros -Angueira F, \nSu\u00e1rez -Pe\u00f1aranda JM, Garc\u00eda -Garc\u00eda A.  Head Face Med  2013 Nov \n5;9:33. doi: \n10.1186/1746 -\n160X -9-33. Origina l Q3 0,981  1746 -160X  \nAtrial fibrillation: From detection to \ntreatment. Role of the family \nphysician, cardiologist and other \nspecialists. New models of clinical \nmanagement  D\u00edaz S\u00e1nchez S, Lobos Bejarano JM, \nGonzalez -Juanatey JR.  Aten Primaria  2013 Apr;45 \nSuppl 1:18 -29. \ndoi: \n10.1016/S0212 -\n6567(13)70020 -\n9. Original  Q3 0,957  0212 -6567   \n \n119 Primary trimethylaminuria or fish \nodour syndrome: early diagnosis \nfrom primary care  Romero Garc\u00eda A, Bermejo Pastor M, \nBenito Alonso E, Barros Angueira F, \nGal\u00e1n G\u00f3mez E.  An Pedi atr (Barc)  2013 \nApr;78(4):272 -4. \ndoi: \n10.1016/j.anped\ni.2012.08.008. \nEpub 2012 Oct \n1. Letter  Q3 0,867  1695 -4033  \nThe situation and management of \nClostridium difficile infection in \nSpain: An opinion document  Bouza E, Mar\u00edn M, Pel\u00e1ez T, Alcal\u00e1 L; \nGroup for Cl ostridium difficile Infection \nof the Spanish Society for \nChemotherapy (Llovo -Taboada J, \nGarc\u00eda -Garrote F, Pita Carretero J)  Rev Esp Quim  2013 \nSep;26(3):261 -\n86. Original  Q4 0,836  0214 -3429  \nA study of in vivo degradation of \ntwo vital home bleaching gels  Alonso De La Pe\u00f1a V, Rodriguez \nCarreira A, Corral Aneiros R, L\u00f3pez \nRat\u00f3n M, Guiti\u00e1n Rivera F.  Dent Mater J  2013;32(4):654 -\n8. Original  Q4 0,809  0287 -4547  \nsmoothHR: an R package for \npointwise nonparametric \nestimation of hazard ratio curves of \ncontinuous predic tors Meira -Machado L, Cadarso -Su\u00e1rez C, \nGude F, Ara\u00fajo A.  Comput Math \nMethods Med  2013;2013:7457\n42. doi: \n10.1155/2013/7\n45742. Epub \n2013 Dec 12.  Original  Q4 0,791  1748 -670X  \nPreoperative statin therapy in \ncardiac surgery is more effective in \npatients who di splay preoperative \nactivation of the inflammatory \nsystem  Mart\u00ednez -Comendador J, Alvarez JR, \nSierra J, Teijeira E, Adrio B.  Tex Heart Inst J  2013;40(1):42 -\n9. Original  Q4 0,674  0730 -2347  \nDiscrepancy between stress \nelectrocardiographic changes and \nnuclear my ocardial perfusion \ndefects in the prognostic \nassessment of patients with chest \npain  Raposeiras -Roubin S, Garrido -Pumar \nM, Pubul -Nu\u00f1ez V, Pe\u00f1a -Gil C, Argibay -\nV\u00e1zquez S, Agra -Bermejo RM, Abu -Assi \nE, Mart\u00ednez -Monzon\u00eds A, Vega M, \nRuibal -Morell A, Gonz\u00e1lez -Juan atey JR.  Rev Port Cardiol  2013 \nOct;32(10):761 -\n8. doi: \n10.1016/j.repc.\n2012.11.014. \nEpub 2013 Oct \n25. Original  Q4 0,592  0870 -2551  \nHigh -sensitivity C -reactive protein \npredicts adverse outcomes after Raposeiras Roub\u00edn S, Barreiro Pardal C, \nRoub\u00edn -Cami\u00f1a F, Ocaranza Sanchez R, Rev Port Cardiol  2013 \nFeb;32(2):117 -Original  Q4 0,592  0870 -2551   \n \n120 non-ST-segment elevation acute \ncoronary syndrome regardless  of \nGRACE risk score, but not after ST -\nsegment elevation myocardial \ninfarction  Alvarez Castro E, Paradela Dobarro B, \nGarc\u00eda -Acu\u00f1a JM, Aguiar Souto P, \nJacquet Hervet M, Castrom\u00e1n M J, \nArufe I, Outes B, Reino -Maceiras MV, \nAbu Assi E, Gonz\u00e1lez -Juanatey JR.  22. doi: \n10.1016/j.repc.\n2012.05.026. \nEpub 2013 Jan \n20. \nTrends in clinical profile and \nmedical treatments of atrial \nfibrillation patients over the last 10 \nyears  Rodr\u00edguez -Ma\u00f1ero M, Bertomeu -\nGonz\u00e1lez V, Cordero A, Moreno -\nArribas J, Maz\u00f3n P, F\u00e1cila L, Cos\u00edn J, \nGalve E, Lekuona I, Gonz\u00e1lez -Juanatey \nJR, Bertomeu -Mart\u00ednez V.  Rev Port Cardiol  2013 \nFeb;32(2):103 -\n9. doi: \n10.1016/ j.repc.\n2012.06.011. \nEpub 2013 Jan \n20. Original  Q4 0,592  0870 -2551  \nBandwidth selection for the \nestimation of transition \nprobabilities in the location -scale \nprogressive three -state model  Meira -Machado, L; Roca -Pardinas, J; \nVan Keilegom, I; Cadarso -Suarez, C. Computation Stat  2013 Oct; 28 \n(5): 2185 -2210.  Original  Q4 0,482  0943 -4062  \nFlexible quantile regression models: \napplication to the study of the \npurple sea urchin  Isabel Mart\u00ednez -Silva, Vicente Lustres -\nP\u00e9rez, Altea Lorenzo -Arribas, Javier \nRoca -Pardi\u00f1as, Carmen Cadarso -\nSu\u00e1rez.  Sort-Stat Oper \nRes T  2013 Jun; 37(1): \n81-94. Original  Q4 0,462  1696 -2281  \nGenetic variants associated with \naddictive behavior in Colombian \naddicted and non -addicted to \nheroin or cocaine  Isaza, C.; Henao, J.; Beltran, L.; Porras, \nL. ; Gonzalez, M.; Cruz, R. y Carracedo, \nA. Colomb Medica  2013 Jan -Mar. \nVolume: 44   \nIssue: 1   Pages: \n19-25 Original  Q4 0,094  1657 -9534  \n \n   \n \n121 ANEXO V. LIBROS E CAP\u00cdTULOS DE LIBROS  \n\uf0b7 Libros 2012  \nT\u00edtulo  Editor  Editorial  Ciudad  ISBN  P\u00e1gs.  \nTherapeutic targets: modul ation, inhibition and activation  Botana LM, Loza M  John Wiley & Sons, Inc  New Jersey  978-0-470-\n58719 -5 502 \nNanostructured Biomaterials for Overcoming Biological Barriers  Alonso M.J. and Csaba N.,  RSC Drug Discovery \nSeries, RSC Publising  Cambridge, \nUK 978-1-84973 -\n363-2 622 \nT\u00e9cnicas de estimaci\u00f3n e inferencia de las curvas ROC: Revisi\u00f3n \nde las t\u00e9cnicas de estimaci\u00f3n e inferencia de las Curvas ROC. \nAplicaci\u00f3n en el \u00e1mbito de la radiolog\u00eda  M\u00f3nica L\u00f3pez Rat\u00f3n , \nCarmen Cadarso Su\u00e1rez , \nMar\u00eda Jos\u00e9 Lado Touri\u00f1o  Editorial Acad\u00e9mica \nEspa\u00f1ola   978-3-8473 -\n6042 -1 184 \nA Xen\u00f3mica: Unha revoluci\u00f3n en Medicina  Carracedo \u00c1lvarez,\u00c1ngel \nMar\u00eda  PubliCan -Editorial \nUniversidad de \nCantabria  Santander  978-84-8102 -\n651-1 21 \n \n\uf0b7 Cap\u00edtulos de libros  \nCapitulo  Libro en el que se incluye e l cap\u00edtulo  \nT\u00edtulo del Cap\u00edtulo  Autores  P\u00e1g. Inicio -\nFin Titulo Libro  Editor  Editorial  Ciudad  ISBN  P\u00e1gs.  \n2012  \nNew approaches \napplied to drug \nscreening  Brea J, Loza MI  455-476 Therapeutic targets: \nmodulation, inhibition \nand activation  Botana LM, Loza \nM John Wiley & \nSons, Inc  New Jersey  978-0-\n470-\n58719 -5 502 \nPlatelet Proteomics: Yotis A Senis, 367-399 Platelets and JM Gibbins, MP Springer New York (USA)  978-1- 409  \n \n122 State of the art and \nfuture perspective  Angel Garc\u00eda  megakaryocytes: \nVolume 3, Additional \nprotocols and \nperspectives. Methods \nin Molecular Bio logy, \nvol. 788  Mahaut -Smith  New York  61779 -\n306-6 \nFunctional Optical \nImaging -based \nBiosensors  Pablo Iglesias Jose \nA . Costoya  3-19 Biosensors and Cancer  Victor R. Preedy  CRC \nPress/Scienc\ne Publishers  Boca Ra ton, \nFlorida, EE.UU.  978-1-\n57808 -\n734-1 408 \nHistorical view of the \ndesign and \ndevelopment of \nnanocarriers for \novercoming biological \nbarriers  Alonso M.J. and \nCouvreur P  3-38 Nanostructured \nBiomaterials for \nOvercoming Biological \nBarriers  Alonso M.J. and \nCsab a N RSC Drug \nDiscovery \nSeries, RSC \nPublising  Cambridge, UK  978-1-\n84973 -\n363-2 622 \nNanostructures for \nimproved brain \ndelivery  de la Fuente M, \nLozano MV, \nUchegbu I, \nSch\u00e4tzlein A.  364-391 Nanostructured \nBiomaterials for \nOvercoming Biological \nBarriers  Alonso  M.J. and \nCsaba N  RSC Drug \nDiscovery \nSeries, RSC \nPublising  Cambridge, UK  978-1-\n84973 -\n363-2 622 \nFisiopatolog\u00eda de los \ntrastornos de la \nnutrici\u00f3n  Jos\u00e9 Cabezas -\nCerrato, David \nAra\u00fajo -Vilar  722-737 Patologia general  Francisco Javier \nGarc\u00eda -Conde \nBru, Jaime \nMer ino-S\u00e1nchez, \nJesus Gonz\u00e1lez \nMac\u00edas  Marban  MADRID  978-84-\n7101 -\n894-6 955 \nReducing False \nPositives in a CAD \nScheme for Detecting \nBreast \nMicrocalcifications: A \nquantitative study \nwith GAMs.  Roca -Pardi\u00f1as, J, \nCadarso -Su\u00e1rez, \nC, Gonz\u00e1lez \nManteiga, W  459-476 Cancer Prevention - \nFrom Mechanisms to \nTranslational Benefits  Dr. Alexandros \nGeorgakilas  InTech   978-953-\n51-0547 -\n3 \n476 \nHigh -Throughput \nGenotyping Beatriz Sobrino \nand Angel 403-414 Pharmacogenetics and \nIndividua lized Therapy  Anke -Hilse \nMaitland -van der John Wiley & \nSons, Inc  New Jersey  978-0-\n470-510  \n \n123 Technologies for \nPharmacogenetics 403  Carracedo  Zee,  Ann K. Daly  43354 -6 \n2013  \nGhrelin, lipid metabolism and \nmetabolic syndrome  Mart\u00ednez de \nMorentin PB, \nTovar S, \nNogueiras R, \nL\u00f3pez M & \nDi\u00e9guez  475-484 Metabolic Sy ndrome and \nNeurological Disorders  Farooqui T, \nFarooqui AA  Wiley -\nBlackwell \nPublishers   978-1-\n118-\n39527 -1. 576 \n \n   \n \n124 ANEXO VI. TESIS  \nNombre  Apellidos  T\u00edtulo  Fecha  Directores  \n2012   \nAna Mar\u00eda  Fern\u00e1ndez \nVicente  Estudo da actividade neuronal do putamen durante a execuci\u00f3n dunha tarea \nmultisensorial  01/06/2012  Maria Jose Alvarez Bermudez, \nFrancisco Gonzalez Garcia  \nBeatriz  Sobrino Rey  Nuevas tecnolog\u00edas en el an\u00e1lisis del ADN: aplicaciones en gen\u00e9tica forense  14/06/2012  Mar\u00eda Jos\u00e9 Bri\u00f3n Mart\u00ednez, Angel \nMaria Carr acedo Alvarez  \nBego\u00f1a  Gra\u00f1a Su\u00e1rez  S\u00edndrome de cancro de mama/ovario hereditario: desenvolvemento dunha \ngu\u00eda cl\u00ednica  e  an\u00e1lise dos xenes  ATM, TP53 y PTEN en familias de alto risco \npara cancro de mama non asociado a BRCA1 e/ou BRCA2  21/12/2012  Joan Brune t i Vidal, Angel Maria \nCarracedo Alvarez, Ana Paula Vega \nGliemmo  \nBel\u00e9n  Joglar Santos  Sistema Renina -Angiotensina e dexeneraci\u00f3n dopamin\u00e9rgica: Papel da \nactivaci\u00f3n microglial, o complexo NADPH -oxidasa e canais de potasio \nmitocondriais dependientes de ATP. Implicacions na neuroprotecci\u00f3n.  25/09/2012  Jose Luis Labandeira Garcia, Jannette \nRodriguez Pallares  \nBerta  Victoria \nMart\u00ednez  Bases moleculares das lipodistrofias familiares  04/12/2012  David Araujo Vilar  \nDavid  Rodr\u00edguez D\u00edaz  M\u00e9todos Computacionais para a Caracterizaci\u00f3n Estrutural e Din\u00e1mica de \nReceptores Acoplados a Prote\u00edna -G: Aplicaci\u00f3ns no Dese\u00f1o de F\u00e1rmacos  09/11/2012  Hugo Guti\u00e9rrez De Ter\u00e1n Casta\u00f1\u00f3n  \nDouglas  Vel\u00e1squez \nRaimundo  Novas acci\u00f3ns de p53: homeostase metab\u00f3lica e efecto orecix\u00e9nico de ghreli n 26/07/2012  Carlos Dieguez Gonzalez, Rub\u00e9n \nNogueiras Pozo  \nEster  Vazquez \nFernandez  Estudos estructurais da PrPSc  13/11/2012  Jesus Rodriguez Requena  \nEva Amanda  Gallego Su\u00e1rez  Regulaci\u00f3n e expresi\u00f3n de TMEFF2 por TGF -B 09/01/2012  Fernando Ignacio Dom\u00ednguez  Puente, \nAnxo Vidal Figueroa  \nFrancesca  Brisighelli  An\u00e1lise xen\u00e9tico de marcadores uniparentales e autos\u00f3micos en poblalci\u00f3ns \nhumanas  25/10/2012  Angel Maria Carracedo Alvarez, \nAntonio Salas Ellacuriaga  \nGiovanna  Lollo  Nanocapsulas de poliamino\u00e1cidos para l a liberaci\u00f3n selectiva de f\u00e1rmacos \nantitumorales  09/07/2012  Maria Josefa Alonso Fernandez, \nMarcos Garcia Fuentes, Maria \nDolores Ramona Torres Lopez  \nGustavo \nRodolfo  Rivera \nRodriguez  Nuevos transportadores de f\u00e1rmacos: nanoc\u00e1psulas de poliasparagina y \ncase\u00ed na 25/05/2012  Maria Josefa Alonso Fernandez, \nMaria Dolores Ramona Torres Lopez  \nKatia Da  Boit Martinello  Influencia do exercicio f\u00edsico sobre a homeostase enerx\u00e9tica e o metabolismo \nlip\u00eddico nos animais expostos a dietas obesox\u00e9nicas  10/04/2012  Carlos Dieg uez Gonzalez, Miguel \nAntonio Lopez Perez   \n \n125 Marcos  Rios Garcia  Papel de AMPK na regulaci\u00f3n do metabolismo e proliferac\u00ed\u00f3n celular durante \no proceso de tumorog\u00e9nesis.  12/01/2012  Jose Antonio Costoya Puente, Rosa \nMaria Se\u00f1aris Rodriguez  \nMaria  Fraile Pi\u00f1eiro  GCK-III: Estr\u00e9s oxidativo e polaridade celular  29/05/2012  Celia Maria Pombo Ramos, Juan \nBautista Zalvide Torrente  \nMaria  Torres Espa\u00f1ol  Desenvolvemento e aplicaci\u00f3ns m\u00e9dicas da an\u00e1lise da variaci\u00f3n xen\u00e9tica \nmediante espectrometr\u00eda de masas MALDI -TOF 13/07/2 012 Francisco Barros Angueira, Angel \nMaria Carracedo Alvarez  \nMontserrat  Garc\u00eda \nLavandeira  Identificaci\u00f3n y caracterizaci\u00f3n das c\u00e9lulas nai da hip\u00f3fise  08/06/2012  Maria Clara Alvarez Villamarin, Carlos \nDieguez Gonzalez  \nNoa Carrera \nCachaza  Estudo xen\u00e9tico en esquizofrenia: an\u00e1lise de variantes funcionais para a \nidentificaci\u00f3n de factores de predisposici\u00f3n  30/04/2012  Angel Maria Carracedo Alvarez, \nJavier Costas Costas  \nPatricia  Pazos Mendoza  Papel de interleuquina -6 na regulaci\u00f3n da homeostasis enerx\u00e9tica du rante a \nxestaci\u00f3n e a lactancia.  11/07/2012  Carlos Dieguez Gonzalez, Maria Del \nCarmen Garcia Garcia, Luis Jesus \nLima Rodriguez  \nRoberto  Leiras Gonzalez  Procesamento da informaci\u00f3n propioceptiva no n\u00facleo cuneatus.  30/10/2012  Antonio Canedo Lamas, Francisco  \nJavier Martin Cora  \nSergio  Cinza Sanjurjo  Hipertrofia ventricular esqueda e variabildad circadiana na presi\u00f3n arterial \nnunha cohorte de doentes diagnosticados de hipertensi\u00f3n arterial.  26/06/2012  Carlos Jose Ramon Calvo Gomez, \nJose Ramon Gonzalez Juanatey  \nSergio  Raposeiras \nRoub\u00edn  Fisiopatolox\u00eda e valor pron\u00f3stico dos productos de glicaci\u00f3n avanzada e o seu \nreceptor soluble na insuficiencia cardiaca  29/06/2012  Ezequiel \u00c1lvarez Castro, Jose Ramon \nGonzalez Juanatey, Lilian Grigorian \nShamagian  \n2013  \nAmigo Le chuga  Jorge  A bioinform\u00e1tica \u00f3 servizo da xen\u00f3mica  09/04/2013  Angel Maria Carracedo Alvarez, \nAntonio Salas Ellacuriaga  \nFern\u00e1ndez \nFormoso  Luis Mar\u00eda  Desenrolo e caracterizaci\u00f3n de novos multiplexes de STRs e evaliaci\u00f3n da sua \naplicaci\u00f3n na predicci\u00f3n de or ixen bioxeogr\u00e1fico e identificaci\u00f3n humana.  17/04/2013  Maria Victoria Lareu Huidobro, Angel \nMaria Carracedo Alvarez  \nBarbaro  Annamaria  Avances en Xen\u00e9tica Forense: Novos Estudios de Validaci\u00f3n de Marcadores e \nDatos Poblacionais  08/05/2013  Maria Victoria La reu Huidobro, Angel \nMaria Carracedo Alvarez  \nFreire Aradas  Ana Mar\u00eda  An\u00e1lise de ADN altamente degradado e inferencia de ancestralidade \nbioxeogr\u00e1fica: novos avances en Xen\u00e9tica Forense.  08/05/2013  Maria Victoria Lareu Huidobro, Angel \nMaria Carracedo Alvarez   \n \n126 Fachal Vilar  Laura  Cancro de pr\u00f3stata: b\u00fasqueda de variantes xen\u00e9ticas causais e de \nsusceptibilidade \u00f3 desenrolo de toxicidade radioinducida  16/07/2013  Angel Maria Carracedo Alvarez, Ana \nPaula Vega Gliemmo  \nVicente Ozores  Sara  Nanoc\u00e1psulas polisacar\u00eddica s como veh\u00edculos adxuvantes de vacinas  22/03/2013  Alejandro Sanchez Barreiro, Maria \nJosefa Alonso Fernandez  \nFern\u00e1ndez \nPargui\u00f1a  Andr\u00e9s  Estudo prote\u00f3mico das plaquetas sangu\u00edneas en pacientes con s\u00edndrome \ncoronaria aguda: an\u00e1lise de v\u00edas de sinalizaci\u00f3n int racelular.  01/02/2013  Angel Garcia Alonso  \nNieto Gutierrez  Ainhoa  Estudo farmacol\u00f3xico da modulaci\u00f3n do receptor 5 -HT2B de serotonina por \ninhibidores selectivos da COX -2 (celecoxib e valdecoxib) e fluoxetina.  10/07/2013  Maria Isabel Loza Garcia, Ines \nSanch ez Sellero, Jose Manuel Brea \nFloriani  \nAtanes Juiz  Patricio  Estudo da funcionalidade de GPCRs mediante o uso de ferramentas biol\u00f3xicas \ne qu\u00edmicas: aplicaci\u00f3n aos receptores 5 -HT2A e 5 -HT7 de serotonina  30/07/2013  Mar\u00eda de los \u00c1ngeles Castro P\u00e9rez, \nMaria Is abel Loza Garcia  \nD\u00edaz Arteaga  Adenis Ibett  Regulaci\u00f3n da expresi\u00f3n e funci\u00f3n do receptor GPR55 na homeostase \nenerx\u00e9tica e metab\u00f3lica  18/01/2013  Carlos Dieguez Gonzalez, Rub\u00e9n \nNogueiras Pozo  \nGarrido Novelle  Marta  Mecanismos involucrados na regulaci\u00f3n da h omeostase enerx\u00e9tica por \ndirerentes factores obesox\u00e9nicos  09/04/2013  Carlos Dieguez Gonzalez  \nBlanco Martinez \nDe Morentin  Pablo  Modulaci\u00f3n  central da homeostasis enerx\u00e9tica por nicotina e estr\u00f3xenos.  06/06/2013  Carlos Dieguez Gonzalez, Miguel \nAntonio Lope z Perez  \nGuerrero L\u00f3pez  Ana CCM3 e senescencia  17/12/2013  Celia Maria Pombo Ramos, Juan \nBautista Zalvide Torrente  \nBorrajo Alonso  Erea  Avaliaci\u00f3n Biol\u00f3xica De Nanomedicamentos En Oncolox\u00eda E Medici\u00f1a \nRexenerativa  19/12/2013  Anxo Vidal Figueroa, Marcos Garc ia \nFuentes  \nA Abuassi  Emad Hussein  Utilidade e fiabilidade das escalas contempor\u00e1neas de estimaci\u00f3n de risco en \nenfermedades cardiovaculares  08/02/2013  Jose Ramon Gonzalez Juanatey   \n \n127 Cabanas \nGrand\u00edo  Mar\u00eda del Pilar  Estudo a longo prazo da calidade de vida e  remodelado estructural  en \ndoentes nos que se realiza ablaci\u00f3n mediante radiofrecuencia do flutter \nauricular t\u00edpico  16/04/2013  Javier Garc\u00eda Seara, Jose Luis \nMartinez Sande, Jose Ramon \nGonzalez Juanatey  \nRamos Amigo  Adriana  Estudo dos mecanismos de acci\u00f3n  da prote\u00edna DISC1.  14/06/2013  Jesus Rodriguez Requena  \nL\u00f3pez Otero  Diego  Tratamento Percutaneo Da Estenose A\u00f3rtica: Resulatdos Iniciais En Situacions \nOff-Label E Determinantes Pron\u00f3sticos  15/07/2013  Jose Ramon Gonzalez Juanatey  \nVidal Perez  Carlos  O valor  dos estudos epidemiol\u00f3xicos promovidos dende Atenci\u00f3n Primaria \ncomo un instrumento para a investigaci\u00f3n en patolox\u00eda cardiovascular. \nAchados do Grupo Barbanza.  12/09/2013  Jose Ramon Gonzalez Juanatey, \nFernando Otero Ravi\u00f1a  \nAgra Bermejo  Rosa Mar\u00eda  Novos m arcadores de grasa epicardica nas enfermedades cardiovasculares  20/12/2013  Jose Ramon Gonzalez Juanatey, \nSonia Eiras Penas  \nCu\u00ed\u00f1as \nLavandeira  Andrea  Efectos de f\u00e1rmacos que modifican os niveis intracelulares de AMP c\u00edclico en \naneis de aorta de rata e en mi ocitos vasculares  12/07/2013  Manuel Campos Toimil, Francisco \nOrallo Cambeiro  \n \nANEXO VII. PATENTES  \n\uf0b7 2012  \nNUEVAS Solicitudes de patentes          \nN\u00ba Solicitud  Fecha de Solicitud  T\u00edtulo  GI Estado  En explotaci\u00f3n  \nP201231956  17/12/2012  Nanocapsulas de protamina  1643  En tramitaci\u00f3n en la OEPM  NO \nPCT/ES2012/070276  24/04/2012  Terapia combinada para el tratamiento de enfermedades 1233  En tramitaci\u00f3n en la OEPM  NO  \n \n128 metab\u00f3licas  \nP201231413   Quinazolinas S - sustituidas y sus aplicaciones terap\u00e9uticas para el \ntratamient o de enfermedades mediadas por PDE7  1685  En tramitaci\u00f3n v\u00eda PCT  SI \nConcesiones de solicitudes anteriores        \nN\u00ba Solicitud \nprioritaria  N\u00famero de \nconcesi\u00f3n  Fecha de \nconcesi\u00f3n  T\u00edtulo  GI En explotaci\u00f3n  \nP201030624  ES2368307 B1  04/10/2012  Hidrogeles elaborados a base de pol\u00edmeros ani\u00f3nicos de origen natural  1643  NO \nP201131074  ES2366255 B2  27/07/2012  Nanocomposiciones sacar\u00eddicas para la liberaci\u00f3n de vacunas  1643  NO \n\uf0b7 2013  \nNUEVAS solicitudes de patente en 2013 (OEPM)  \nn\u00ba solicitud  Fecha solic itud T\u00edtulo  GI Estado  En explotaci\u00f3n    \nP201330557  18/04/2013  USO DE PART\u00cdCULAS \nPROTEICAS \nPOLIMERIZADAS DE \nORIGEN  \nRECOMBINANTE PARA EL \nTRATAMIENTO DE \nPRIONOPAT\u00cdAS  1698  En tramitaci\u00f3n en la OEPM  NO  EXTENSIONES internacionales de solicitudes anteriores (Prioridad 2011) por la v\u00eda PCT        \nN\u00ba Solicitud  Fecha de \nsolicitud a PCT  T\u00edtulo  GI Estado  En explotaci\u00f3n  \nPCT/ES2012/000008  9/1/2 012 Nanoc\u00e1psulas con cubierta polim\u00e9rica  1643  En tramitaci\u00f3n v\u00eda PCT  NO \nPCT/ES2012/070111  23/2/2012  Uso de inhibidores de p53 para reducir la ingesta y para reducir el \npeso corporal  1233  En tramitaci\u00f3n v\u00eda PCT  NO \nPCT/ES2012/070293  27/04/2012  Derivados he teroc\u00edclicos inhibidores de fosfodiestersasa 7  1685  En tramitaci\u00f3n v\u00eda PCT  SI Licenciada  \nPCT/ES2012/070470  26/6/2012  Nanocomposiciones sacar\u00eddicas para la liberaci\u00f3n de vacunas  1643  En tramitaci\u00f3n v\u00eda PCT  NO \nPCT/ES2012/070774  8/11/2012  Sistemas nanopar ticulares elaborados a base de \u00e9steres de sorbit\u00e1n  1643  En tramitaci\u00f3n v\u00eda PCT  NO  \n \n129 P201331689  20/11/2013  An\u00e1logos de la vitamina \nD con inter \u00e9s \nfarmac\u00e9utico  2105  En tramitaci\u00f3n en la OEPM  NO  \nEntradas en fases nacionales reivindicando prioridad de solicitudes anteriores  \nn\u00ba solicitud  Fecha entrada en \noficina nacional  T\u00edtulo  GI Estado  En explotaci\u00f3n  N\u00ba solicitud \nprioritaria  \nEP12734760.7  09/08/ 2013  Nanocapsules with a \npolymer shell  1643  En tramitaci\u00f3n en EPO  NO P201130015  \nUS13/979,092  30/09/2013  Nanocapsules with a \npolymer shell  1643  En tramitaci\u00f3n en USPTO (USA)  NO P201130015  \nBR112013017750.0  10/07/2013  Nanocapsules with a \npolymer shell  1643  En tramitaci\u00f3n en INPI (Brasil)  NO P201130015  \nCN201280012254.4  09/09/2013  Polymer coated \nnanocapsules  1643  En tramitaci\u00f3n en CIPO (China)  NO P201130015  \nConcesiones de solicitudes anteriores  \nOficina  N\u00famero de \nconcesi\u00f3n  Fecha de concesi\u00f3n  T\u00edtulo  GI En e xplotaci\u00f3n  N\u00ba solicitud \nprioritaria  \nOEPM  ES2385995 B2  08/05/2013  Nanoc\u00e1psulas con cubierta \npolim\u00e9rica  1643  NO P201130015  \nOEPM  ES2387294 B1  01/07/2013  M\u00c9TODO DE \nMONITORIZACI\u00d3N DE \nCLOPIDOGREL Y \u00c1CIDO \nACETILSALIC\u00cdLICO  1736  NO P201130204  \nOEPM  ES2387431 B2  15/02/2013  Uso de inhibidores de p53 \npara reducir la ingesta y para \nreducir el peso corporal  1233  NO P201130250  \nOEPM  ES2391732 B1  30/09/2013  DERIVADOS HETEROC\u00cdCLICOS \nINHIBIDORES DE \nFOSFODIESTERASA 7  1685  VER APTDO \nLICENCIAS  P201130712  \nJPO JP5191884 B2  08/02/2013  Nanoparticles comprising \nchitosan and cyclodextrins  1643  NO P200501331   \n \n130 OEPM  ES2397874 B2  27/09/2013  L\u00cdNEAS CELULARES Y SU USO \nPARA LA IDENTIFICACI\u00d3N DE \nF\u00c1RMACOS PARA EL \nCARCINOMA TIROIDEO  1233  NO P201031322  \n \nANEXO VIII. SPI N-OFF \n \nANEXO IX. CONFERENCIAS  \nConferenciante  Filiaci\u00f3n  Pais T\u00edtulo  Fecha  \n   Apoio a creaci\u00f3n e consolidaci\u00f3n de spin \noff  universitarios no \u00e1mbito da saude  26/01/2012  \nDr. Javier Fern\u00e1ndez  Director Internacional de Janssen Research & \nDevelopment  Espa\u00f1a  OPEN INNOVATION: beyond the hype: how to find true \ninnovation and incorporate it successfully into a pharma \ncompany  03/02/2012  \nProfessor \nDavid  Brayden  School of Agriculture, Food Science and Veterinary \nMedicine; UCD Conway Institute, University College \nDublin Irlanda  Oral peptide delivery / Careers / Permeation enhancers / In \nvivo models  22-\n24/02/2012  \nFr\u00e9deric Lallemand  Novagali Pharma  Francia   28/02/2012  \nMichel Herranz  Director Programa Imagen en Servicio Galego de Espa\u00f1a  Molecular imaging  23/03/2 012 Nom e comercial  Denominaci\u00f3n social  Fecha constituci\u00f3n  GI Actividade  \nBiostatech  \n Biostatech Advice, Training & \nInnovation in Biotatistics S.L.  16/03/2012  2127  Servicios de asesoramiento en bioestad\u00edstica e produ tos \nformativos en ferramenta s, t\u00e9cnicas e m\u00e9todos esta t\u00edsticos.  \n \n \n131 Saude  \nDra. Cristina P\u00e9rez  Universidad de Navarra  Espa\u00f1a  An\u00e1lisis del Metiloma en el desarrollo de Neoplasias \nHematol\u00f3gicas. Implicaci\u00f3n de los genes JAK2 y TET2  13/04/2012  \nAntonio Almeida   Espa\u00f1a  Vacunas  2-9-\n11/05/2012  \nDra. Mar\u00eda Luz L\u00f3pez \nRodr\u00edguez  Cate dr\u00e1tica de Qu\u00edmica Org\u00e1nica, Universidad \nComplutense de Madrid  Espa\u00f1a  Donde la Qu\u00edmica M\u00e9dica encuentra a la Qu\u00edmica Biol\u00f3gica  25/05/2012  \nPhilippe Roby  Senior Scientist en I+D en Perkin -Elmer   Aproximaci\u00f3n a t\u00e9cnicas de epigen\u00e9tica por ALpha -Screen y \nLANCE (TR -FRET)\".  19/06/2012  \nJoseline Ratman  BioFarma group, CIMUS  Espa\u00f1a  Public -Private Partnerships for Drug Discovery  16/11/2012  \nDra. Guadalupe Sabio  Department Vascular Biology and Inflammation, \nCentro Nacional de Investigaciones \nCardiovasculares Carlos  III(CNIC)  Espa\u00f1a  Role of SAPK in obesity related diseases  \n29/11/2012  \nSara Vicente  Nanobiopharmaceuticals group , CIMUS  Espa\u00f1a  Chitosan -based nanovaccines  30/11/2012  \nProf. Francesc \nVillarroya  Departamento de Bioqu\u00edmica de la Universidad de \nBarcelona  Espa\u00f1a FGF21, causa y efecto en el s\u00edndrome metab\u00f3lico  05/12/2012  \nAna Guerrero  Vascular Biology group, CIMUS  Espa\u00f1a  CCM3, ENDOTHELIUM AND SENESCENCE  14/12/2012  \nProf. Brigitte Holst  \n Department of Neuroscience and Pharmac ology, \nUniversity of Copenhagen  Dinam arca  The Ghrelin Receptor: Actions on Energy Balance  \n 08/02/2013  \nDr. Eduardo \nDominguez   Biofarma Research Group  Espa\u00f1a  Targeting Fat to Treat Diabetes  08/02/2013  \nDr. Giles Yeo  \n Senior Research Associate  \nDirector of Genomics/Transcriptomics  \nInstitute of M etabolic Science  \nUniversity of C ambridge  Reino \nUnido  Investigating the molecular function of FTO (fat mass and \nobesity related)  \n 22/02/2013  \nIsabel Martinez  Biostatistics group  Espa\u00f1a  Testing quantile regression curves: applications in Pediatrics  22/02/201 3 \nDr. Xos\u00e9 R. Bustelo  \n Full Professor, CSIC  \nCancer Research Center CSIC University of  \nSalamanca  Espa\u00f1a  Modeling the therapeutic value of Vav oncoproteins using \ngenetic approaches  \n 25/02/2013  \nDra. Nuria Casals  \n \u00c1rea  \nde Farmacolog\u00eda de la Facultad de Medi cina y \nCiencias de la Salud  Espa\u00f1a  CPT1C y las ceramidas hipotal\u00e1micas en el control de la \ningesta alimentaria  \n 08/03/2013   \n \n132 Alberto Coelho Cot\u00f3n  CIQUS  Espa\u00f1a  Multidisciplinary approach to the development of \nantimitotic drugs  08/03/2013  \nProf. Cl\u00e0udia Cavad as  \n Assistant Professor  \nFaculty of Pharmacy  \nUniversity of Coimbra  Portugal  Neuropeptide Y(NPY) regulates autophagy in \nhypothalamus: Is NPY a caloric restriction mimetic?  \n 13/03/2013  \nProf. Andries \nKalsbeek  Netherlands Institute for Neuroscience  \n Holanda  Hypothalamic control of hepatic glucose and lipid \nproduction  \n 15/03/2013  \nDr. David B. Savage  Department of Clinical Biochemistry, University of \nCambridge, UK  Reino \nUnido  Lipodystrophy: the perils of life without fat   02/04/2013  \nF\u00e1tima Martins  Funtional O besomic  Espa\u00f1a  Role of Nitric Oxide in the regulation of Insulinemia  05/04/2013  \nFernando Meizoso \nLoza  Group of Cell cycle and oncology  Espa\u00f1a  Conspiring to control chondrocyte differentiation: when \nSnail met p107  19/04/2013  \nDra. Lora Heisler  \n Lecturer  \nDepartment of Pharmacology University of \nCambridge  Reino \nUnido  New treatment for obesity - 5-HT2C receptor agonists  \n 06/05/2013  \n \nDeborah Clegg, Ph.D.  \n Professor of  Internal Medicine, Clinical Nutrition  \nUniversity of Texas Southwestern, Touchstone \nDiabetes  Center, Dallas, Texas  USA Estrogens, Critical Regulators of Metabolism  \n24/05/2013  \nBiff F. Palmer, M.D..  \n Professor of Internal Medicine  \nUniversity of Texas Southwestern Medical Center, \nDallas, Texas  USA Altitude and Weight Loss: It Is All About HIF  \n 24/0 5/2013  \nManuel Tena -\nSempere MD, PhD . \n  Full Professor of Physiology at the Department of \nCell Biology, Physiology and  \nImmunology  \nUniversity of C\u00f3rdoba  Espa\u00f1a  Novel mechanisms for the metabolic control of puberty and  \nfertility: Kisspeptins and Beyond  24/05 /2013  \nDr Justin Rochford  \n Senior Research Associate  \nMetabolic Research Laboratories and NIHR \nCambridge Biomedical Research  \nUniversity of Cambridge  Reino \nUnido  Defining the molecular functions of seipin , an essential \nregulator of human adipose tissue deve lopment  \n 30/05/2013  \nProf. Juan Jes\u00fas \nG\u00f3mez -Reino  \n Catedr\u00e1tico de Medicina de la USC y jefe del servicio \nde Reumatolog\u00eda del Hospital Cl\u00ednico de Santiago de \nCompostela  Espa\u00f1a  Safety of protein kinase inhibitors in the treatment of \nrheumatoid arthritis: A clinician\u00b4s view  \n 03/06/2013   \n \n133 Atsushi Kamiya MD, \nPhD Department of Psychiatry and Behavioral Sciences  \nJohns Hopkins University  USA Genetic risk factors for major mental disorders in prefrontal \ncortex development and function  \n(Programa Frontiers in Science ) 14/06/2013  \nCarlos de la Cruz \nHerrera  Virus and Cancer group  Espa\u00f1a  Activation of PKR by SUMO proteins down -regulates protein \ntranslation and virus infection  14/06/2013  \nDr. Valent\u00edn Ce\u00f1a  \n Unidad Asociada Neurodeath  \nFacultad de Medicina  \nUniversidad de Ca stilla -La Mancha  \n Espa\u00f1a  Dendr\u00edmeros y sus acciones en la osteoporosis diab\u00e9tica  \n 20/06/2013  \nArturo Roca  Obesidomic group (IDIS)  Espa\u00f1a  IRISIN: A new communication signal between adipose tissue \nand muscle tissue  28/06/2013  \nProf. Inder Verma  \n Irwin and Jo an Jacobs Chair in Exemplary Life \nScience  \nAmerican Cancer Society Professor of Molecular \nBiology  \nEditor in Chief of PNAS  \nhe Salk Institute, Laboratory of Genetics  \nLa Jolla, CA, USA  USA Glioblastoma: Reprograming, Dedifferentiation & \nTransdifferentiation  \n(Programa Frontiers in Science)  \n 13/09/2013  \nDra. Yeesim Khew -\nGoodall  \n Centre for Cancer Biology, SA Pathology, Adelaide, \nSouth Australia, Australia ; School of Molecular and \nBiomedical Science, the University of Adelaide  Australia  Regulation of protein tra fficking to suppress metastasis  \n 5/11/2013  \nProf. Gregory J. \nGoodall  \n Centre for Cancer Biology, SA Pathology, Adelaide, \nSouth Australia, Australia ; School of Molecular and \nBiomedical Science, the University of Adelaide  Australia  Roles of miR -200 in EMT a nd metastasis - molecular switch \nor network controller?  \n 5/11/2013  \nGustavo Duarte \nPimentel  Departamento de Cl\u00ednica M\u00e9dica, Laborat\u00f3rio de \nInvestiga\u00e7\u00e3o Cl\u00ednica em Resist\u00eancia \u00e0 Insulina \n(LICRI)/Laborat\u00f3rio de Oncologia Molecular \nUniversidade Estadual de Ca mpinas (UNICAMP) and \nNeurObesity Research Group  Brasil  Hypothalamic mTOR signaling is crucial for induction of \ninflammation in cancer -induced anorexia  08/11/2013  \nDr. Ra\u00fal Luque  Departamento de Biolog\u00eda Celular, Fisiolog\u00eda e \nInmunolog\u00eda de la Universidad de C\u00f3rdoba e \nInvestigador Co -responsable del grupo \u201cHormonas y \nC\u00e1ncer\u201d  Espa\u00f1a  M\u00e1s all\u00e1 del crecimiento: importancia del eje GH/IGF -I en el \nmetabolismo y la obesidad  22/11/2013   \n \n134 Prof. Jos\u00e9 Luis \nMascare\u00f1as  Catedr\u00e1tico de Qu\u00edmica Org\u00e1nica e investigador del \nCIQUS  Espa\u00f1a  Herramientas sint\u00e9ticas en qu\u00edmica biol\u00f3gica  29/11/2013  \nAdam McGlone. PhD  Nanobiopharmaceuticals research lab  Espa\u00f1a  Nanocarriers and oral peptide delivery  29/11/2013  \nDr. Arkaitz Carracedo  CIC bioGUNE, IKERBASQUE del Pais Vasco  Espa\u00f1a  Chasin g metabolic alterations in cancer  05/12/2013  \nDr. Iv\u00e1n Quesada  Universidad Miguel Hern\u00e1ndez (Elche)  Espa\u00f1a  Functional and anatomical adaptation of pancreatic alpha - \nand beta -cells to obesity  13/12/2013  \nJorge Barbazan, phD   Medical and Translational Onco logy, Health \nResearch Institute of Santiago de Compostela (IDIS)  Espa\u00f1a  Cancer cells on the move! Circulating Tumor Cells in \nmetastatic dissemination  13/12/2013  \nDra. Sonia Villapol  Centro de Neurociencias y Medicina Regenerativa \nen Washington  EUA  Neuropr otective effects of sartans: a novel therapeutic \navenue for traumatic brain injury  19/12/2013  \n  \n \n135 ANEXO X ESTADIAS DE INVESTIGACI\u00d3N  \n\uf0b7 Estad\u00edas no CIMUS  \nNombre  Instituci\u00f3n de \nprocedencia  Ciudad, Pais  Fechs  Proyectos  Grupo del CIMUS (destino)  \n2012   \nInmaculada  Serramito \nG\u00f3mez  Universidad de \nSalamanca  Salamanca, Espa\u00f1a  18/06 -18/09/2012  Lab training program \n(AECC)  Molecular Oncology Lab  \nLara Enr\u00edquez Bouza  USC Santiago de Compostela, \nEspa\u00f1a  02/07 -28/09/2012  Lab training program \n(AECC)  Molecular Oncology Lab  \nAlexandre  \nDe la Fuente Gonz\u00e1lez  CHUS  Santiago  01/09/2012 -31/12/2013  Fundaci\u00f3n Barri\u00e9  Nanobiopharmaceuticals \nresearch lab  \nClaudia  \nConte  Universidad de N\u00e1poles  N\u00e1poles, Italia  01/09 -31/12/2012   Nanobiopharmaceuticals \nresearch lab  \nEduardo  \nCaminos  Universidad N acional  Bogot\u00e1, Colombia  01/09 -10/09/2012  ERC Funtional Obesomics and \nMolecular Metabolism group  \nMar\u00eda Fernanda  \nGarc\u00e9s  Universidad Nacional  Bogot\u00e1, Colombia  01/09 -10/09/2012  ERC Funtional Obesomics and \nMolecular Metabolism group  \nPilar  \nAlvari\u00f1o  IDIS Santi ago de Compostela, \nEspa\u00f1a    Cell Cycle and Oncology \ngroup  \nJessica  \nVilas  IDIS Santiago de Compostela, \nEspa\u00f1a     \nRuth Tunn  Universidad de Oxford  Oxford, Inglaterra  17-30/06/2012   Funtional Obesomics and \nMolecular Metabolism group  \nJuan Suarez  Fundaci\u00f3n IM ABIS  Malaga, Espa\u00f1a  mayo -junio 2012  \n1-12 septiembre 2012   Funtional Obesomics and \nMolecular Metabolism group  \n2013       \nAna L\u00facia  \nBatista Oliveira  University of Beira \nInterior  Covilh\u00e3, Portugal  05/08/2013 -04/11/2013  Participation of NADPH \noxidase in endot helial \ncell signalling  Cardiovascular area group  \nHaidara  \nAlmansour   Damasco, Siria  01/10/20 13-30/06/20 14 Search and \ndevelopment of new Cardiovascular area group   \n \n136 therapeutic strategies \nagainst coronary artery \ndisease based on the \nAGE -RAGE axis.  \nSamah  Ahma d  Damasco, Siria  01/10/2013 -30/06/2014  Adipose tissue \u2013vessels \ncross -talk in coronary \nartery disease. New \nbiomarkers and \ntherapeutic targets  Cardiovascular area group  \nJosep  Garc\u00eda  Peptides and Proteins  \nIRB Barcelona, Espa\u00f1a  03/06/ 2013-24/06/2013   Nanobio pharmaceuticals \nresearch lab  \nPatricia  Horcajada  Institut Lavoisier CNRS  \nUniv. Versaiiles  Paris  01/11/2012 -30/12/2013   Nanobiopharmaceuticals \nresearch lab  \nVasiliki  Karageorgou   Grecia  01/09/2013 -30/09/2013  Epicardial Adipose \nTissue  Cardiovascular area gro up \nM\u00f3nica  L\u00f3pez Bartolom\u00e9  MIDATECH, LTD  Bilbao, Espa\u00f1a  20/05/2013 -24/05/2013  CDTI  Molecular Oncology Lab  \nM\u00f3nica L\u00f3pez Bartolom\u00e9  MIDATECH, LTD  Bilbao, Espa\u00f1a  10/06/2013 -14/06/2013  CDTI  Molecular Oncology Lab  \nM\u00f3nica L\u00f3pez Bartolom\u00e9  MIDATECH, LTD  Bilbao, E spa\u00f1a  24/06/2013 -28/06/2013  CDTI  Molecular Oncology Lab  \nM\u00f3nica L\u00f3pez Bartolom\u00e9  MIDATECH, LTD  Bilbao, Espa\u00f1a  29/07/2013 -02/08/2013  CDTI  Molecular Oncology Lab  \nM\u00f3nica L\u00f3pez Bartolom\u00e9  MIDATECH, LTD  Bilbao, Espa\u00f1a  14/10/2013 -17/10/2013  CDTI  Molecular Oncolog y Lab  \nBasanta  Lamichhane  Kathmandu University  Kathmandu, Nepal  03/09/2012 -01/03/2013   Molecular Oncology Lab  \nGustavo  Duarte Pimentel  Universidade Estadual \nde Campinas  Campinas -Sao Paulo, Brasil  01/09/2013 -01/05/2014   NerObesity group  \nDilek  Dabanli  Erciy es University  Kayseri, Turqu\u00eda  12/10/2012 -01/08/2014   Neoplasia and Endocrine \nDifferentiation  \nKatrina Jukevika  University of Latvia  Riga, Letonia  19/02 -13/05/2013   BioFarma group  \nLiva Rozkalne  University of Latvia  Riga, Letonia  19/02 -13/05/2013   BioFarm a group  \nLowri Ann Jones  Cardiff University  Cardiff,  Inglaterra  25/06 -05/09/2013   BioFarma group  \nKelleigh Callaghan  Cardiff University  Cardiff,  Inglaterra  25/06 -05/09/2013   BioFarma group  \nF\u00e1tima Martins  Universidad Nova de Lisboa, Portugal  12/9/2012 a 30/9/ 2013   Funtional Obesomics and  \n \n137 \uf0b7 Estadias de persoal do CIMUS noutras instituci\u00f3ns:  \nNombre  Instituci\u00f3n destino  Ciudad, Pais  Fechas  Grupo de CIMUS(origen)  \n2012      \nMar\u00eda Jose Varela Liste  Universidad de Glasgow  Glasgow, Inglaterra  01/0 9-30/08/2014  BioFarma group  \nMario  Orozco  Instituto Politecnico Nacional (IPN)/ \nEscuela Nacional de Ciencias Biologicas \n(ENCB)  M\u00e9jico  09/11/2012 -Actually  Molecular Oncology Lab  \nMaria Jose  Alvarez  Institute de Neurosciences de la Timone  Marsella, Francia  01/06 -31/12/2012  Visual Science  \nHugo  Guti\u00e9rrez de Ter\u00e1n  The Scripps Research Institute  La Jolla, California( EEUU)  15/01 -30/06/2012  Bioinformatics  \nHugo  Guti\u00e9rrez de Ter\u00e1n  Uppsala University  Uppsala, Suecia  15/08 -31/12/2012  Bioinformatics  \n2013      \nFernando Torrres And\u00f3n  Karolinska Institutet  Estocolmo, Suecia  29/04/2013 -31/12/20 13 Nanobiopharmaceuticals \nresearch lab  \nRaquel  Abell\u00e1n Pose  Universidad de La Laguna  La Laguna, Tenerife  19/05/2013 -20/06/2013  Nanobiopharmaceuticals \nresearch lab  \nJorge  Correi a Pinto  Center for Cancer Research, National \nCancer Institute  Maryland, USA  21/04/2013 -26/07/2013  Nanobiopharmaceuticals \nresearch lab  \nAmparo P\u00e9rez D\u00edaz  Centro Nacional de Biotecnolog\u00eda -CSIC  Madrid (Espa\u00f1a)  21/04/2013 -25/04/2013  Biofarma group  \nPatricio At anes Juiz  Centro Nacional de Biotecnolog\u00eda -CSIC  Madrid (Espa\u00f1a)  21/04/2013 -25/04/2013  Biofarma group  \nDiego Rodriguez Penas  Centro Nacional de Investigaciones \nCardiovasculares (CNIC)  Madrid, Espa\u00f1a  04/02/2013 -08/03/2013  Cardiovascular area group  \nBeatriz  Paradela Dobarro  Langone Medical Center  Nueva York, EEUU  01/05/2013 -31/12/2013  Cardiovascular area group  \nMayte  \u00c1lvarez Crespo  The Wenner Gren Institute  Estocolmo , Suecia  01/05/2013 -18/12/2013  NeurObesity group  \n  Lisboa   Molecular Metabolism group  ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}